

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number  
**WO 01/83691 A2**

(51) International Patent Classification<sup>7</sup>:

C12N

(74) Agent: DOCHERTY, Pamela, A.; Calfee, Halter & Griswold LLP, 1400 McDonald Investment Center, 800 Superior Avenue, Cleveland, OH 44114 (US).

(21) International Application Number: PCT/US01/11993

(22) International Filing Date: 12 April 2001 (12.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/196,870 12 April 2000 (12.04.2000) US

(71) Applicants (*for all designated States except US*): THE CLEVELAND CLINIC FOUNDATION [US/US]; 9500 Euclid Avenue, Cleveland, OH 44195 (US). KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE [SA/SA]; P.O. Box 3354 - MBC-03, 11211 Riyadh (SA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ABU-KHABAR, Khalid, S. [SA/SA]; P3354, MBC-03, 11211 Riyadh (SA). WILLIAMS, Bryan, R., G. [NZ/US]; 2909 Fairfax Road, Cleveland, OH 44118 (US). FREVEL, Mathias [DE/US]; 4470 Chagrin River Road, Chagrin Falls, OH 44022 (US). SILVERMAN, Robert, H. [US/US]; 24607 Letchworth Road, Beachwood, OH 44122 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SYSTEM FOR IDENTIFYING AND ANALYZING EXPRESSION OF ARE-CONTAINING GENES

(57) Abstract: The present invention relates to a gene discovery system and gene expression systems specific for genes encoding ARE-containing mRNAs. In one aspect, the present invention relates to computational methods of selecting coding sequences of ARE-genes from databases using a one or more ARE search sequences. The ARE search sequences are from 10 to 80 nucleotides in length and comprise a sequence which is encompassed by one of the following two sequences: (a) WU/T(AU/TU/TU/TA)TWWW, SEQ ID NO. 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U, or T; and (b) U/T(AU/TU/TU/TA)n, SEQ ID NO. 2, wherein n indicates that the search sequence comprises from 3 to 12 of the tetrameric sequences contained within the parenthesis. The method comprises extracting from the databases, those nucleic acids whose protein coding sequences are upstream and contiguous with a 3' untranslated region (UTR) that comprises one of the ARE search sequences. The present invention also relates to methods of selectively amplifying RNA and cDNA molecules using primers derived from and complementary to the consensus 5' sequence motifs and primers derived from and complementary to the ARE search sequence. The present invention also relates to methods of selectively amplifying ARE genes which employ a 3' primer which is from 15 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT. The pentameric sequences in the primers are either overlapping or non-overlapping. The 3' primers are used in the reverse transcription step of the methods, the polymerase chain reaction (PCR) amplification step of the methods, or in both the reverse transcription step and the PCR amplification step of the methods. The present invention also relates to methods of making libraries which comprise portions of the ARE genes that are selectively amplified by the present methods and to methods of making microarrays which comprise probes that hybridize under stringent conditions to portions of the protein coding sequences of the ARE genes that are selectively amplified by the present methods. The present invention also relates to libraries and the microarrays that are made by such methods.

WO 01/83691 A2

**SYSTEM FOR IDENTIFYING AND ANALYZING EXPRESSION  
OF ARE-CONTAINING GENES**

**Field of the Invention**

The field of this invention is identification and isolation of genes; more particularly, it is computational identification of consensus nucleotide sequences common to mRNAs that contain adenylate uridylate-rich elements (AREs), and use of these consensus sequences: i) to 5 search gene databases to identify genes containing consensus ARE sequences, and ii) to design primers, and selectively amplify and clone isolated cellular mRNAs that contain ARE sequence elements. Genes encoding ARE-containing mRNAs or unique fragments thereof are used as probes on microarrays for analysis of gene expression.

**Background**

10 Adenylate uridylate-rich elements (AREs) are cis-acting sequences, usually found in the 3' untranslated region (3'UTR) of many labile mRNAs. Such ARE-containing mRNAs have relatively short half lives and are rapidly degraded after they have been transcribed. Studies have shown that certain AREs act as instability determinants (Chen and Shyu, 1995, Trends Biochem Sci, 20:465-70.). For example, the half lives of specific 15 long-lived mRNAs were significantly decreased by inclusion of ARE sequences in the 3'UTR of such mRNAs (Shaw and Kamen, 1986, Cell, 46:659-67.). Early studies suggested the minimal necessary sequence for a functional ARE was UUAUUUAUU (Chen and Shyu, 1995, Trends Biochem Sci, 20:465-70.; Lagnado, et al., 1994, Mol Cell Biol, 14:7984-95.; Lewis, et al., 1998, J Biol Chem, 273:13781-6.; Zubiaga, et al., 1995, 20 Mol Cell Biol, 15:2219-30.). Studies have described the binding of specific proteins to the ARE elements in mRNA and it may be that these proteins mediate the short half life of such mRNAs (Bakheet, et al., 2001, Nucleic Acids Res, 29:246-54.).

Known ARE-containing mRNAs are encoded by many early response genes that function to regulate cell proliferation and respond to exogenous agents, such as inflammatory 25 stimuli, radiation, and viruses. Among these gene products are proteins that participate in growth control, such as the proto-oncogene, c-fos, and the hematopoietic growth factor, granulocyte monocyte colony stimulating factor; cytokines that respond to inflammatory

stimuli, such as TNF- $\alpha$  and IL-8; interferons, such as IFN- $\alpha$  and IFN- $\beta$ , that are responsible for early defenses against viruses; and cellular receptors, such as tissue factor, an initiator of blood coagulation.

ARE-mediated changes in mRNA stability are important in processes that require transient responses such as cellular growth, immune response, cardiovascular toning, and external stress-mediated pathways. Abnormal expression of genes encoding ARE-containing mRNAs, by stabilization of the mRNAs for example, may cause increased concentrations of proteins encoded by such mRNAs and lead to disease. For example, removal of the ARE element of the proto-oncogene c-fos correlates with increased oncogenicity (Raymond, et al., 1989, Oncogene Res, 5:1-12). The ARE-containing Bcl-2 mRNA, encodes an anti-apoptotic protein whose increased concentrations can lead to neoplastic transformation of follicular B-cells (Capaccioli, et al., 1996, Oncogene, 13:105-15; Schiavone, et al., 2000, Faseb J, 14:174-84.). Another example of disease, possibly caused by misregulated ARE-containing mRNAs, is the chronic inflammatory arthritis and Crohn's-like inflammatory bowel disease that were detected in mice whose ARE-containing region was deleted from the TNF gene (Kontoyiannis, et al., 1999, Immunity, 10:387-98.). Chromosomal alterations led to deletion of ARE-3'UTR in the CCND1 gene (cyclin D1, PRAD1, parathyroid adenomatosis 1) that resulted in overexpression of CCND1 mRNA in mantle cell lymphoma, a deregulation event that is thought to perturb the G1-S transition of the cell cycle and thereby contributes to tumor development (Rimokh, et al., 1994, Blood, 83:3689-96.). The tumorigenicity of small neuroblastic cells correlates with overexpression of the ARE-mRNA, MYCN, and also correlated with a large amount of a p40 ELAV-protein that targets AREs and stabilizes ARE-mRNAs when compared to substrate adherent cells (Chagnovich and Cohn, 1997, Eur J Cancer, 33:2064-7.). Tumor necrosis factor (TNF- $\alpha$ ) is a typical ARE-mRNA and, although it is both pro-inflammatory and has anti-tumor activity to specific solid cancers, there is experimental evidence that it can act as a growth factor in certain leukemias and lymphomas (Liu, et al., 2000, J Biol Chem, 275:21086-93.).

Misregulation in ARE-mRNA pathways can result in other transiently regulated biological processes being affected. The 70-year phenomenon of the Warburg effect which is the oxygen-dependent enhanced glycolysis in cancer cells has been linked to the increased constitutive expression of a novel ARE-mRNA isoform for 6-phosphofructoso-2-kinase in cancer cells and was required for tumor growth *in vitro* and *in vivo* (Chesney, et al., 1999,

Proc Natl Acad Sci U S A, 96:3047-52.). In the same context of enhanced glucose metabolism in cancer, the stability of glucose transporter Glut1 mRNA has been shown to be regulated by ARE and ARE binding proteins and correlated with certain tumors including gliomas (Hamilton, et al., 1999, Biochem Biophys Res Commun, 261:646-51.). The high 5 invasiveness of the breast cancer cell line, MDA-MB231, has been shown to be mediated by increased constitutive levels of urokinase-type plasminogen activator (uPA) due to impairment in the ARE-mediated decay of uPA mRNA (Montero and Nagamine, 1999, Cancer Res, 59:5286-93.). The increased activity of uPA and its receptor has been associated with invasiveness in a number of tumors (Reuning, et al., 1998, Int J Oncol, 13:893-906.).

10 Interestingly, both the uPA and its receptor belong to the ARE-gene family (Bakheet, et al., 2001, Nucleic Acids Res, 29:246-54.) indicating the tightly regulated process of cell adhesiveness in normal situations. The mRNA of the transcription factor CHOP, which is involved in cell division and apoptosis in response to stress, is regulated by ARE (Ubeda, et al., 1999, Biochem Biophys Res Commun, 262:31-8.). Increased production of 15 hematopoietic growth factors, e.g., GM-CSF, acting as autocrine growth factors, due to defects in ARE-mediated stability, may contribute to the pathogenesis of leukemia (Hoyle, et al., 1997, Cytokines Cell Mol Ther, 3:159-68.; Paul, et al., 1997, Am J Hematol, 56:79-85.). Growth-regulated alterations in the abundance of ARE-mRNA regulating proteins, AU<sub>1</sub> and HuR may have pleiotropic effects on the expression of many highly regulated ARE-mRNAs 20 and this may significantly impact the onset, maintenance, and progression of the neoplastic phenotype (Blaxall, et al., 2000, Mol Carcinog, 28:76-83.).

Despite their significance, however, probably less than 100 ARE-containing mRNAs have so far been identified. Other ARE-containing genes likely exist whose misregulation may contribute to human disease. Therefore, it would be desirable to identify additional 25 genes that encode ARE-containing mRNAs.

### Summary of the Invention

The present invention relates to a gene discovery system and gene expression systems specific for genes encoding ARE-containing mRNAs. In one aspect, the present invention relates to computational methods of selecting coding sequences of ARE-genes 30 from databases using one or more ARE search sequences. The ARE search sequences are from 10 to 80 nucleotides in length and comprise a sequence which is encompassed by one of the following two sequences: (a) WU/T(AU/TU/TU/TA)TWWW, SEQ ID NO. 1,

wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U or T; and (b) U/T(AU/TU/T/U/T)n, SEQ ID NO. 2 , wherein n indicates that the search sequence comprises from 3 to 12 of the tetrameric sequences contained within the parenthesis. The method comprises extracting  
5 from the databases, those nucleic acids whose protein coding sequences are upstream and contiguous with a 3'untranslated region (UTR) that comprises one of the ARE search sequences. Examples of such databases are mRNA databases, cDNA databases, and genomic databases, including the human genome project. The invention also relates to methods of making DNA libraries and microarrays that comprise a plurality of the nucleic  
10 acids that are selected by the computational methods. The invention also relates to the DNA libraries and microarrays that are made by such methods. In one embodiment, the microarray comprises probes that hybridize to the coding sequences of a plurality of the genes that are listed in Table 6.

The present invention also relates to a method of identifying primer sets target to the initiation region of genes whose 3' UTR comprise ARE sequences. In one preferred embodiment, the method employs the ARE search sequences. The ARE genes are grouped into four classes or sixteen classes. The four class grouping is based upon the the nucleotide base that is attached to the 3' end of the start codon of the ARE genes. The sixteen class grouping is based on the nucleotide bases that are attached to both the 5' end and the 3' end  
20 of the start codon, ATG, of the ARE genes. Using the ARE genes that are found in the database, consensus sequences for each of the classes are determined. The consensus sequences are useful for preparing 5' primer sets, e.g. degenerate primers, which can be used to selectively amplify full-length and partial length ARE genes.

The present invention also relates to methods of selectively amplifying RNA and  
25 cDNA molecules using primers derived from and complementary to the consensus 5' sequence motifs and primers derived from and complementary to the ARE search sequence. Such amplified RNA and cDNA molecules comprise the full-length or partial length sequences of new ARE genes.

The present invention also relates to methods of selectively amplifying ARE genes  
30 which employ a 3' primer which is from 15 to 50 nucleotides and length and comprises from 2 to 10 pentamers having the sequence TAAAT. The pentameric sequences in the primers are either overlapping or non-overlapping. The 3' primers are used in the reverse

transcription step of the methods, the polymerase chain reaction (PCR) amplification step of the methods, or in both the reverse transcription step and the PCR amplification step of the methods. The present invention also relates to methods of making libraries which comprise portions of the ARE genes that are selectively amplified by the present methods 5 and to methods of making microarrays which comprise probes that hybridize under stringent conditions to portions of the protein coding sequences of the ARE genes that are selectively amplified by the present methods. The present invention also relates to libraries and the microarrays that are made by such methods.

10 The present invention also relates to microarrays comprising probes which hybridize under stringent conditions to the coding sequences of the genes which comprise the sequences shown in Figure 7.

The present invention also relates to methods of using the ARE genes for generation of PCR products or oligonucleotides for use as immobilized probes in cDNA or oligonucleotide microarray, respectively.

15 The present invention also relates to methods of using the microarrays of the present invention to obtain the ARE expression profile of a subject, particularly a subject with a disease such as cancer.

#### Brief Description of the Figures

**Figure 1.** Selection of ARE-containing cDNA by reverse transcription. Total RNA (0.5 µg) 20 was extracted from THP-1 cells that were treated with CHX (5 µg/ml) and LPS (10µg/ml). cDNA was synthesized from this RNA using SuperScript II with AT-P primer (WWWTAAATAAAT) at a concentration of either 15 µg/ml (lanes 2 and 3) or 25 µg/ml (lanes 4 and 5). Different RT reaction temperatures were used, 42°C (lanes 2 and 4) and 52°C (lanes 3 and 5). Specific PCRs for IL-8 (upper box) and β-actin (lower box) were 25 performed using standard PCR conditions. The regular abundance of IL-8 and β-actin is shown in lane 1. Lack of DNA contamination was verified by absence of larger specific amplified products (upper arrows) or negative control containing RNA (NC).

**Figure 2.** Effect of trehalose on the efficiency of specific ARE priming and reversal of abundant cDNA. Total RNA was extracted from CHX+LPS treated THP-1 cells. cDNA was 30 synthesized using SuperScript II with TA-P primer (TAAATWVATAAAT) at a

concentration of 25 µg/ml. RT was performed in the absence (lanes 1, 2 and 3) or presence of trehalose (lanes 4 and 5) at a priming annealing temperature of 60°C. Specific PCRs (cDNA input: lanes 2 and 3, 0.5 µg; lanes 4 and 5, 0.25), for IL-8 and β-actin were performed using standard PCR conditions. Lane 1 shows the regular abundance of β-actin and IL-8 at 5 the same PCR conditions used. Upper bands are of the expected size of β-actin product, while, the lower bands are IL-8 product of the expected size. Lack of DNA contamination was verified by absence of larger specific amplified products.

**Figure 3.** Effect of initial annealing temperature and number of cycles on selectivity of the discontinuous and continuous ARE-cDNA. Total RNA (1 µg) from LPS + CHX-treated 10 THP-1 cells was extracted and subjected to RT. 40 ng cDNA was used for the ARE-cDNA PCR using the 5' primer, Ca (Table 3), and the 3' ARE primer using different initial annealing temperatures (4 cycles) followed by different cycles (lane 1, 20 cycles; lane 2, 25 cycles; lane 3, 30 cycles, lane 4, 35 cycles) at high annealing temperature (60°C). Aliquots of the amplified ARE-products were subjected to a second PCR at stringent conditions specific 15 to IL-8 (a) and TNF-α (b) in addition to β-actin to monitor selectivity of ARE amplification. Specific amplified products of IL-8 was not due to cDNA carryover from original cDNA as PCR from the amount of carryover cDNA (4 ng) failed to show detectable IL-8 and TNF-α messages at the same PCR conditions.

**Figure 4.** Schematic of the RNA-ligase directed amplification of full-length coding regions 20 of ARE-cDNA. RL oligo is a 30-mer oligonucleotide that was phosphorylated at its 5'-end and modified at its 3'-end with an amino group.

**Figure 5.** Selective amplification of ARE-cDNA by RNA-ligase directed ARE-PCR (ARE-RL-PCR). Total RNA was extracted from THP-1 cells. cDNA was synthesized by SuperScript II (at two different annealing temperatures, 42°C and 52°C) with oligo(dT) 25 primer followed by linking a 5'-phosphorylated and 3'-amino modified oligomer (RL oligomer) to the 3'-end of the cDNA using RNA ligase. PCR using a 5' primer specific to the RL oligomer, and 3' primer specific to the ARE region was performed at an annealing temperature of 42.5°C. Second specific PCR for TNF-α and β-actin was performed using either 1/10 of cDNA (lanes 1 and 3) or 1/50 of cDNA (lanes 2 and 4). PCR was used with 30 two different dNTP concentrations: 10µM, lanes 1 and 2 and 40µM (lane 3 and 4). Upper bands are of the expected size of TNF-α (548 bp), while lower bands indicate the size of β-

actin product (838 bp), while lack of DNA contamination was verified by absence of larger bands of 1450 and 1216 bp, respectively. C indicates cDNA carryover control from the original cDNA.

**Figure 6.** Test of the first generation ARE-cDNA microarray. THP-1 cells were treated with LPS (10 $\mu$ g/ml) and cycloheximide (5  $\mu$ g/ml). Total RNA samples (100  $\mu$ g) from treated and untreated cells were labeled with Cy3 and Cy5, respectively, and hybridized to the ARE-cDNA microarray (a). (b) The average fluorescence signals of treated versus untreated samples, as measured using the GenePix 4000A scanner over duplicate spots, are plotted demonstrating two gene expression profiles in case of LPS and LPS plus CHX, the percentages of expressed ARE genes in relation to approximately 1000 cDNA in the array, and their maximum fold induction. (c) Example of the bell-shaped transient response curves characteristic of ARE-genes (approximately 100 genes) using cluster analysis using the hierarchical Ward's cluster model (SAS-JMP).

**Figure 7.** DNA sequences obtained after sequencing of ARE cDNAs obtained after reverse transcription of ARE mRNA followed by either PCR of ARE sequences or RNA-ligase directed ARE-PCR.

#### Detailed Description of the Invention

##### Identification of ARE Genes

The present invention relates to computational and laboratory methods for identifying ARE genes.

Generally, the term "gene" refers to a contiguous stretch of nucleotide bases within the genome that is transcribed into an RNA, more specifically an mRNA. Such mRNA is subsequently translated into a protein. As used herein, the term can refer not only to the DNA within the genome (i.e., genomic sequences), but also to the mRNA transcribed from the DNA, and a DNA copy of the mRNA, also called "cDNA." Such a gene has multiple sections, parts or regions, as described below (i.e., coding sequence, 3'UTR and 5'UTR). A "complete" gene comprises all of the sections. A "fragment" of a gene consists of less than all the sections. A fragment of a gene may comprise less than one entire section of a gene. A fragment of a gene that is used for the purpose of hybridization is referred to as a "probe."

As used herein, the terms "protein coding sequence" or "coding sequence," refer to an area of a gene (e.g., genomic DNA, mRNA or cDNA) that contains the genetic information responsible for the linear positioning of amino acids into a protein. The genetic information in such a coding region normally comprises contiguous groups of three nucleotide bases, called codons, each specifying a single amino acid within the encoded protein. Such coding sequence is said to be "full length" if it encodes a protein that is of the length and sequence normally found within a cell. Such coding sequence is said to be "partial length" if it encodes a protein that is shorter than the length of the protein normally found within a cell. Such partial length coding sequences can arise, for example, when enzymes that are used to copy DNA or RNA, do not faithfully copy the entire length of DNA or RNA being used as a template.

As used herein, "3'UTR" refers to an area of a gene, cDNA or mRNA that is located 3' or downstream of the protein coding region of said gene, cDNA or mRNA.

As used herein, "5'UTR" refers to an area of a gene, cDNA or mRNA that is located 5' or upstream of the protein coding region of said gene, cDNA or mRNA.

As used herein, "ARE" means "adenylate uridylylate-rich element." Such AREs are found in the 3'UTR of a gene. As used herein, an ARE gene, refers to a gene which contains an ARE within its 3'UTR.

#### Computational Derivation of the ARE Search Sequence

In one aspect, the present invention provides an ARE search sequences which can be used to select ARE genes from public databases. One group of ARE search sequence comprise the sequence WU/T(AU/TU/TU/TA)U/TWWW, SEQ ID NO. 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U, or T. Another group of search sequences comprise the sequence U/T(AU/TU/TU/T)n, SEQ ID NO. 2, wherein n indicates that the search sequences comprises from 3 to 12 of the tetrameric sequences within the parenthesis. The ARE search sequences were derived through analysis of the sequences of 57 mRNAs that are known to contain ARE sequences in their 3'UTR. The two rules used to include an mRNA among the 57 mRNAs are: i) an mRNA in which the ARE sequence has been shown to control mRNA stability or half-life, or ii) an ARE-containing mRNA that is known to be transiently induced. From the 3'UTR of these 57 mRNAs, consensus ARE sequences were generated through use

of multiple expectation maximization for motif elicitation (MEME) program (Bailey and Gribskov, 1998, J Comput Biol, 5:211-21.). The sequence, TATTTAWW (W = A or T) was obtained. Using the 57 sequences, a consensus analysis was then performed around the TATTTAWW motif. In one embodiment, the parameters of the analysis specify a 75% 5 certainty of a stated nucleotide being at each position. Using these parameters, the ARE search sequences were derived.

Derivation of the mRNA Database to be Searched with the ARE Search Sequence

A total of 36,951 human mRNA/cDNA sequences were extracted from GenBank Release 113 (National Center for Biotechnology Information, NCBI). Those sequences that 10 encode full-length open reading frames were retained and others discarded. The 3'UTR sequences were extracted from each mRNA/cDNA sequence. The sequences containing no 3'UTR were discarded. A list of 13,057 sequences remained.

Searching the mRNA Database with ARE Search Sequences

In one embodiment, the 13,057 sequences were searched for the 15 WWWTATTATWWW sequence using the FindPattern analysis routine (Genetics Computer Group/Oxford Molecular Company; Madison, Wisconsin) allowing 1 bp mismatch on each side, outside of the core TATTAT sequence. Redundant sequences were eliminated. The sequences found comprised 897 independent mRNA/cDNA sequences (see listing shown in Table 6 at end of examples).

20 In other embodiments of the invention, other variations of the ARE search sequence were used to search the mRNA database. Examples of the ARE search sequences which can be used include: WWWT(ATTTA)TWWW, SEQ ID NO. \_\_, WWWT(ATTTA)TWW, SEQ ID NO. \_\_, WWWT(ATTTA)TTWW, SEQ ID NO \_\_, WWWT(ATTTA)TWWW. SEQ ID NO. \_\_, WW(ATTTATTTA)WW, SEQ ID NO. \_\_, ATTT(ATTTA)TTTA, SEQ ID NO. \_\_, A(TTTA)<sub>n</sub>, where n can be from 3 to 12. These search sequences can be further varied by allowing between 0 and 2 nucleotides outside of the nucleotides shown in parenthesis above not to match (i.e., mismatches).

Searching Genomic Databases with ARE Search Sequences

In another embodiment, ARE search sequences are used to search existing databases of genomic DNAs. A major difference between searching a genomic database as compared to searching a database comprised of 3'UTR sequences is that the ARE search sequence can be found in regions of genes other than the 3'UTR. Identification of a sequence matching the 5 ARE search sequence within the coding region of a gene is not useful. Only ARE search sequences present in the context of the 3'UTR likely function as determinants of mRNA stability.

To determine the possibility that ARE search sequences are found in a context other than the 3'UTR of a gene, diagnostic computational tests are performed. In one test, for 10 example, the full protein coding sequence plus 3'UTR (not just the 3'UTR) of the 13,057 mRNAs/cDNAs described above are searched for the WWWTATTATWWW sequence. The results of this search are 897 matches, the same number as found previously, when only the 3'UTR regions of these genes are searched. This result indicates that the ARE search sequence is not found within the coding region of these genes.

15 In another diagnostic computational test, the ARE search sequence is searched in a database of genomic sequences from the human genome project. While the ARE search sequence is not found with significant frequency in protein coding or 5'UTR regions of genes, ARE search sequences are frequently found in introns of genes throughout the genome.

20 Therefore, additional computational methods are used to eliminate from consideration those genes in which the ARE search sequence is found in regions other than the 3'UTR. These additional computational methods can also be used independently as methods of finding ARE-containing genes in genomic databases. The GENSCAN computer prediction program (Burge and Karlin, 1997, J Mol Biol, 268:78-94.) is one program used for this 25 purpose. GENSCAN is a program that predicts the presence of genes within DNA databases using probabilistic models to detect gene structures such as exons, introns, transcriptional promoters and polyadenylation signals. Using GENSCAN, it is possible to rapidly determine whether ARE search sequences are found in regions other than the 3'UTR of genes. This eliminates genes in which the ARE search sequence is found in other areas of genes (e.g., 30 within introns).

As an alternative to the GENSCAN program, the FGENSEH program (Solovyev and Salamov, 1997, Proc Int Conf Intell Syst Mol Biol, 5:294-302; Solovyev, et al., 1995, Proc Int Conf Intell Syst Mol Biol, 3:367-75) is also used. FGENSEH has been developed based on the exon recognition functions that uses linear discriminant functions for splice sites, 5'-coding, internal exon, and 3'-coding region recognition.

Once GENSCAN or FGENSEH software are used to identify ARE-containing genes, 6-20 kilobase pairs of contiguous sequence upstream of the ARE sequence and 1-3 kilobase pairs of contiguous sequence downstream of the ARE sequence are obtained. The open reading frame of the genes are obtained by analysis of these contiguous regions.

10 Selective Amplification of ARE mRNAs by Reverse Transcription

In addition to computational identification of ARE genes that are present in databases, laboratory methods allow identification and cloning of ARE genes that are not present in computer databases.

15 As a first step toward laboratory-based identification of ARE genes, cDNA is synthesized from total cellular RNA using reverse transcriptase. RNA may be total cellular RNA or mRNA. Isolation of such RNA is common to those knowledgeable in the art. Such RNA could come from cells or tissues.

20 In one embodiment, oligo(dT) is used as the primer in the reverse transcription reaction. Oligo(dT) hybridizes to the poly(A) tails of mRNAs during first strand cDNA synthesis. Since all mRNAs normally have a poly(A) tail, first strand cDNA is made from all mRNAs present in the reaction (i.e., there is no specificity).

25 In another embodiment, first strand cDNA is synthesized only from those mRNAs that contain an ARE sequence in their 3'UTR. Such selectivity is achieved by replacing oligo(dT) with degenerate universal 3' primers that specifically hybridize to ARE sequences in the 3'UTR of such mRNAs. Such degenerate universal 3' primers are based on the ARE search sequence derived earlier and are complementary to sequences encompassed by one or more of the search sequences. The 3' primer are from 15 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT. These pentameric sequences may be overlapping, i.e. where the fifth nucleotide in the upstream pentamer is the 30 first nucleotide in the downstream pentamer or non-overlapping. In those cases where the

primers contain nonoverlapping pentamers, the primers either are not separated, i.e. they are adjacent, or, preferably are separated by from one to five nucleotides.

Examples of 3' primers suitable for use in the reverse transcription reaction are AATAAATAAAATVA (Down-ATP), SEQ ID NO. 3, TAAATWWVATAAAAT (Down-TAP), 5 SEQ ID NO. 4, AATAAATAAAATAA (S-MOTIFP), SEQ ID NO. 5, CTCGAGWHWWAAATAAAATA (TA-XHOP), SEQ ID NO. 6, AND CTCGAGTAAATWNATAAAAT (AT-XHOP), SEQ ID NO. 7, where W = A or T, H = A or C or T, V = A or G or C, and N = A or G or C or T.

In further embodiments, additional variations of the 3' primers may be used. Such 3' 10 primers include: AATAAATAATCA, SEQ ID NO. 8, AATAAATAATGA, SEQ ID NO. 9, AWTAATAAAATWA, SEQ ID NO. 10, and WWWTAAATAAAAT, SEQ ID NO. 11, for example. Longer primers can be used, such as those with multiple overlapping or non-overlapping ARE pentamer elements (i.e., ATTAA). Examples of such longer primers are 15 AATAAATAAAATAAAATAAT, SEQ ID NO. 12, and GCGGGATCCGGGCTAAATAAAATAAA, SEQ ID NO. 13.

Preferably, the reverse transcriptase enzyme used in the reaction is stable at temperatures above 60°C, for example, SuperScript II RT (GIBCO-BRL). However, MMLV reverse transcriptase can also be used.

In a preferred embodiment, the disaccharide, trehalose, is added to the reverse 20 transcriptase reaction. Trehalose is a disaccharide that has been shown to stabilize several enzymes including RT at temperatures as high as 60°C (Mizuno, et al., 1999, Nucleic Acids Res, 27:1345-9.). Trehalose addition allows the use of high temperatures in the reverse transcription reaction (e.g., as high as 60°C). Preferably, trehalose is added to the reverse transcriptase reaction such that it is present in a final concentration of between 20 to 30%. 25 Preferably, the reverse transcriptase reaction is then performed at a temperature between 35 to 75 C, more preferably at a temperature from between 50 to 75 C, most preferably at a temperature of 60 C.

#### Amplification of ARE cDNAs by PCR

To clone the cDNAs representative of new ARE-containing genes, the first strand 30 cDNAs synthesized is designed to be specific for first strand cDNAs that contain ARE-

sequences. In one embodiment this employs two primer sets, the 3' set and the 5' set, which are designed to selectively amplify ARE genes.

The first set of primers, the 3' set, are similar, and could be identical, to the 3' primers used in the aforementioned specific reverse transcription of ARE-containing mRNAs. 5 Preferably, however, the primers of the 3' set are longer than those used for reverse transcription and have a high percentage of GC in their sequence. Examples of the 3' set of primers used for PCR are GGCGGATCCGGGCTAAATAWATAAAATWA (MOTIF-AA), SEQ ID NO. 14, and GGCGGATCCGGGCAATAATAWATAAAAT (MOTIF-T), SEQ ID NO. 15. Other variations in sequence of these 3' primers could be made to facilitate PCR or 10 cloning in subsequent steps, such as inclusion of restriction enzyme cleavage sites, for example.

The second set of primers, directed to the 5' end of the genes represented by the first strand cDNAs, are determined by computational analysis of sequences in known databases. For example, 897 mRNA/cDNA sequences that were identified as containing ARE sequences 15 in their 3' UTRs (these 897 genes were discussed above in the section entitled, "Searching the mRNA Database for the ARE Search Sequence."). The region in the 5'UTR that flanked the ATG start codon for each of these 897 sequences was compared. There is some sequence conservation in all eukaryotic genes known to be present surrounding the translation start codon (Kozak, 1987, Nucleic Acids Res, 15:8125-48.; Kozak, 1987, J Mol Biol, 196:947-20 50.).

By analysis of this 5' region of the 897 sequences a set of four degenerate primers, or alternatively, sixteen degenerate primers is designed, such that the set of primers hybridize to 99% of the first strand cDNAs derived from the 897 mRNA/cDNA sequences (Table 4). Individual degenerate primers are selected from this list to be used in PCR. The 5' primers 25 are designed in such a way that they hybridize to the 5' end of a subset of the 897 ARE genes. Therefore, to amplify all possible ARE-containing mRNAs different PCR reactions using different sets of primers are used.

Using the 3' and 5' primers, the PCR reaction preferably is performed using Taq polymerase and is preferably hot start PCR (i.e., adding Taq polymerase to the reaction 30 during heating for 10 min. at 95 C) or using anti-Taq antibody (i.e., Taq polymerase is pre-incubated with anti-Taq antibody which renders the polymerase inactive until reactivated by

heating). Preferably, annealing temperature of the first four PCR cycles is between 32 and 50 C. Thereafter, the annealing temperature is raised to between 60 and 65 C for 22 to 35 cycles. A final extension step is performed at 7 C for 3 minutes.

5 RNA-Ligase Based cDNA Synthesis Followed by Specific PCR Amplification of ARE Sequences

In another embodiment, synthesis of cDNA uses an RNA ligase based method, followed by amplification of such cDNAs using PCR (Fig. 4).

In such embodiment, total cellular RNA is reverse transcribed into first strand cDNA, preferably by SuperScript II reverse transcriptase and oligo(dT) primers that are modified at 10 the 5' ends by NH<sub>2</sub> (amino group prevents self ligation or inter-ligation of the oligo(dT) and the RL oligo primer). The first strand cDNA that results has the modified oligo(dT) primer incorporated and, therefore, its 5' end blocked by NH<sub>2</sub> (see Fig. 4). RNase H is then used to degrade RNA in the reaction. The single-stranded, first strand cDNA that remains is then ligated to, at its 3' end, an oligonucleotide, called the RL oligomer, that is phosphorylated at 15 its 5' end and protected at its 3' end by an NH<sub>2</sub> group. Such RL oligomer can be from 10 to 70 nucleotides in length and is modified at its 5' end with a phosphate group, and at its 3' end with an amino group. The sequence of such RL oligomer preferably does not have homology to human mRNAs.

Amplification of this resulting cDNA is performed by PCR using a 3' primer 20 containing the consensus ARE sequence, and a 5' primer homologous to the RL oligomer.

ARE Gene Libraries

The present invention also relates to cDNA libraries that comprise the protein coding sequences of the ARE genes that are identified by the present methods. To produce such 25 libraries, double-stranded DNA produced after PCR amplification of first strand cDNA is cloned into plasmid vectors. The cDNA may or may not be fractionated by size before cloning. Cloning of cDNA uses appropriate vectors, such as for example, T/A vectors or other cloning techniques known to those skilled in the art. Such cDNA cloning of PCR products can be accomplished through the use of commercial kits from, for example, Clontech (Palo Alto, California), Invitrogen (Carlsbad, California), Novagen (Madison, 30 Wisconsin), Stratagene (LaJolla, California), or other companies.

Library clones containing inserts are selected, further cloned, DNA extracted and purified. DNA samples are sequenced using primers specific to vector sequences flanking the inserts. Performance of these procedures is well known among those experienced in the art.

Such ARE cDNA libraries contain a plurality of DNA molecules that together represent a plurality of different ARE genes. Such individual DNA molecules normally contain a fragment of a given ARE gene. Such fragments can comprise a full length or partial length coding sequence. Such partial length coding sequences can comprise from about 10% to about 90% of the full length coding sequence. Preferably, such a partial length coding sequence comprises a unique sequence which is not contained within the protein coding sequences of genes that are not ARE-genes. The uniqueness of such sequence is determined through computational search of publicly available sequence databases. Sequences of some ARE genes isolated in this way are not found in public databases. Some such sequences are shown in Fig. 7. The library, referred to hereinafter as an "ARE library" is substantially free of nucleic acid molecules whose protein coding sequences are not part of an ARE gene. As used herein, a library is substantially free of non-ARE genes if no more than 10% of the molecules or clones that comprise the library contain coding sequences from non-ARE genes.

#### ARE Microarrays

The present invention also relates to microarrays that comprise probes which are nucleotide molecules derived from the nucleotide sequences of ARE genes. As used herein, the term "microarray" refers to a solid support that comprises a plurality of ARE gene probes. Preferably, fewer than 20%, more preferably fewer than 10% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE genes. Such microarrays can comprise substantially the entire protein coding sequence of the ARE gene.

The probes that comprise the microarrays are derived from ARE genes which are identified both by computational search methods and by laboratory generation of ARE cDNA libraries as described above. The sequences derived from the ARE genes are matched to genes present in the publicly-available Unigene database (<http://www.ncbi.nlm.nih.gov/UniGene/>) by searching for the sequence in the BLAST

database and determining the Unigene number. The Unigene database is a resource for gene discovery in which each Unigene sequence, or cluster, represents a unique gene. Clones corresponding to Unigene cluster identification numbers are used to identify clones that are then obtained from either a commercial set of 40,000 cDNA clones (human 40K set; 5 Research Genetics; Huntsville, Alabama) or from the I.M.A.G.E. Consortium clone set (<http://image.llnl.gov/>).

The sources of immobilized nucleic acids (i.e., probes) placed on the microarrays may depend on the microarray and comprise several different types of probe. Such probes may comprise nucleic acids amplified from clones present in an ARE library, or obtained from 10 Research Genetics or the I.M.A.G.E. Consortium. In such case, the insert DNAs (i.e., ARE cDNAs) from these clones are amplified by PCR using primers that hybridize to vector DNA sequences that flank the cloned insert. Alternatively, they are amplified using the 3' primers and 5' primer specific to the sequence of the cloned insert. In addition to PCR products amplified from ARE clones, probes may comprise fragments from ARE clones, such as 15 fragments generated through restriction endonuclease cleavage of the ARE clones.

In addition, other types of molecules may be used as the gene probes in the microarrays. For example, oligonucleotides which contain at least 10 nucleotides, preferably from about 10 to about 100 nucleotides, more preferably from about 10 to about 30 nucleotides can be used. Sequence information from ARE genes is used to design and 20 synthesize such oligonucleotides which are then placed onto the microarrays. Such oligonucleotides can be designed based on any region of an ARE-containing gene (i.e., 5'UTR, coding region, 3'UTR) as long as the sequences encoded by such oligonucleotide are unique (i.e., the sequence is not present in any other gene within the genome). Such oligonucleotides preferably have a GC ratio (i.e., the percentage of the nucleotide bases that 25 comprise G and C) of at least 40%. Such oligonucleotides also preferably do not internally hybridize to themselves (i.e., they do not form "hairpin" structures). In addition to oligonucleotides, other gene probes which comprise nucleobases including synthetic gene probes such as, for example, peptide nucleic acids (PNAs) can also be used.

In addition to containing sequences representative of ARE genes, microarrays will, 30 for control purposes, also contain a smaller number of sequences representative of genes that do not contain an ARE element. Such non-ARE genes are preferably so-called "housekeeping" genes, such as for example, β-actin or GAPDH.

Microarrays are made in a variety of ways. Probes can be loaded into a robotic instrument which precisely places a predetermined amount of the probe onto the solid support. In one embodiment, probes are spotted onto glass slides that had been coated with poly-L-lysine using a SDDC-2 microarray robot (Engineering Services Inc.; Toronto, Canada), followed by UV-crosslinking and neutralization of remaining poly-L-lysine. In another embodiment, oligonucleotide probes are synthesized directly on the surface of the solid support. Making of microarrays has been described in several publications (Southern, et al., 1999, Nat Genet, 21:5-9.; Duggan, et al., 1999, Nat Genet, 21:10-4.; Cheung, et al., 1999, Nat Genet, 21:15-9.; Lipshutz, et al., 1999, Nat Genet, 21:20-4.) and U.S. patents (Nos. 5,837,832, 6,110,426 and 6,153,743, for example). These publications and patents are incorporated herein by reference.

The ARE microarrays are then used in hybridization experiments. Hybridization of mRNA, more preferably cDNA made from mRNA, from a cell line or tissue, to a probe on the microarray is indicative of expression, at the level of transcription, of the ARE gene in the cell line or tissue that corresponds to the specific probe on the microarray. Through determination of the amount of hybridization of the cell line or tissue RNA to the totality of probes on the microarray, the expression pattern of all ARE genes comprising that cell line or tissue can be determined.

The mRNA or cDNA made from the mRNA (i.e., target nucleic acids) is normally fluorescently labeled. In one embodiment, total RNA that is to be tested for the presence and amount of ARE transcripts, is extracted from cells or tissues, labeled with Cyanine-5-dUTP (Cy5, red, Amersham; Piscataway, New Jersey) in a reverse transcriptase reaction using oligo(dT)<sub>11-18</sub> primers and SuperScript II RT. Similarly, control RNA is labeled with Cyanine-3-dUTP (Cy3, green). The labeled cDNA samples are hydrolyzed by NaOH, purified by column chromatography and concentrated in TE buffer. The labeled cDNAs are mixed and hybridized to the sequences on the glass slide.

Conditions for hybridization of the target to the probe are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex or probe, as described (Wahl, et al., 1987, Methods Enzymol, 152:399-407). The term "stringent conditions," as used herein, is the "stringency" which occurs within a range from about  $T_m$ -5 (5° below the melting temperature of the probe) to about 20°C below  $T_m$ . As used herein, "highly stringent" conditions employ at least 0.2X SSC buffer and at least 65°C. As recognized in the art,

stringency conditions are attained by varying a number of factors such as the length and nature of the probe, the length and nature of the target sequences (i.e., the labeled cDNA), the concentration of the salts and other components, such as formamide, dextran sulfate, and polyethylene glycol, of the hybridization solution. All of these factors may be varied to 5 generate conditions of stringency which are equivalent to the conditions listed above

In one embodiment, in addition to the labeled cDNA, the hybridization solution contains poly dA<sub>40-60</sub> (8 mg/ml), yeast tRNA (4 mg/ml), and CoT1 DNA (10 mg/ml), 3 µl of 20X SSC, and 1 µl 50X Denhardt's blocking solution. Conditions for hybridization of such targets to the probes on the microarray are known to those experienced in the art. Such 10 conditions have been well published. One source for such information is a series of articles in the January 1999 issue (supplement) of Nature Genetics (1999, Nat Genet, supplement, 21:1-60) which are incorporated herein by reference.

After hybridization, determination of the amount of hybridization of the target nucleic acids to individual probes on the microarray, the expression pattern of ARE genes in the cell 15 line or tissue from which the mRNA originated is determined. In one embodiment, the glass slides are washed and read by a GenePix 4000A scanner (Axon Instruments; Foster City, California) to yield gene expression data. The scanner program allows normalization of Cy3 (control sample) and Cy5 (experimental sample) ratios using the β-actin control probe on the array. The intensity ratios (Cy3 versus Cy5) represent the relative expression profile of the 20 ARE-genes. Through comparison of such ratios for a specific gene between different samples (e.g., two different cell lines, the same cell line wherein one sample is treated with a drug compared to the other sample which is untreated, two different tissues, etc.) changes in expression of specific ARE genes are determined.

### Examples

25 The following examples are meant to illustrate the preferred aspects of the invention and are not to be construed as limiting the aspects of the invention in any way.

#### Example 1: Computational Derivation of the ARE Motif

An ARE search sequence was defined using sequences that belonged to 57 previously identified ARE-containing mRNAs were used for the computational derivation of the ARE 30 motif.

The selection of these mRNAs for the analysis was based on the ability of the mRNA to meet one of two criteria: i) an mRNA in which the ARE in the 3'UTR had been experimentally shown to affect the half life of that mRNA or, ii) an mRNA in which the ARE in the 3'UTR had not been experimentally shown to affect half life, but the mRNA was 5 known to be transiently induced.

Based on these criteria, the 57 previously identified ARE-containing mRNAs that were used for this computation are: early lymphocyte activation antigen CD69 (Santis, et al., 1995, Eur J Immunol, 25:2142-6.), 6-phosphofructo-2-kinase (PFK-2)/fructose-2,6-biphosphate (Chesney, et al., 1999, Proc Natl Acad Sci U S A, 96:3047-52.), B-cell 10 leukemia/lymphoma2 oncogene (Bcl-2) (Capaccioli, et al., 1996, Oncogene, 13:105-15), c-fos proto-oncogene (Chen, et al., 1994, Mol Cell Biol, 14:416-26.), CHOP/Growth arrest and DNA-damage inducible factor (Ubeda, et al., 1999, Biochem Biophys Res Commun, 262:31-8.), c-myb proto-oncogene (Reeves and Magnuson, 1990, Prog Nucleic Acid Res Mol Biol, 38:241-82), c-myc proto-oncogene (Brewer, 1991, Mol Cell Biol, 11:2460-6.), cyclin D1 15 (Rimokh, et al., 1994, Blood, 83:3689-96.), cyclooxygenase (Lasa, et al., 2000, Mol Cell Biol, 20:4265-74.), endothelin-2 (Saida, et al., 2000, Genomics, 64:51-61.), epidermal growth factor receptor (McCulloch, et al., 1998, Int J Biochem Cell Biol, 30:1265-78.), estrogen receptor  $\alpha$  (Kenealy, et al., 2000, Endocrinology, 141:2805-13.), fibroblast growth factor 2 (Touriol, et al., 1999, J Biol Chem, 274:21402-8.), granulocyte monocyte colony stimulating 20 factor (Reeves and Magnuson, 1990, Prog Nucleic Acid Res Mol Biol, 38:241-82; Brown, et al., 1996, J Biol Chem, 271:20108-12.), glucose transporter 1 (Hamilton, et al., 1999, Biochem Biophys Res Commun, 261:646-51.), granulocyte monocyte colony stimulating factor (Shaw and Kamen, 1986, Cell, 46:659-67.; Winzen, et al., 1999, Embo J, 18:4969-80.), gro- $\alpha$  (Sirenko, et al., 1997, Mol Cell Biol, 17:3898-906.), inducible nitric oxide synthase 25 (Rodriguez-Pascual, et al., 2000, J Biol Chem, 275:26040-9.), interferon- $\alpha$  (Reeves and Magnuson, 1990, Prog Nucleic Acid Res Mol Biol, 38:241-82; Caput, et al., 1986, Proc Natl Acad Sci U S A, 83:1670-4.), interferon- $\alpha$ AA (Caput, et al., 1986, Proc Natl Acad Sci U S A, 83:1670-4.), interferon- $\alpha$ 1 (Reeves and Magnuson, 1990, Prog Nucleic Acid Res Mol Biol, 38:241-82; Caput, et al., 1986, Proc Natl Acad Sci U S A, 83:1670-4.), interferon- $\alpha$ 1B 30 (Caput, et al., 1986, Proc Natl Acad Sci U S A, 83:1670-4.), interferon- $\alpha$ F (Reeves and Magnuson, 1990, Prog Nucleic Acid Res Mol Biol, 38:241-82; Caput, et al., 1986, Proc Natl Acad Sci U S A, 83:1670-4.), interferon- $\alpha$ G (Reeves and Magnuson, 1990, Prog Nucleic Acid Res Mol Biol, 38:241-82; Caput, et al., 1986, Proc Natl Acad Sci U S A, 83:1670-4.),

interferon- $\alpha$ H (Reeves and Magnuson, 1990, *Prog Nucleic Acid Res Mol Biol*, 38:241-82; Caput, et al., 1986, *Proc Natl Acad Sci U S A*, 83:1670-4.), interferon- $\alpha$  (Gorospe and Baglioni, 1994, *J Biol Chem*, 269:11845-51.), interferon- $\beta$  (Peppel, et al., 1991, *J Exp Med*, 173:349-55.; Grafi, et al., 1993, *Mol Cell Biol*, 13:3487-93.), interferon- $\gamma$  (Gillis and Malter, 1991, *J Biol Chem*, 266:3172-7.), interleukin-1 $\beta$  (Kastelic, et al., 1996, *Cytokine*, 8:751-61.), interleukin-10 (Kishore, et al., 1999, *J Immunol*, 162:2457-61.), interleukin-2 (Lindstein, et al., 1989, *Science*, 244:339-43.; Henics, et al., 1994, *J Biol Chem*, 269:5377-83.), interleukin-3 (Stoecklin, et al., 2000, *Mol Cell Biol*, 20:3753-63.), interleukin-4 (Reeves and Magnuson, 1990, *Prog Nucleic Acid Res Mol Biol*, 38:241-82), interleukin-6 (Winzen, et al., 1999, *Embo J*, 18:4969-80.), interleukin-8 (Winzen, et al., 1999, *Embo J*, 18:4969-80.), interleukin-11 (Yang and Yang, 1994, *J Biol Chem*, 269:32732-9.), lymphotoxin (Reeves and Magnuson, 1990, *Prog Nucleic Acid Res Mol Biol*, 38:241-82), K-ras proto-oncogene (Quincoces and Leon, 1995, *Cell Growth Differ*, 6:271-9.), leukemia inhibitory factor (Carlson, et al., 1996, *Glia*, 18:141-51.), macrophage colony stimulating factor (Chambers and Kacinski, 1994, *J Soc Gynecol Investig*, 1:310-6.), macrophage chemotaxis protein-1 (Bhattacharya, et al., 1999, *Nucleic Acids Res*, 27:1464-72.), macrophage inflammatory protein- $\alpha$  (Wang, et al., 1999, *Inflamm Res*, 48:533-8.), macrophage inhibitory protein-2 $\alpha$  (Hartner, et al., 1997, *Kidney Int*, 51:1754-60.), Mda-7 (Madireddi, et al., 2000, *Oncogene*, 19:1362-8.), Monocyte Chemotactic Protein-3 (Kondo, et al., 2000, *Immunology*, 99:561-8.), MYCN (Chagnovich and Cohn, 1997, *Eur J Cancer*, 33:2064-7.), Nerve growth factor (Caput, et al., 1986, *Proc Natl Acad Sci U S A*, 83:1670-4.; Sherer, et al., 1998, *Exp Cell Res*, 241:186-93.), platelet-derived growth factor/c-sis proto-oncogene (Liang and Pardee, 1992, *Science*, 257:967-71.), Pim-1 proto-oncogene (Wingett, et al., 1991, *J Immunol*, 147:3653-9.), plasminogen activator inhibitor type 2 (Maurer, et al., 1999, *Nucleic Acids Res*, 27:1664-73.), thioredoxin reductase (Gasdaska, et al., 1999, *J Biol Chem*, 274:25379-85.), tissue factor (Ahern, et al., 1993, *J Biol Chem*, 268:2154-9.), tumor necrosis factor (Shaw and Kamen, 1986, *Cell*, 46:659-67.; Zubiaga, et al., 1995, *Mol Cell Biol*, 15:2219-30.), urokinase-type plasminogen receptor (Montero and Nagamine, 1999, *Cancer Res*, 59:5286-93.), urokinase-type plasminogen activator (Montero and Nagamine, 1999, *Cancer Res*, 59:5286-93.) and vascular endothelial growth factor (Pages, et al., 2000, *J Biol Chem*, 275:26484-91.).

The 3'UTR regions of these mRNA sequences were extracted computationally using the Assemble program (Genetics Computer Group; Madison, Wisconsin) which extracted the sequences downstream of the coding sequence (i.e., >CDS). The 57 3' UTRs were then

analyzed by the MEME (multiple expectation maximization for motif elicitations) program which finds conserved ungapped short motifs within a group of related, unaligned sequences (Bailey and Gribskov, 1998, J Comput Biol, 5:211-21.). MEME yielded the motif pattern UAUUUAWW. Next, a consensus analysis around this motif was performed, which resulted  
 5 in the pattern WWWUAUUUAUWWWW (W = A or U) with a certainty level of 75% at each position (Table 1).

Table 1. Context Frequency Analysis around the 8-bp MEME-derived ARE search sequence

Base	-3	-2	-1	U	A	U	U	U	A	W	W	+1	+2	+3
A	53	28	23	0	100	0	0	0	100	0	25	29	17	55
T(U)	28	50	56	100	0	100	100	100	0	100	75	71	68	27
C	8	13	10	0	0	0	0	0	0	0	0	0	6	6
G	11	9	11	0	0	0	0	0	0	0	0	0	9	13
Consensus: AUUUAUUUAUUUUA (at 50% certainty level)														
WWWUAUUUAUWWWW (at 75% certainty level)														

Example 2: Determination of the Sequence Database to Search for AREs

10 The goal was to search a human database to identify sequences containing the ARE search sequence, WWWUAUUUAUWWWW, that was determined in Example 1. To do this, the sequences to be searched had to be obtained. This was done as described below.

15 A total of 36,951 human mRNA/cDNA sequences were extracted from GenBank Release 113 (National Center for Biotechnology Information, NCBI) using Lookup program (Genetics Computer Group) that was used to find mRNA or cDNA in the Definition Field along with *Homo sapiens* in the Organism Field (Source) in GenBank entries. Subsequently, a PERL code (Practical Extraction and Report Language) was written to extract the sequences that contained the field CDS in the Features Table (indicating the sequence

included a protein coding region) in order to exclude those sequences which did not have CDS. This resulted in 27,403 CDS-containing mRNA/cDNA sequences. This file was used as the input to another PERL program that extracted sequences with complete CDS (i.e., without ambiguous CDS such as <, >, complement or join). The output was 15,148 full-length CDS-containing sequences in an mRNA/cDNA file. The 3'UTRs of the sequences in this file were constructed using the Assemble program (Genetics Computer Group), which extracted the sequences downstream of CDS (i.e., >CDS). This was done in order to obtain the 3'UTR region of the genes where the ARE sequences would be found. This 3'UTR extraction step was necessary because most of the GenBank records lack the 3'UTR as an annotated Feature key, despite the fact this information can be extracted computationally from CDS Feature as executed here. The UNIX command, Stream Editor (Sed), was used to remove sequences that had no 3'UTR. A resultant list of 13,057 human full-length CDS/3'UTR-containing mRNA sequences was finally compiled.

Example 3: Searching the Database for ARE Search Sequences

The 13-bp pattern determined in Example 1 (WWWUAUUUUAUWWW ) was searched in the 13,057 sequences determined in Example 2 using FindPattern (Genetic Computer Group). The stringency was decreased by allowing one mismatch in each direction of the nucleotides flanking the core pattern (UAUUUAU), in order to allow maximum recovery from the search. This step was performed on the 3'UTRs of the full-length CDS/3'UTR-containing mRNA list. The resulting subset of sequences was made minimally redundant using the CLEANUP program (Grillo, et al., 1996, Comput Appl Biosci, 12:1-8.) with the parameters of 90% similarity and 90% overlap, which produced an output file that contained the longest available sequences. Approximately 17% redundancy in the ARE-mRNA list was computationally removed. A total of 897 minimally redundant sequences (see listing at end of examples), approximately 8% of the human mRNA sequences analyzed, were finally obtained and subsequently termed the "ARE-mRNA database (ARED)." This database was stored as flat GenBank files and imported for further analysis into the commercial Vector NTI software version 5.5 (InforMax; Bethesda, Maryland). Each sequence in the database contained the 3'UTR, full-length CDS (i.e., protein coding sequence), and at least 10 bp of 5'UTR.

Example 4: Testing the Specificity of the ARE Search Sequence

In Example 3, the consensus ARE sequence determined in Example 1 was used to search a database of 3'UTR sequences, as determined in Example 2. As an independent check on the specificity of the consensus ARE sequence (i.e., that it is specific to the 3'UTR), the ARE sequence was searched in the complete ARED database, which contained both 5 3'UTR sequences as well as coding sequences, using Assemble and FindPattern. The data show that the 13-bp ARE pattern with 2 mismatches (one on each side of the core UAUUUUAU pattern) was highly selective (89% specificity) towards the 3'UTR when compared to CDS ( $P<0.0001$ ). The selectivity could also be increased to 96%, although this was at the expense of losing some ARE-containing sequences (Table 2).

Table 2. Statistical characteristics of the computationally-derived ARE pattern in 3'UTR and CDS

3'UTR					CDS					<i>P</i> value <sup>6</sup>
No. Mismatch	No. <sup>1</sup>	Finds <sup>2</sup>	Mean <sup>+</sup> S.D. <sup>3</sup>	% <sup>4</sup>	No. <sup>1</sup>	Finds <sup>2</sup>	Mean <sup>+</sup> S.D. <sup>3</sup>	% sp <sup>5</sup>		
0	276	349	1.3 $\pm$ 0.7	31%	2	3	N.A.	>99%	N.A.	
1	736	3670	4.9 $\pm$ 6	82%	27	50	1.85 $\pm$ 3	96%	0.0001	
2	897	9781	10.9 $\pm$ 12	100%	98	233	2.37 $\pm$ 3.7	89%	0.0001	

The ARE-mRNA list of 897 was verified against 3'UTR and CDS for the specificity and database coverage of the 13-bp pattern under different search stringency conditions (e.g., with 1 mismatch and 2 mismatches in nucleotides flanking the conserved core) used for computational compilation of the ARE-containing database.

<sup>1</sup>No. of mRNA sequences with the 13-bp ARE search sequence present either in the 3'-UTR or in the CDS (protein coding sequence) retrieved by the search..

<sup>2</sup>Indicates the number of ARE patterns found in each subset.

<sup>3</sup> Mean of finds of the 13-bp ARE pattern per 3'UTR or CDS.

<sup>4</sup>% Coverage = % (no. of 3'UTR with ARE pattern /total 897 mRNA sequences).

<sup>5</sup>% Specificity (% sp) = 1- (CDS containing the pattern/total 897 mRNA sequences).

<sup>6</sup>P values indicate statistical significance between the mean of 13-bp ARE pattern per ARE mRNA using unpaired t-test with Welch correction (used because of the significantly different variances as verified by F test, P<0.0001).

N.A = not applicable due to the small number of finds.

A distinguishable feature of the 13-bp ARE search sequence in typical ARE-mRNAs is that a significant number of ARE mRNAs (about 40% of total ARE-mRNAs) have continuous patterns of AUUUA ( $n > 1$ ) with the predominant pattern of  
5 WWWUAUUUAUUUAWW.

#### Example 5: Mining for ARE Genes using GENSCAN

GENSCAN is a software program designed to predict complete gene structures based on a probabilistic model of the gene structure of human genomic sequences (Burge and Karlin, 1997, J Mol Biol, 268:78-94.). Such model incorporates descriptions of the basic  
10 transcriptional, translational and splicing signals, as well as length distributions and compositional features of exons, introns and intergenic regions.

There are two instances in which the GENSCAN program is used. In the first instance, GENSCAN is used to analyze the gene sequences obtained after searching a genomic database for genes containing an ARE search sequence using a program such as  
15 FindPattern. Such an analysis is used to eliminate those genes that contain the ARE consensus sequence in a region of the gene other than the 3'UTR (e.g., in an intron or intergenic regions). In the second instance, the GENSCAN program is used as an alternative

to using the FindPattern analysis routine. FindPattern identifies a gene that contains a consensus ARE sequence, for example, wherever that sequence occurs within the gene. GENSCAN, however, can be used to identify only those genes in which the ARE consensus sequence occurs in the 3'UTR of the gene. GENSCAN predicts the coding segments of a genomic area. Thus, GENSCAN can be used to predict an ARE gene. First, the FindPattern program is used to locate the ARE gene upstream of the ARE region. This upstream genomic region is then subjected to GENSCAN or another computer gene prediction program to give an output of protein coding region and predicted amino acid sequence.

Example 6: Isolation of RNA from Cells

In addition to computational identification of genes containing ARE sequences, laboratory isolation of these, as well as previously unidentified ARE-containing genes, was also performed. The first step in laboratory isolation of ARE-containing genes was isolation of RNA from cells.

In this study, the monocytic leukemia cell line, THP-1 (American Type Culture Collection; Rockville, MD), was used. This cell line was known to produce the ARE mRNA, interleukin-8 (IL-8) and  $\beta$ -actin, which will be discussed later. The cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum. This cell line was treated with lipopolysaccharide (LPS), an inducer of cytokines (Al-Humidan, et al., 1998, Cell Immunol, 188:12-8.), and cycloheximide (CHX), which blocks protein synthesis and increases expression of early response genes that do not require protein synthesis for transcription (Reeves and Magnuson, 1990, Prog Nucleic Acid Res Mol Biol, 38:241-82) and increases ARE-mRNA stability (Shaw and Kamen, 1986, Cell, 46:659-67.)

Total RNA was extracted from the cells using the guanidine isothiocyanate method using Tri Reagent (Molecular Research Center; Cincinnati, Ohio). The RNA was subject to DNase I treatment, followed by chloroform extraction, precipitation and resuspension in diethyl pyrocarbonate-treated (DEPC) water.

Example 7: Selective Amplification of ARE mRNAs by Reverse Transcription

To isolate ARE genes, the isolated RNA described in Example 6 was reverse transcribed into DNA. Reverse transcription of the isolated RNA used a 13 nucleotide long degenerate primer of sequence WWWTAAATAAAT. Reverse transcription was performed

in a 20  $\mu$ l volume in a nuclease-free microcentrifuge tube. Total RNA (0.5  $\mu$ g) was heated with different concentrations of primer to 70°C for 10 min before quick chill on ice. Contents were collected by brief centrifugation and the following were added: 1X First Strand Buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl<sub>2</sub>), 500  $\mu$ M dNTP mixture (GIBCO BRL; Gaithersburgh, Maryland), 10  $\mu$ M dTT (GIBCO BRL), and 20 U RNAsin (Pharmacia; Uppsala, Sweden). Contents of the tube were mixed gently and incubated at appropriate temperatures. SuperScript II (Rnase H-minus MMLV; GIBCO BRL) enzyme then was then added and incubated for two hours. The reaction was inactivated by boiling.

At this point, a pool of first strand cDNA was obtained. Because the WWWTAAATAAAAT primer should have hybridized specifically to mRNAs containing ARE elements, those mRNAs should have been preferentially reverse transcribed into first strand cDNA. mRNAs that did not contain ARE elements should have been less preferentially reverse transcribed.

To test whether mRNAs containing ARE elements had been preferentially reverse transcribed, the amounts of cDNAs in the first strand cDNA pool corresponding to two sample genes was determined. The first gene, interleukin-8 (IL-8), contains discontinuous multiple nonamers, VWAUUUAUU, in its 3'UTR. IL-8, therefore, is a gene that encodes an ARE-containing mRNA. The second gene, the housekeeping gene  $\beta$ -actin, contains a single non-typical ARE pentamer, UCAGG(AUUUA)AAAA in its 3'UTR.  $\beta$ -actin, therefore, encodes an mRNA that is considered not to contain an ARE element. This is the control.

The first strand cDNA pool was used as a template for PCR amplification of IL-8 and  $\beta$ -actin. Determination of the ratio of PCR products of IL-8 relative to  $\beta$ -actin is a measure of the relative abundance of the two first strand cDNAs in the pool of cDNAs made by reverse transcription.

For amplification of IL-8 cDNA, the primers were as follows: IL-8, sense, ATGACTTCCAAGCTGGCCGTGGCT; IL-8 antisense, TCTCAGCCCTCTTCAAAAACTTCTC. For amplification of  $\beta$ -actin cDNA, the primers were as follows:  $\beta$ -actin sense; ATGGATGATGATATGCCGCG;  $\beta$ -actin, antisense; CTCCTTAATGTCACGCACGATTTC. PCR was performed using 40  $\mu$ g of cDNA with the following reagents in their final concentrations of: 1 unit of Taq polymerase (Perkin-Elmer),

1X PCR buffer (Perkin-Elmer), 10  $\mu$ M of each of dATP, dCTP, dGTP, and dTTP, 1  $\mu$ M of both sense and antisense primers. Hot start, (i.e., adding Taq polymerase to the reaction tubes during heating tubes for 10 min. at 95°C) was used or, alternatively, Taq polymerase was pre-incubated with antibody to Taq (Sigma; St.Louis, Missouri.) which rendered the Taq 5 polymerase inactive until reactivated by heating in the first denaturation cycle. The cycling conditions were as follows: Four initial cycles of 94°C for 1 min, 35°C (variable temperature) for 2 min, 72°C for 2 min; Twenty five cycles of 94°C for 45 sec, 60°C for 1 min, 72°C for 2 min; Final extension cycle of 72°C for 7 min, 4°C for overnight storage.

The results of this experiment are shown in Fig. 1. cDNAs made with different 10 concentrations of primer and at different temperatures were tested. By comparing the intensities of the IL-8 bands with the intensities of the  $\beta$ -actin bands when moving from left to right in Fig. 1, it is seen that the ratio of IL-8 to  $\beta$ -actin increases. In lane 5 of Fig. 1, synthesis of cDNA from  $\beta$ -actin was almost completely suppressed. Under these conditions (25  $\mu$ g/ml of primer and 52°C reaction temperature ), cDNA synthesis was specific for the 15 ARE-containing IL-8 mRNA.

The disaccharide, trehalose, was used for further refinement for suppression of  $\beta$ -actin 20 cDNA abundance while maintaining selection of ARE cDNAs (Fig. 2). RNA was mixed with ARE primers and heated in a 30% glycerol solution at 65°C for 10 min, and cooled to 50°C. The RT buffer mix was as described above, but contained trehalose (80% w/v) and 0.1% BSA. The final concentration of trehalose in the RT reaction was approximately 20% w/v. Superscript II was added at 200 U per reaction, and the reactions were brought to an annealing temperature of 55-60°C for 2 min. Finally, the reaction proceeded by further incubation for 1 hr until inactivated by boiling. PCR was then performed as described above.

The result of trehalose addition to the reverse transcription reactions was higher 25 specificity of the reverse transcription reaction for the ARE-containing mRNAs as compared to reverse transcription of mRNAs that did not contain an ARE consensus sequence.

As shown in Fig. 2, the inclusion of trehalose, and thus, higher annealing temperature of as high as 60°C, resulted in dramatic suppression of abundant cDNA without affecting the less abundant IL-8 cDNA signal

30 Example 8: Computational Derivation of Motifs in the 5'UTR or ARE-containing mRNAs

In order to clone the sequences representative of ARE-containing first-strand cDNAs made in Example 7, the cDNAs were amplified. In one embodiment, this was done by PCR amplification. This PCR amplification used the 3' primers representative of the consensus ARE sequence motif. An additional primer, derived from the 5' region of the ARE-containing cDNA was also required. Such 5' primers were derived from the region of the gene encompassing the translation start site of the gene, which includes the ATG start codon. Design of the 5' primers is described in this example below.

The 5'UTR initiation context sequences (i.e., those that flank the start codon, ATG) of sequences in the ARE-mRNA database (the 897 genes described in Example 3) were analyzed. It is known that nucleotide sequences surrounding ATG start codons are conserved (Kozak, 1987, Nucleic Acids Res, 15:8125-48.; Kozak, 1987, J Mol Biol, 196:947-50.). Thus, this region was chosen to design 5' primers with the idea that ARE genes would have a slightly different conservation of sequences surrounding the ATG as compared to all genes.

Out of 897 ARE genes, 605 had at least 10 bp upstream (or 5') of the ATG start codon in the database. These 605 sequences were used to examine the region around the ATG start codon. The 605 sequences were divided into either four or sixteen subsets by using the sequence designations ATGN and NATGN, respectively (N = A or C or G or T). This was followed by alignment of the truncated 5'UTR (-7bp ATG, +2bp) of the 605 sequences using the PileUP program (Genetics Computer Group). Four and sixteen consensus patterns at a certainty level of 75% at each position were derived from the alignment (Table 3). It is important to note that the consensus sequences in Table 3 are the most frequently occurring. Therefore, not every sequence in the ARED database is represented here.

The overall consensus initiation site in the ARE mRNA database was SSMAMSATGRM at a 50% certainty level at each position. In comparison, the initiation consensus of non-clustered random human sequences was SSSRMSATGRM. The conserved pattern, CACCATGG was also noted in Table 3 and appears in approximately 30% of total ARE mRNAs. It is similar to the Kozak sequence CRCCATG previously reported and to the pattern of the larger lists available at the TransTerm database<sup>1</sup>, CAMCATGGC.

---

<sup>1</sup>TransTerm is a database containing sequence information on the start and stop codons, as well as the codon usage data, for many different species. The URL is: <http://uther.otago.ac.nz/Transterm.html>

Table 3. Consensus sequences of initiation context sequences in human ARE mRNAs

*Based on 4 divisions (ATGN):*

A	VRVVRVV <u>ATGAV</u>
C	VVVDRV <u>BATGCH</u>
G	VVBVRVV <u>ATGGM</u>
T	VDBVRHV <u>ATGTY</u>

*Based on 16 divisions (NATGN):*

Aa	BHDVMMA <u>ATGAV</u>
Ca	BSHMRVC <u>ATGAV</u>
Ga	HBVVRV <u>GATGAD</u>
Ta	BDDVRHT <u>ATGAM</u>
Ac	HDDVRBA <u>ATGCD</u>
Cc	VRSVRMC <u>ATGCB</u>
Gc	SSBBRMG <u>ATGCB</u>
Tc	VBDWWRT <u>ATGCM</u>
Ag	VVBVRMA <u>ATGGV</u>
Cg	VVVVRSC <u>ATGGM</u>
Gg	BVVSRVG <u>ATGGM</u>
Tg	VDBHRBT <u>ATGGM</u>
At	DRBVRMA <u>ATGTY</u>

Ct	BVBMRYCATGTS
Gt	VDBVRRGATGTY
Tt	DVBVWDTATGTY
<p>Truncated 5'UTRs regions of 605 ARE mRNAs that include -7bp, ATG, +2bp were stratified into either four or sixteen subsets from ARE mRNA sequences based on the formulas ATGN and NATGN, respectively. The truncated 5'UTR regions in each subset were aligned using PileUP (Genetics Computer Group) and consensus sequences were obtained using the Consensus program (Genetics Computer Group) at 75% probability. Letter codes follow ambiguous DNA IUB codes, e.g., N = A, C, G, or T. M = A or C; R = A or G; W = A or T; S = C or G; Y = C or T; K = G or T; V = A or C or G; H = A or C or T; D = A or G or T; B = C or G or T.</p>	

Statistical analysis of the four and sixteen 10-mer (-6 ATG, +1) consensus sequences was performed (Table 4). Sequences in each of the sixteen subsets were analyzed for initiation context sequences. Each consensus pattern contains five conserved nucleotides (i.e., ATG with one flanking nucleotide in each direction), and six additional upstream degenerate nucleotides and one additional downstream nucleotide. The most common consensus in initiation regions is Cg consensus VVVVRSCATGGM (Table 4). Other frequent initiation consensus are Ca, Ag, and Gg. Each accounts for approximately 9-10% of all ARE mRNAs.

Not all consensus sequences were unique to the initiation regions. This means that the consensus sequences could be found in areas of the mRNA sequence that did not contain the translation initiator ATG (e.g., within the protein coding sequence). Depending on the specific consensus sequence, there were varying degrees of internal sites in addition to the initiation region. The most common consensus sequence around any ATG was the Aa consensus (Table 4) which existed in 39% of the entire ARE-mRNA molecules. The least occurring consensus sequences were those flanked by a T upstream of ATG, e.g., Ta, Tc, Tg, and Tt consensus. The highest proportion of consensus in initiation regions in any subset was the Gc consensus in which 71% of the sites (initiation plus internal) were initiation

sequences. The overall consensus site per mRNA ranged from 1.0 to 1.65 (i.e., >1 if the consensus sequence found in mRNAs other than at the translation initiation region).

Table 4. Theoretical Behavior of Amplified ARE cDNA

## (a) Statistics based on Cluster Group II

	No. mRNA/ Subset <sup>1</sup>	No. mRNA targeted by 10-mer <sup>2</sup>	No. total sites <sup>3</sup>	Site per mRNA <sup>4</sup>	% full length-CD- containing mRNAs
A	24 (24%)	61 (62%)	102	1.7	40%
C	22 (22%)	23 (23%)	23	1	96%
G	42 (42%)	76 (77%)	124	1.6	55%
T	11 (11%)	36 (36%)	50	1.4	30%

## (b) Statistics based on Cluster Group III

Primer	No. mRNA/ Subset <sup>1</sup>	No. mRNA targeted by 10-mer <sup>2</sup>	No. Total sites <sup>3</sup>	Site per mRNA <sup>4</sup>	% Full length-CD- containing mRNAs
aA	22 (6%)	134 (39%)	249	1.9	16%
cA	42 (12%)	143 (42%)	198	1.4	29%
gA	19 (6%)	128 (38%)	185	1.4	29%
tA	14 (4%)	81 (24%)	97	1.2	17%
aC	8 (2%)	104 (31%)	150	1.4	8%
cC	16 (5%)	99 (29%)	130	1.3	16%

gC	22 (6%)	94 (28%)	114	1.2	23%
tC	10 (3%)	50 (15%)	58	1.2	20%
aG	27 (8%)	116 (34%)	144	1.2	23%
cG	68 (20%)	165 (49%)	227	1.4	41%
gG	34 (10%)	130 (38%)	173	1.3	26%
tG	8 (2%)	60 (18%)	62	1	13%
aT	12 (3%)	47 (14%)	48	1	25%
cT	11 (3%)	49 (14%)	54	1.1	22%
gT	8 (2%)	85 (25%)	109	1.3	9%
tT	7 (2%)	60 (18%)	68	1.1	12%

<sup>1</sup>Number of mRNA sequences (percentage) of the total ARE-containing mRNA sequences in each of the 4 (ATGN) or 16 (NATGN) subsets.

<sup>2</sup>Number of sequences (percentage) of ARE-containing mRNA sequences in the overall ARE-containing mRNA database (i.e., includes consensus sequences found other than at the translation initiation site).

<sup>3</sup>Total number of sites (hits) in mRNA sequences in the ARED database (includes consensus sequences found other than at the translation start).

<sup>4</sup>Average number of hits per mRNA.

<sup>5</sup>% full length mRNA (i.e., the percentage of mRNAs recognized by the consensus probe that are full length mRNAs) is obtained by dividing column 2 (No. mRNA/subset) by column 4 (No. total sites). If the consensus sequence is infrequently found at sites other than the translation start, this percentage will be nearer to 100%).

#### Example 9: Amplification of ARE cDNAs by PCR

Once first strand cDNA was synthesized from cellular RNA, the first strand cDNA had to be made into double-stranded DNA and the double-stranded DNA had to be amplified.

- 5 In this example, amplification of the double-stranded DNA was done using PCR, 5' primers

comprising those described in Example 8 and 3' ARE-specific primers described earlier in this application.

A PCR-protocol called ARE-cDNA PCR was used to selectively amplify ARE-cDNA. The selective amplification of ARE cDNA was verified using specific PCR to known 5 ARE mRNA molecules with various numbers of ARE repeats (IL-8, c-fos, and TNF- $\alpha$ ), and monitoring the abundance of the non-ARE  $\beta$ -actin signal, as in Example 7. TNF- $\alpha$  mRNA contains continuous stretches UUAUUUAUU (AUUUA)<sub>5</sub>, while IL-8 contains discontinuous multiple nonamers in the ARE flanking region. The proto-oncogene, c-fos, has two continuous overlapping nonamers, i.e., UAAUUUAUUUAUU. As discussed earlier,  $\beta$ -actin, 10 encodes an mRNA that is considered not to contain an ARE element. The goal of ARE-cDNA PCR was to amplify the typical ARE-cDNAs and concurrently suppress amplification of non-ARE sequences.

Using the optimized ARE-cDNA PCR (as described in Example 6 and as modified in the Brief Description of Fig. 3), both IL-8 and TNF- $\alpha$  cDNAs were specifically amplified 15 when compared to  $\beta$ -actin cDNA signal (Fig. 3). Fig. 3 also shows additional data on the optimum annealing temperature and PCR cycle number. For example, small differences in ARE annealing temperatures, i.e., during the first four cycles, have significant effects on specificity in the case of IL-8 which has discontinuous multiple nonamers (Fig. 3a), but not with TNF- $\alpha$  which has continuous overlapping multiple nonamers (Fig. 3b).  $\beta$ -actin signal 20 abundance was virtually suppressed in all lanes.

In all of the experiments, DNA contamination was monitored by lack of larger PCR products, as primers for the specific PCR were designed to span more than one exon. The specific amplifications of TNF- $\alpha$  and IL-8 cDNA, which were performed following ARE-cDNA PCR was not due to carryover cDNA, which has an amount of 4 ng, and was 25 performed under high stringency conditions including the use of 50  $\mu$ M of dNTP and 25 cycles.

Example 10: RNA-ligase mediated amplification followed by specific PCR amplification of sequences containing ARE

As an alternative to selective reverse transcription or selective amplification of ARE-containing mRNAs into first strand cDNA, an alternative is RNA-ligase mediated amplification (Fig. 4).

To perform this procedure, called RL-ARE-PCR, total RNA was reversed transcribed by SuperScript II as described in Example 7 except that the primer used was oligo(dT) that had been modified at its 3'-end by the addition of NH<sub>2</sub>. To this cDNA reaction, 2 units of RNase H were added and incubated at 37°C for 20 min, then incubated at 90°C for 2 min. The cDNA in the reaction was then ligated with 5'-phosphorylated and NH<sub>2</sub> 3'-end modified oligomers (RL oligo; Operon Technologies, Inc.; Alameda, CA). The 3'end of oligo(dT) and the RL oligo primer were blocked with the amino (NH<sub>2</sub>) groups to prevent the self ligation or the inter-ligation of the oligo(dT) and RL oligomers. The 25 µl reaction contained the following: 2.5 µl of 10X ligase buffer, 16.7 ul (2ug) of cDNA, 01.0 ul (10U) of T4 RNA ligase, 01.0 ul (0.5ug) of the 3'-end NH<sub>2</sub> blocked and 5'-end phosphorylated primer. This reaction was incubated at 37°C for 1.5 hrs, followed by incubation at 16°C for 1.5 hrs, and then at 100°C for 2 mins.

This was followed by amplification of the RL-ligated cDNA with a 5'-primer specific to the RL sequence and 3'primer specific to ARE-regions. PCR was performed as described in Example 7. The primers used for this PCR were GACTCCACAAACCACGACACA and PTGTGTCGTGGTTGTGGAGTCL, where P = phosphate and L = amino linker. This PCR experiment verified amplification of the ARE-cDNA, TNF-α, but not β-actin (Fig. 5).

#### Example 11. Cloning of the PCR products

Cloning of the PCR products was needed to construct libraries of the ARE genes. A pilot construction of a pUC19 mini-library was performed using the amplified ARE-PCR products generated from the optimum conditions of RL-ARE-PCR (Fig. 5). This was done by taking the PCR products and then treating them with the Klenow fragment of DNA polymerase I and dNTPs to make the DNA ends of the PCR products blunt. The blunted ends were then phosphorylated using T4 kinase. The DNA was extracted with phenol and chloroform. The PCR products were then ligated into pUC19 plasmid vectors which had been made linear with a restriction endonuclease. Such plasmid had ends that were blunt and had been enzymatically dephosphorylated, preferably with alkaline phosphatase. The ligated plasmids were used to transform bacteria.

Bacterial colonies resulting from the transformation were randomly picked and mini-plasmid preparations were performed for evaluation purposes. The average size of the amplified inserts was 600 bp and the insert size range from 350-800 bp. This size range was satisfactory for the purpose of generating cDNA spotted probes of the microarray. The 5 inserts of said clones were sequenced to provide DNA sequence information of said inserts. The sequences of many of these clones were found in publicly available sequence databases. The sequences of other of these clones were not found in such databases, suggesting that such clones identify previously unknown genes. The sequences of a number of such clones are shown in Fig. 7.

10 Example 12. Making and using ARE Microarrays

This study describes making a microarray containing DNA sequences representative of ARE genes. Such microarrays are for use in gene expression analysis.

To make such a microarray, Unigene cluster IDs were obtained for the 897 genes in the ARE database (ARED). For genes among the 897 that had no Unigene cluster ID, and for 15 ARE genes contained in the ARE libraries (Example 11), sequence information from those genes was used as input for BLASTN to retrieve genes corresponding to those sequences, and the corresponding Unigene cluster IDs. The Unigene cluster IDs were then used to extract the corresponding clones from the 40K set of clones of Research Genetics, Inc., which has the majority of ARE-cDNAs. In addition, individual IMAGE clones were also purchased and 20 custom sequence-verified. Additionally; a list of 30 housekeeping genes (control genes) was compiled to be included on the array for purposes of quality control and normalization.

The cDNA clones, as glycerol culture stocks, were grown in 96-well growth blocks. The probe cDNAs that were spotted onto glass slides were obtained by PCR amplification of the insert DNAs from the clones. Purified plasmid DNA served as templates for the PCR 25 reactions. The plasmids were prepared using commercial plasmid mini-preparation kits. All PCR reactions were carried out in 96-well thin wall PCR plates. The reaction mixtures contained 20 mM Tris-HCL (pH 8.4), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.8 mM of each dATP, dGTP, dTTP, and dCTP, 0.1 μM forward oligonucleotide primer (5'GTTGTAAAACGACGGCCAGTG), 0.1 μM reverse oligonucleotide primer 30 (5'CACACAGGAAACAGCTATG), and 5 units Taq DNA polymerase. The reactions had a total volume of 100 μl, and contained 100-300 ng of purified plasmid to provide the template

DNA. PCRs were performed using the following thermal cycler program: 1 cycle of 94 °C for 2 min, 27 cycles of 94 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 2.5 min, 1 cycle of 72 °C for 5 min. The PCR products (5 µl of the reaction) were then analyzed by agarose gel electrophoresis and could be stored at -20 °C until further processing. The PCR products were 5 further processed in 96-well format either by ethanol precipitation or using commercially available DNA purification plates. Purified or precipitated PCR products were resuspended in a salt solution (e.g. 3X SSC).

These resuspended DNAs were the probe DNAs that were spotted onto glass slides to give the ARE-containing gene array. The slides were first coated with poly-L lysine. The 10 poly-L-lysine slide coating procedure was as follows. A batch of plain Gold Seal microscope slides was incubated in cleaning solution (2.5 M NaOH in 60 % ethanol) under agitation for two hours. Subsequently, the slides were rinsed with distilled water five times, each rinse lasting 5 minutes. The slides were then incubated in poly-L-lysine solution (0.01% poly-L-lysine in 0.1X standard tissue culture PBS) for one hour under agitation. Slides were then 15 rinsed in distilled water for one minute, and any free liquid was removed by centrifugation of the slides at low speed. The coated slides were stored dust free and could be used for array printing for several weeks.

The probe DNAs were arrayed onto the slides using a SDDC-2 microarray robot from ESI (Engineering Services Inc.; Toronto, Canada). The setup used eight print-pins, 20 delivering eight individual probe DNAs simultaneously to each slide, and washing the pins twice in water between every probe pick-up step. The probe DNAs were contained in 384-well plates to minimize loss by evaporation during the printing procedure. The size of the array area on each slide depended on the number of probe DNAs in the array. The distance between the centers of neighboring DNA spots was 200 µm. All probe DNAs were spotted 25 onto each array at least in duplicate. For example, an array of 1000 genes (hence 2000 array spots) printed from a 384-well plate using eight print-pins will covered an area on the slide of approximately 170 mm<sup>2</sup>. After the printing, the array slides were stored dust free for 2-4 days before UV cross-linking.

The arrayed probe DNA was cross linked to the poly-L-lysine coat using a 30 Stratalinker (Stratagene) with a UV dose of 450 mJ. The positive charges of the lysine residues on the array slides were neutralized by incubating the slides in a freshly prepared solution of 1.7% succinic anhydride in 1-methyl-2-pyrrolidinone/77mM borate buffer for 30

minutes. The slides were then submerged for two minutes in first, distilled water of 95 C, and second 95% ethanol. Excess ethanol was then removed by centrifugation at low speed, and the cDNA microarray was stored dust free at room temperature ready to be used for hybridization.

5 To use the ARE microarrays for gene expression experiments, total RNA (100 ug) samples were extracted from THP-1 cells that were previously treated with CHX and LPS using the Qiagen Rneasy RNA purification kit and refined by Trizol reagent (GibcoBRL). The RNA samples were labeled with Cyanine-3-dUTP (Cy3, green) and Cyanine-5-dUTP (Cy5, red, Amersham), in two separate RT reactions using olig(dT)<sub>11-18</sub> primers and  
10 SuperScript II RT. The labeled cDNA samples were hydrolyzed by NaOH and purified on Micro Bio-Spin® 6 chromatography column (Bio-Rad) and concentrated in TE buffer. The labeled cDNA sample mixture was hybridized to the microarray. The hybridization solution contained poly dA<sub>40-60</sub> (8 mg/ml), yeast tRNA (4 mg/ml), and CoT1 DNA (10 mg/ml), 3μl of 20x SSC, and 1 μl 50x Denhardt's blocking solution. This mixture was applied to the ARE-  
15 cDNA glass slides and hybridized under stringent conditions. Subsequently, the glass slides were washed.

Analysis of hybridization to the microarray used scanning of the microarray with a GenePix 4000A scanner (Axon Instruments). The scanner program allowed normalization of Cy3 (THP-1 control sample) and Cy5 (LPS+CHX treated THP-1 sample) ratios using the β-actin control on the array. Most of the duplicates gave similar readings. The intensity ratios from two cDNA samples measured using the ARE-cDNA microarray represented the relative expression profile of the ARE genes in the two starting RNA samples. Fig.6 shows the expression profile of the ARE-cDNA array showing the differential expression of many ARE-cDNAs (Fig. 6a, 6b). The results supported the ARE functionality, (i) a large proportion were induced at early time points (20 min., Fig. 6b), (ii) many displayed a transient expression pattern (Fig.6c), (iii) a large proportion were independent of protein synthesis (CHX treatment), and (iv) a large proportion were upregulated with CHX treatment.  
20  
25

Table 6

List of ARE-containing mRNA sequences and accession numbers	
A12140	H.sapiens IFN-omega 1 gene.
A18397	Human uPA cDNA.
A18757	u-PA receptor.
A19048	H.sapiens mRNA for thromboplastin (clone 2b-Apr5).
A21239	H.sapiens BTA 1916 mRNA for Pai-2.
A21240	H.sapiens BTA 1922 mRNA for Pai-2.
A26481	Human NPY receptor Y1 gene cDNA.
A30262	H.sapiens beta-casein cDNA.
A35395	H.sapiens u-PA cDNA sequence.
AB000220	Homo sapiens mRNA for semaphorin E, complete cds.
AB000509	Homo sapiens mRNA for TRAF5, complete cds.
AB001106	Homo sapiens mRNA for glia maturation factor, complete cds.
AB001466	Homo sapiens mRNA for Efs1, complete cds.
AB001467	Homo sapiens mRNA for Efs2, complete cds.
AB002292	Human mRNA for KIAA0294 gene, complete cds.
AB002303	Human mRNA for KIAA0305 gene, complete cds.
AB002311	Human mRNA for KIAA0313 gene, complete cds.
AB002314	Human mRNA for KIAA0316 gene, complete cds.
AB002329	Human mRNA for KIAA0331 gene, complete cds.
AB002343	Human mRNA for KIAA0345 gene, complete cds.
AB002350	Human mRNA for KIAA0352 gene, complete cds.
AB002371	Human mRNA for KIAA0373 gene, complete cds.
AB002372	Human mRNA for KIAA0374 gene, complete cds.
AB002373	Human mRNA for KIAA0375 gene, complete cds.

AB002375	Human mRNA for KIAA0377 gene, complete cds.
AB002389	Human mRNA for KIAA0391 gene, complete cds.
AB002804	Homo sapiens mRNA for hSLK, complete cds.
AB003103	Homo sapiens mRNA for 26S proteasome subunit p55, complete cds.
AB003698	Homo sapiens mRNA for Cdc7-related kinase, complete cds.
AB005754	Homo sapiens mRNA for LAK-1, complete cds.
AB006623	Homo sapiens mRNA for KIAA0285 gene, complete cds.
AB006626	Homo sapiens mRNA for KIAA0288 gene, complete cds.
AB006651	Homo sapiens EXLM1 mRNA, complete cds.
AB007454	Homo sapiens mRNA for chemokine LEC precursor, complete cds.
AB007860	Homo sapiens KIAA0400 mRNA, complete cds.
AB007866	Homo sapiens KIAA0406 mRNA, complete cds.
AB007870	Homo sapiens KIAA0410 mRNA, complete cds.
AB007874	Homo sapiens KIAA0414 mRNA, partial cds.
AB007879	Homo sapiens KIAA0419 mRNA, complete cds.
AB007886	Homo sapiens KIAA0426 mRNA, complete cds.
AB007927	Homo sapiens mRNA for KIAA0458 protein, complete cds.
AB007939	Homo sapiens mRNA for KIAA0470 protein, complete cds.
AB007940	Homo sapiens mRNA for KIAA0471 protein, complete cds.
AB007942	Homo sapiens mRNA for KIAA0473 protein, complete cds.
AB007944	Homo sapiens mRNA for KIAA0475 protein, complete cds.
AB007945	Homo sapiens mRNA for KIAA0476 protein, complete cds.
AB007949	Homo sapiens mRNA for KIAA0480 protein, complete cds.
AB007950	Homo sapiens mRNA for KIAA0481 protein, complete cds.
AB008226	Homo sapiens FCMD mRNA for fukutin, complete cds.

AB011103	Homo sapiens mRNA for KIAA0531 protein, complete cds.
AB011107	Homo sapiens mRNA for KIAA0535 protein, complete cds.
AB011109	Homo sapiens mRNA for KIAA0537 protein, complete cds.
AB011122	Homo sapiens mRNA for KIAA0550 protein, complete cds.
AB011134	Homo sapiens mRNA for KIAA0562 protein, complete cds.
AB011137	Homo sapiens mRNA for KIAA0565 protein, complete cds.
AB011141	Homo sapiens mRNA for KIAA0569 protein, complete cds.
AB011143	Homo sapiens mRNA for KIAA0571 protein, complete cds.
AB011420	Homo sapiens mRNA for DRAK1, complete cds.
AB012851	Homo sapiens mRNA for Musashi, complete cds.
AB014517	Homo sapiens mRNA for KIAA0617 protein, complete cds.
AB014526	Homo sapiens mRNA for KIAA0626 protein, complete cds.
AB014528	Homo sapiens mRNA for KIAA0628 protein, complete cds.
AB014551	Homo sapiens mRNA for KIAA0651 protein, complete cds.
AB014552	Homo sapiens mRNA for KIAA0652 protein, complete cds.
AB014560	Homo sapiens mRNA for KIAA0660 protein, complete cds.
AB014569	Homo sapiens mRNA for KIAA0669 protein, complete cds.
AB014585	Homo sapiens mRNA for KIAA0685 protein, complete cds.
AB014588	Homo sapiens mRNA for KIAA0688 protein, complete cds.
AB014598	Homo sapiens mRNA for KIAA0698 protein, complete cds.
AB014605	Homo sapiens mRNA for KIAA0705 protein, complete cds.
AB016193	Homo sapiens Elk1 mRNA, complete cds.
AB016247	Homo sapiens mRNA for sterol-C5-desaturase, complete cds.
AB016899	Homo sapiens HGC6.1.1 mRNA, complete cds.
AB017642	Homo sapiens mRNA for oxidative-stress responsive 1, complete cds.

AB017915	Homo sapiens mRNA for condroitin 6-sulfotransferase, complete cds.
AB018254	Homo sapiens mRNA for KIAA0711 protein, complete cds.
AB018259	Homo sapiens mRNA for KIAA0716 protein, complete cds.
AB018279	Homo sapiens mRNA for KIAA0736 protein, complete cds.
AB018287	Homo sapiens mRNA for KIAA0744 protein, complete cds.
AB018307	Homo sapiens mRNA for KIAA0764 protein, complete cds.
AB018341	Homo sapiens mRNA for KIAA0798 protein, complete cds.
AB018351	Homo sapiens mRNA for KIAA0808 protein, complete cds.
AB018413	Homo sapiens mRNA for Gab2, complete cds.
AB019517	Homo sapiens PKIG mRNA for protein kinase inhibitor gamma, complete
AB020316	Homo sapiens mRNA for dermatan/chondroitin sulfate
AB020639	Homo sapiens mRNA for KIAA0832 protein, complete cds.
AB020642	Homo sapiens mRNA for KIAA0835 protein, complete cds.
AB020651	Homo sapiens mRNA for KIAA0844 protein, complete cds.
AB020655	Homo sapiens mRNA for KIAA0848 protein, complete cds.
AB020659	Homo sapiens mRNA for KIAA0852 protein, complete cds.
AB020686	Homo sapiens mRNA for KIAA0879 protein, complete cds.
AB020700	Homo sapiens mRNA for KIAA0893 protein, complete cds.
AB022663	Homo sapiens HFB30 mRNA, complete cds.
AB023021	Homo sapiens FUT9 mRNA for alpha-1,3-fucosyltransferase IX,
AB023141	Homo sapiens mRNA for KIAA0924 protein, complete cds.
AB023153	Homo sapiens mRNA for KIAA0936 protein, complete cds.
AB023155	Homo sapiens mRNA for KIAA0938 protein, complete cds.
AB023158	Homo sapiens mRNA for KIAA0941 protein, complete cds.
AB023169	Homo sapiens mRNA for KIAA0952 protein, complete cds.

AB023172	Homo sapiens mRNA for KIAA0955 protein, complete cds.
AB023183	Homo sapiens mRNA for KIAA0966 protein, complete cds.
AB023187	Homo sapiens mRNA for KIAA0970 protein, complete cds.
AB023188	Homo sapiens mRNA for KIAA0971 protein, complete cds.
AB023207	Homo sapiens mRNA for KIAA0990 protein, complete cds.
AB023214	Homo sapiens mRNA for KIAA0997 protein, complete cds.
AB023225	Homo sapiens mRNA for KIAA1008 protein, complete cds.
AB026118	Homo sapiens mRNA for MALT1, complete cds.
AB026190	Homo sapiens mRNA for Kelch motif containing protein, complete cds.
AB028964	Homo sapiens mRNA for KIAA1041 protein, complete cds.
AB028965	Homo sapiens mRNA for KIAA1042 protein, complete cds.
AB028967	Homo sapiens mRNA for KIAA1044 protein, complete cds.
AB028996	Homo sapiens mRNA for KIAA1073 protein, complete cds.
AB029024	Homo sapiens mRNA for KIAA1101 protein, complete cds.
AB030653	Homo sapiens mRNA for epsilon-adaptin, complete cds.
AF000145	Homo sapiens germinal center kinase related protein kinase mRNA,
AF000367	Homo sapiens cdc14 homolog mRNA, complete cds.
HSAF000982	Homo sapiens dead box, X isoform (DBX) mRNA, alternative transcript
HSAF000984	Homo sapiens dead box, Y isoform (DBY) mRNA, alternative transcript
HSAF000993	Homo sapiens ubiquitous TPR motif, X isoform (UTX) mRNA,
AF001042	Homo sapiens RNA editase (RED1) mRNA, complete cds.
AF001437	Homo sapiens dihydrolipoamide dehydrogenase-binding protein mRNA,
AF001846	Homo sapiens lymphoid phosphatase LyP1 mRNA, complete cds.

AF002697	Homo sapiens E1B 19K/Bcl-2-binding protein Nip3 mRNA, nuclear gene
AF003837	Homo sapiens Jagged1 (JAG1) mRNA, complete cds.
AF004291	Homo sapiens germ cell nuclear factor (GCNF) mRNA, complete cds.
AF004562	Homo sapiens hUNC18a alternatively-spliced mRNA, complete cds.
AF004563	Homo sapiens hUNC18b alternatively-spliced mRNA, complete cds.
AF004715	Homo sapiens jerky gene product homolog mRNA, complete cds.
AF004841	Homo sapiens CDO mRNA, complete cds.
AF005418	Homo sapiens retinoic acid hydroxylase mRNA, complete cds.
AF006011	Homo sapiens dishevelled 1 (DVL1) mRNA, complete cds.
AF006514	Homo sapiens CHD2 mRNA, complete cds.
AF006621	Homo sapiens embryonic lung protein (HUEL) mRNA, complete cds.
AF007111	Homo sapiens MDM2-like p53-binding protein (MDMX) mRNA, complete
AF008915	Homo sapiens EVI5 homolog mRNA, complete cds.
AF009301	Homo sapiens TEB4 protein mRNA, complete cds.
AF009801	Homo sapiens homeodomain protein (BAPX1) mRNA, complete cds.
AF012072	Homo sapiens eIF4GII mRNA, complete cds.
AF012126	Homo sapiens zinc finger protein (ZNF198) mRNA, complete cds.
AF012535	Homo sapiens death receptor 5 (DR5) mRNA, complete cds.
AF013168	Homo sapiens hamartin (TSC1) mRNA, complete cds.
AF013970	Homo sapiens MTG8-like protein MTGR1b mRNA, complete cds.
AF015592	Homo sapiens Cdc7 (CDC7) mRNA, complete cds.
AF016005	Homo sapiens chromosome 1 atrophin-1 related protein (DRPLA) mRNA,

AF016266	Homo sapiens TRAIL receptor 2 mRNA, complete cds.
AF016268	Homo sapiens death receptor 5 (DR5) mRNA, complete cds.
AF016833	Homo sapiens maltase-glucoamylase mRNA, complete cds.
AF016849	Homo sapiens apoptosis inducing receptor TRAIL-R2 (TRAILR2) mRNA,
AF019047	Homo sapiens receptor activator of nuclear factor kappa B ligand
AF019386	Homo sapiens heparan sulfate 3-O-sulfotransferase-1 precursor
AF019770	Homo sapiens macrophage inhibitory cytokine-1 (MIC-1) mRNA,
AF020089	Homo sapiens PEN11B mRNA, complete cds.
AF021336	Homo sapiens DNA damage-inducible RNA binding protein (A18hnRNP)
AF022375	Homo sapiens vascular endothelial growth factor mRNA, complete cds.
AF022654	Homo sapiens homeodomain protein (OG12) mRNA, complete cds.
AF023456	Homo sapiens protein phosphatase with EF-hands-2 long form (PPEF-2)
AF025654	Homo sapiens mRNA capping enzyme (HCE) mRNA, complete cds.
AF026245	Homo sapiens yotiao mRNA, complete cds.
AF027706	Homo sapiens serine/threonine kinase RICK (RICK) mRNA, complete
AF028593	Homo sapiens transmembrane protein Jagged 1 (HJ1) mRNA, complete
AF029729	Homo sapiens neuralized mRNA, complete cds.
AF030186	Homo sapiens glypican-4 (GPC4) mRNA, complete cds.
AF030409	Homo sapiens sodium-hydrogen exchanger 6 (NHE-6) mRNA, nuclear gene
AF030455	Homo sapiens epithelial V-like antigen precursor (EVA) mRNA,
AF030555	Homo sapiens acyl-CoA synthetase 4 (ACS4) mRNA, complete cds.
AF030880	Homo sapiens pendrin (PDS) mRNA, complete cds.

AF031167	Homo sapiens interleukin 15 precursor (IL-15) mRNA, complete cds.
AF032885	Homo sapiens forkhead protein (FKHR) mRNA, complete cds.
AF035013	Homo sapiens cell cycle related kinase mRNA, complete cds.
AF035582	Homo sapiens CASK mRNA, complete cds.
AF036718	Homo sapiens FGFR signalling adaptor SNT-2 mRNA, complete cds.
AF038392	Homo sapiens pre-mRNA splicing factor (PRP17) mRNA, complete cds.
AF038563	Homo sapiens atrophin-1 interacting protein 1 (AIP1) mRNA, complete
AF039067	Homo sapiens anti-death protein (IEX-1L) mRNA, complete cds.
AF039747	Homo sapiens cadherin-10 (CDH10) mRNA, complete cds.
AF040701	Homo sapiens TATA binding protein associated factor (TAFII150)
AF042378	Homo sapiens spindle pole body protein spc98 homolog GCP3 mRNA,
AF042729	Homo sapiens lithium-sensitive myo-inositol monophosphatase A1
AF043976	Homo sapiens CLCA homolog (hCLCA3) mRNA, complete cds.
AF044221	Homo sapiens HCG-1 protein (HCG-1) mRNA, complete cds.
AF044588	Homo sapiens protein regulating cytokinesis 1 (PRC1) mRNA, complete
AF045451	Homo sapiens transcriptional regulatory protein p54 mRNA, complete
AF046059	Homo sapiens cytokine receptor related protein 4 (CYTOR4) mRNA,
AF047033	Homo sapiens sodium bicarbonate cotransporter 3 (SLC4A7) mRNA,
AF047440	Homo sapiens ribosomal protein L33-like protein mRNA, complete cds.
AF047472	Homo sapiens spleen mitotic checkpoint BUB3 (BUB3) mRNA, complete

AF048731	Homo sapiens cyclin T2a mRNA, complete cds.
AF049140	Homo sapiens MMS2 (MMS2) mRNA, complete cds.
AF049910	Homo sapiens TACC1 (TACC1) mRNA, complete cds.
AF051323	Homo sapiens Src-associated adaptor protein (SAPS) mRNA, complete
AF051850	Homo sapiens supervillin mRNA, complete cds.
AF051894	Homo sapiens 15 kDa selenoprotein mRNA, complete cds.
AF052224	Homo sapiens neuronal double zinc finger protein (ZNF231) mRNA,
AF053304	Homo sapiens mitotic checkpoint component Bub3 (BUB3) mRNA,
AF053712	Homo sapiens osteoprotegerin ligand mRNA, complete cds.
AF054176	Homo sapiens angiotensin/vasopressin receptor AI/AVP mRNA,
AF055013	Homo sapiens clone 24695 guanine nucleotide-binding protein alpha-i
AF055467	Homo sapiens monotactin-1 mRNA, complete cds.
AF055636	Homo sapiens leucine-rich glioma-inactivated protein precursor
AF056032	Homo sapiens kynurenine 3-hydroxylase mRNA, complete cds.
AF056320	Homo sapiens inducible 6-phosphofructo-2-kinase/fructose
AF056929	Homo sapiens sarcosin mRNA, complete cds.
AF058291	Homo sapiens estrogen-related receptor gamma mRNA, complete cds.
AF059569	Homo sapiens actin binding protein MAYVEN mRNA, complete cds.
AF059611	Homo sapiens nuclear matrix protein NRP/B (NRPB) mRNA, complete
AF059617	Homo sapiens serum-inducible kinase mRNA, complete cds.
AF060877	Homo sapiens Gz-selective GTPase-activating protein (ZGAP1) mRNA,
AF061016	Homo sapiens UDP-glucose dehydrogenase (UGDH) mRNA, complete cds.

AF061326	Homo sapiens T41p (C8orf1) mRNA, complete cds.
AF061573	Homo sapiens protocadherin (PCDH8) mRNA, complete cds.
AF061936	Homo sapiens diacylglycerol kinase iota (DGKi) mRNA, complete cds.
AF063301	Homo sapiens keratan sulfate proteoglycan mRNA, complete cds.
AF063605	Homo sapiens brain my047 protein mRNA, complete cds.
AF064244	Homo sapiens intersectin long form mRNA, complete cds.
AF064548	Homo sapiens low-density lipoprotein receptor-related protein 5
AF064607	Homo sapiens GC20 protein mRNA, complete cds.
AF067170	Homo sapiens alpha endosulfine mRNA, complete cds.
AF068006	Homo sapiens haemopoietic progenitor homeobox HPX42B (HPX42B) mRNA,
AF068302	Homo sapiens choline/ethanolaminephosphotransferase (CEPT1) mRNA,
AF068836	Homo sapiens cytohesin binding protein HE mRNA, complete cds.
AF069313	Homo sapiens WSB-1 mRNA, complete cds.
AF069747	Homo sapiens MTG8-like protein MTGR1a mRNA, complete cds.
AF070674	Homo sapiens inhibitor of apoptosis protein-1 (MIHC) mRNA, complete
AF071309	Homo sapiens OPA-containing protein mRNA, complete cds.
AF071594	Homo sapiens MMSET type I (MMSET) mRNA, complete cds.
AF073310	Homo sapiens insulin receptor substrate-2 (IRS2) mRNA, complete
AF073518	Homo sapiens small EDRK-rich factor 1, short isoform (SERF1) mRNA,
AF073519	Homo sapiens small EDRK-rich factor 1, long isoform (SERF1) mRNA,
AF073958	Homo sapiens cytokine-inducible SH2 protein 6 (CISH6) mRNA,
AF076844	Homo sapiens Hus1-like protein (HUS1) mRNA, complete cds.
AF077036	Homo sapiens HSPC012 mRNA, complete cds.

AF077041	Homo sapiens SIH002 mRNA, complete cds.
AF077052	Homo sapiens protein translation factor su1 homolog mRNA, complete
AF077205	Homo sapiens HSPC019 mRNA, complete cds.
AF077599	Homo sapiens hypothetical SBBI03 protein mRNA, complete cds.
AF077820	Homo sapiens LDL receptor member LR3 mRNA, complete cds.
AF078165	Homo sapiens conductin mRNA, complete cds.
AF079566	Homo sapiens ubiquitin-like protein activating enzyme (UBA2) mRNA,
AF081259	Homo sapiens testis-specific chromodomain Y-like protein (CDYL)
AF083106	Homo sapiens sirtuin type 1 (SIRT1) mRNA, complete cds.
AF083217	Homo sapiens WD repeat protein WDR3 (WDR3) mRNA, complete cds.
AF084530	Homo sapiens cyclin-D binding Myb-like protein mRNA, complete cds.
AF089744	Homo sapiens xenotropic and polytropic murine leukemia virus
AF090384	Homo sapiens SUMO-1-activating enzyme E1 C subunit (UBA2) mRNA,
AF091083	Homo sapiens clone 628 unknown mRNA, complete sequence.
AF092051	Homo sapiens beta-1,3-N-acetylglucosaminyltransferase mRNA,
AF093774	Homo sapiens type 2 iodothyronine deiodinase mRNA, complete cds
AF097159	Homo sapiens UDP-Gal:glucosylceramide
AF099989	Homo sapiens Ste-20 related kinase SPAK mRNA, complete cds.
AF100740	Homo sapiens ARF-family of Ras related GTPases mRNA, complete cds.
AF100779	Homo sapiens connective tissue growth factor related protein WISP-1
AF101441	Homo sapiens bone morphogenetic protein 10 (BMP10) mRNA, complete

AF103796	Homo sapiens placenta-specific ATP-binding cassette transporter
AF104032	Homo sapiens L-type amino acid transporter subunit LAT1 mRNA,
AF104419	Homo sapiens decoy receptor 3 (DcR3) mRNA, complete cds.
AF105365	Homo sapiens K-Cl cotransporter KCC4 mRNA, complete cds.
AF105377	Homo sapiens heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B
AF106622	Homo sapiens mitochondrial inner membrane preprotein translocase
AF106683	Homo sapiens WSB-1 mRNA, complete cds.
AF106684	Homo sapiens WSB-1 isoform mRNA, complete cds.
AF109126	Homo sapiens stromal cell-derived receptor-1 beta mRNA, complete
AF109219	Homo sapiens Mcd4p homolog mRNA, complete cds.
AF109735	Homo sapiens ubiquitous 6-phosphofructo-2-kinase/fructose
AF110146	Homo sapiens eukaryotic translation initiation factor 2 alpha
AF110400	Homo sapiens fibroblast growth factor 19 (FGF19) mRNA, complete
AF112227	Homo sapiens TDE homolog mRNA, complete cds.
AF112299	Homo sapiens integral inner nuclear membrane protein MAN1 mRNA,
AF114263	Homo sapiens clone HH114 unknown mRNA.
AF116846	Homo sapiens bright and dead ringer gene product homologous protein
AF117210	Homo sapiens host cell factor 2 (HCF-2) mRNA, complete cds.
AF117754	Homo sapiens thyroid hormone receptor-associated protein complex
AF120151	Homo sapiens cytokine receptor-like molecule 9 (CREME9) mRNA,
AF121951	Homo sapiens CAAX prenyl protein protease RCE1 (RCE1) mRNA,
AF123094	Homo sapiens API2-MLT fusion protein (API2-MLT) mRNA, complete cds.

AF124250	Homo sapiens SH2-containing protein Nsp2 mRNA, complete cds.
AF125042	Homo sapiens bisphosphate 3'-nucleotidase mRNA, complete cds.
AF125101	Homo sapiens HSPC040 protein mRNA, complete cds.
AF130356	Homo sapiens MALT lymphoma associated translocation (MLT) mRNA,
AF132297	Homo sapiens cytokine-inducible SH2-containing protein (G18) mRNA,
AF132944	Homo sapiens CGI-10 protein mRNA, complete cds.
AF132960	Homo sapiens CGI-26 protein mRNA, complete cds.
AF132968	Homo sapiens CGI-34 protein mRNA, complete cds.
AF133820	Homo sapiens titin-like protein (TTID) mRNA, complete cds.
AF133845	Homo sapiens corin mRNA, complete cds.
AF134802	Homo sapiens cofilin isoform 1 mRNA, complete cds.
AF134803	Homo sapiens cofilin isoform 2 mRNA, complete cds.
AF135794	Homo sapiens AKT3 protein kinase mRNA, complete cds.
AF139658	Homo sapiens origin recognition complex subunit 6 (ORC6) mRNA,
AF148213	Homo sapiens aggrecanase-1 mRNA, complete cds.
AF151522	Homo sapiens hairy and enhancer of split related-1 (HESR-1) mRNA,
AF151837	Homo sapiens CGI-79 protein mRNA, complete cds.
AF151865	Homo sapiens CGI-107 protein mRNA, complete cds.
AF151869	Homo sapiens CGI-111 protein mRNA, complete cds.
AF151881	Homo sapiens CGI-123 protein mRNA, complete cds.
AF151899	Homo sapiens CGI-141 protein mRNA, complete cds.
AF151900	Homo sapiens CGI-142 protein mRNA, complete cds.
AF151903	Homo sapiens CGI-145 protein mRNA, complete cds.
AF151906	Homo sapiens CGI-148 protein mRNA, complete cds.

AF153330	Homo sapiens thiamine carrier 1 (TC1) mRNA, complete cds.
AF158555	Homo sapiens glutaminase C mRNA, complete cds.
AF165522	Homo sapiens ras-related GTP-binding protein 4b (RAB4B) mRNA,
HSJ001388	Homo Sapiens, RP58 cDNA for complete mRNA.
HSA5821	Homo sapiens mRNA for X-like 1 protein.
HSAJ6470	Homo sapiens mRNA for cartilage-associated protein (CASP).
HS010046	Homo sapiens mRNA for Rho guanine nucleotide-exchange factor,
HSA011785	Homo sapiens mRNA for Six9 protein.
HSA012370	Homo sapiens mRNA for NAALADase II protein.
HSA012755	Homo sapiens mRNA for TL132.
HSA132545	Homo sapiens mRNA for protein kinase.
HSAJ4741	Homo sapiens mRNA for matrilin-3.
HSAJ4901	Homo sapiens mRNA for ZNF198 protein.
HSA238243	Homo sapiens mRNA for phospholipase A2 activating protein.
HSA238248	Homo sapiens mRNA for centaurin beta2.
HSA238701	Homo sapiens mRNA for alpha-3-fucosyltransferase.
HS1039K5A	Novel human mRNA similar to mouse gene PICK1 (TR:Q62083).
HSM800381	Homo sapiens mRNA; cDNA DKFZp566D213 (from clone DKFZp566D213).
HSM800571	Homo sapiens mRNA; cDNA DKFZp564M112 (from clone DKFZp564M112).
HSM800697	Homo sapiens mRNA; cDNA DKFZp434K151 (from clone DKFZp434K151).
HSM800724	Homo sapiens mRNA; cDNA DKFZp434F122 (from clone DKFZp434F122).
HUMPRSI	Homo sapiens mRNA for phosphoribosyl pyrophosphate synthetase
HUM2OGDH	Human mRNA for 2-oxoglutarate dehydrogenase, complete cds.

HUMHM63	Human mRNA for FMLP-related receptor (HM63).
HUMHM89	Human mRNA for HM89.
HUMTF147	Human mRNA for transcription factor, E4TF1-47, complete cds.
HUMRSC192	Human mRNA for KIAA0003 gene, complete cds.
HUMRSC1083	Human mRNA for KIAA0010 gene, complete cds.
D13641	Human mRNA for KIAA0016 gene, complete cds.
HUMLYK	Homo sapiens mRNA for ITK, complete cds.
HUMID2HC	Human mRNA for Id-2H, complete cds.
HUMMGC24	Human mRNA for MGC-24, complete cds.
HUMAREB6	Human mRNA for transcription factor AREB6, complete cds.
HUM6PTS1	Human mRNA for 6-pyruvoyl-tetrahydropterin synthase, complete cds.
HUMPTPB1	Human mRNA for protein tyrosine phosphatase (PTP-BAS, type 1),
HUMPTPB2	Human mRNA for protein tyrosine phosphatase (PTP-BAS, type 2),
HUMPTPB3	Human mRNA for protein tyrosine phosphatase (PTP-BAS, type 3),
HUMORFKA	Human mRNA for KIAA0032 gene, complete cds.
HUMORFR	Human mRNA for KIAA0040 gene, complete cds.
HUMHGLUT1	Human mRNA for glutamate transporter, complete cds.
HUMPTKA	Human mRNA for Tec protein-tyrosine kinase, complete cds.
D30783	Homo sapiens mRNA for epiregulin, complete cds.
HUMDRPLA1	Human DRPLA mRNA for ORF, complete cds.
HUMORFKG1L	Human mRNA for KIAA0059 gene, complete cds.
HUMKIAAB	Human mRNA for KIAA0087 gene, complete cds.
HUMPLCE	Human mRNA for phospholipase C, complete cds.
HUMSCM1A	Human mRNA for SCM-1 (single cysteine motif-1), complete cds.
HUMUPST2	Human apM1 mRNA for GS3109 (novel adipose specific collagen-like)

HUMEOTAXIN	Human mRNA for eotaxin, complete cds.
HUMNAK1	Human NAK1 mRNA for DNA binding protein, complete cds.
HUMNRAMP1A	Human mRNA for NRAMP1, complete cds.
HUMHRH1	Human mRNA for RNA helicase (HRH1), complete cds.
D50678	Human mRNA for apolipoprotein E receptor 2, complete cds.
HUMPLAA	Homo sapiens mRNA for placental leucine aminopeptidase, complete
HUMCGA	Homo sapiens mRNA for ceramide glucosyltransferase, complete cds.
D50917	Human mRNA for KIAA0127 gene, complete cds.
D50931	Human mRNA for KIAA0141 gene, complete cds.
D63476	Human mRNA for KIAA0142 gene, complete cds.
D64015	Homo sapiens mRNA for T-cluster binding protein, complete cds.
HUMCIRPA	Homo sapiens mRNA for CIRP, complete cds.
D78579	Homo sapiens mRNA for neuron derived orphan receptor, complete cds.
D79993	Human mRNA for KIAA0171 gene, complete cds.
D82347	Homo sapiens mRNA for NeuroD, complete cds.
D83017	Homo sapiens mRNA for nel-related protein, complete cds.
D83175	Homo sapiens WNT7a mRNA, complete cds.
D83197	Homo sapiens mRNA for ankyrin repeat protein, complete cds.
D84145	Human WS-3 mRNA, complete cds.
D84276	Homo sapiens mRNA for CD38, complete cds.
HUMHAS	Homo sapiens mRNA for hyaluronan synthase, complete cds.
D84454	Human mRNA for UDP-galactose translocator, complete cds.
D85181	Homo sapiens mRNA for fungal sterol-C5-desaturase homolog, complete
D86958	Human mRNA for KIAA0203 gene, complete cds.

D86959	Human mRNA for KIAA0204 gene, complete cds.
D86967	Human mRNA for KIAA0212 gene, complete cds.
D86979	Human mRNA for KIAA0226 gene, complete cds.
D86985	Human mRNA for KIAA0232 gene, complete cds.
D87328	Homo sapiens mRNA for HCS, complete cds.
D87434	Human mRNA for KIAA0247 gene, complete cds.
D87445	Human mRNA for KIAA0256 gene, complete cds.
D87447	Human mRNA for KIAA0258 gene, complete cds.
D87461	Human mRNA for KIAA0271 gene, complete cds.
D87467	Human mRNA for KIAA0277 gene, complete cds.
D87717	Human mRNA for KIAA0013 gene, complete cds.
D88153	Homo sapiens mRNA for HYA22, complete cds.
HUMAPR	Human ATL-derived PMA-responsive (APR) peptide mRNA.
HUMLCA1	Human mRNA for l-caldesmon I.
HUMLCA2	Human mRNA for l-caldesmon II.
E00044	DNA coding of LeIF B.
E00047	DNA coding of LeIF E.
E00048	DNA coding of LeIF F.
E00051	DNA coding of LeIF I.
E00052	DNA coding of LeIF J.
E00095	DNA coding of interferon-gamma.
E00102	DNA coding of interferon(LyIFN-alpha-1).
E00104	DNA coding of interferon(LyIFN-alpha-2).
E00124	DNA coding of alpha-interferon Gx-1.
E00173	cDNA encoding human interferon-8'(1).
E00176	cDNA encoding human interferon-alpha-3.

E00294	cDNA encoding human interferon.
E00372	cDNA encoding human interleukin-2.
E00380	DNA coding for human interferon gamma.
E01058	cDNA encoding human interleukin-1 precursor.
E01219	cDNA encoding human G-CSF.
E01275	cDNA encoding human lymphotoxin polypeptide.
E01467	DNA encoding human prourokinase.
E01483	cDNA encoding T cell replacing factor.
E01537	DNA encoding human B-cell differentiation factor.
E01804	cDNA encoding human polypeptide having lymphotoxin activity.
E02167	cDNA encoding human TL-4.
E03588	DNA encoding human NGF-like peptide.
E07650	cDNA encoding endothelin receptor,ETB-receptor.
E07862	DNA encoding the pro region,NGF2/NT-3 and its vicinity.
HUMSRF	Human serum response factor (SRF) mRNA, complete cds.
HUMGRO	Human gro (growth regulated) gene.
HUMPTHL	Human, parathyroid-like protein (associated with humoral)
HUMCALLA	Human common acute lymphoblastic leukemia antigen (CALLA) mRNA,
HUMPTHLHA	Human renal carcinoma parathgrad hormone-like peptide mRNA,
HUMALPHLA	Human phosphatase 2A mRNA, complete cds.
HUMLGTPA	Human liver glucose transporter-like protein (GLUT2), complete cds.
HUMACT2A	Human activation (Act-2) mRNA, complete cds.
HUMGFB	Human basic fibroblast growth factor (bFGF) 22.5 kd, 21 kd and 18 kd
HUMET3	Human endothelin 3 (EDN3) mRNA, complete cds.

HUMIL1	Human monocyte interleukin 1 (IL-1) mRNA, complete cds.
HUMCALREC	Human calcitonin receptor mRNA, complete cds.
HUMBASONU	Human zinc finger protein basonuclin mRNA, complete cds.
HUMGUABIND	Human nucleotide binding protein mRNA, complete cds.
HUMERCC6A	Human excision repair protein ERCC6 mRNA, complete cds.
HUMATPCU	Human putative Cu++-transporting P-type ATPase mRNA, complete cds.
HUMTRANSCR	Human transcription factor mRNA, complete cds.
HUMGPCR	Human (clone L5) orphan G protein-coupled receptor mRNA, complete
HUMCD40L	Human CD40-ligand mRNA, complete cds.
HUMTGFB3C	Human transforming growth factor-beta type III receptor (TGF-beta)
HUMTKTCS	Homo sapiens T cell-specific tyrosine kinase mRNA, complete cds.
HUMCELGROR	Human cellular growth-regulating protein mRNA, complete cds.
HUMPDE7A	Homo sapiens cAMP phosphodiesterase PDE7 (PDE7A1) mRNA, complete
HUMTHRSPO	Human thrombospondin 2 (THBS2) mRNA, complete cds.
HUMTR3A	Human TR3 orphan receptor mRNA, complete cds.
HUMAF4Y	Human AF-4 mRNA, complete cds.
HUMMHCREP	Human MHC class I-related protein mRNA, complete cds.
HUMENDOSYN	Human endoperoxide synthase type II mRNA, complete cds.
HUMGAD67X	Human glutamate decarboxylase (GAD67) mRNA, complete cds.
HUMAHREC	Human AH-receptor mRNA, complete cds.
HUMOCTF1A	Human octamer binding transcription factor 1 (OTF1) mRNA, complete
HUMIPLAS	Human I-plastin mRNA, complete cds.
HUMWNT5A	Homo sapiens proto-oncogene (Wnt-5a) mRNA, complete cds.

HUMPDEG	Human phosphodiesterase mRNA, complete cds.
HUMATP2B2X	Human plasma membrane calcium ATPase isoform 2 (ATP2B2) mRNA,
HUMGALC	Homo sapiens galactocerebrosidase (GALC) mRNA, complete cds.
HUMPWD	Homo sapiens (PWD) gene mRNA, 3' end.
HUMPBXPROA	Homo sapiens paired box protein mRNA, complete cds.
HUMX104A	Human X104 mRNA, complete cds.
HUMB2CHIM	Homo sapiens beta2-chimaerin mRNA, complete cds.
HUMIQGA	Homo sapiens ras GTPase-activating-like protein (IQGAP1) mRNA,
HUMRPTK	Homo sapiens receptor protein-tyrosine kinase (HEK11) mRNA,
HUMGT198A	Homo sapiens GT198 mRNA, complete ORF.
HUMTFSL1B	Homo sapiens transcription factor SL1 mRNA, complete cds.
HUMSCPB	Homo sapiens TNFR2-TRAF signalling complex protein mRNA, complete
HUMCOX17R	Homo sapiens COX17 mRNA, complete cds.
HUMPTPC	Human protein tyrosine phosphatase mRNA, complete cds.
HUMKI32R	Homo sapiens inwardly rectifying potassium channel (Kir3.2) mRNA,
HUMTNFAA	Human tumor necrosis factor (TNF) mRNA.
HUMIFNAIP	Human interferon-alpha type I' mRNA, complete cds.
HUMGMCSFA	Human granulocyte-macrophage colony stimulating factor (GM-CSF)
HUMSISPDG	Human c-sis/platelet-derived growth factor 2 (SIS/PDGF2) mRNA,
HUMBCL2A	Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA
HUMVTNR	Human cell adhesion protein (vitronectin) receptor alpha subunit
HUMBCL2C	Human bcl-2 mRNA.
HUMIL1BA	Human interleukin 1-beta (IL1B) mRNA, complete cds.

HUMIF4E	Homo sapiens cap-binding protein mRNA, complete cds.
HUMUKPM	Human pro-urokinase mRNA, complete cds.
HUMLPL	Human lipoprotein lipase mRNA, complete cds.
HUMCYES1	Human c-yes-1 mRNA.
HUMSTS	Human steroid sulfatase (STS) mRNA, complete cds.
HUMTHM	Human endothelial cell thrombomodulin mRNA, complete cds.
HUMPIM1	Human pim-1 oncogene mRNA, complete cds.
HUMMCR	Human mineralocorticoid receptor mRNA (hMR), complete cds.
HUMHOXB	Human homeo box c8 protein, mRNA, complete cds.
HUMPTHRP	Human parathyroid hormone-related protein mRNA, complete cds.
HUMPAI2B	Human plasminogen activator inhibitor 2 (PAI-2) mRNA, complete cds.
HUMTGFB2A	Human transforming growth factor-beta-2 mRNA, complete cds.
HUMTRO	Human tropomyosin mRNA, complete cds.
HUMIL3A	Human interleukin 3 (IL-3) mRNA, complete cds, clone pcD-SR-alpha.
HUMGTLPA	Human glucose transporter-like protein-III (GLUT3), complete cds.
HUMGFIBP	Human insulin-like growth factor (IGF) binding protein mRNA,
HUMSRTR2A	Human steroid receptor TR2 mRNA, complete cds.
HUMENOG	Human neuron-specific gamma-2 enolase, complete cds.
HUMSTCPC	Homo sapiens secreted T cell protein (H400; SIS-gamma) mRNA,
HUMTHYP	Human parathymosin mRNA, complete cds.
HUMEAR1A	Human triiodothyronine receptor (THRA1, ear1) mRNA, complete cds.
HUMELK1A	Homo sapiens tyrosine kinase (ELK1) oncogene mRNA, complete cds.
HUMNATPEP	Human natriuretic peptide precursor mRNA, complete cds.

HUMCYTNEWA	Homo sapiens (clone pAT 464) potential lymphokine/cytokine mRNA,
HUMCYTNEWB	Homo sapiens (clone pAT 744) potential lymphokine/cytokine mRNA,
HUMPFKM23	Human muscle phosphofructokinase (PFKM) mRNA, complete cds.
HUMMONAP	Human monocyte-derived neutrophil-activating protein (MONAP) mRNA,
HUME2B	Homo sapiens nuclear-encoded mitochondrial branched chain
HUMIFNAM1	Human interferon (IFN-alpha-M1) mRNA, complete cds.
HUMIL1RA	Human interleukin 1 receptor mRNA, complete cds.
HUMCREB	Human transactivator protein (CREB) mRNA, complete cds.
HUMIFNN	Human leukocyte interferon-alpha mRNA, complete cds, clone pIFN105.
HUMIFNB1	Human interferon beta-1 (IFN-beta-1) mRNA, complete cds.
HUMCFTRM	Human cystic fibrosis mRNA, encoding a presumed transmembrane
HUMRNPB1A	Human hnRNP B1 protein mRNA.
HUMRNPA2A	Human hnRNP A2 protein mRNA.
HUMCNRA1	Human calcineurin A1 mRNA, complete cds.
HUMCNRAB	Human calcineurin A2 mRNA, complete cds.
HUMZFX	Human zinc finger protein X-linked (ZFX) mRNA, complete cds.
HUMELAMA1A	Human endothelial leukocyte adhesion molecule I (ELAM1) mRNA,
HUMARXC	Human amphiregulin (AR) mRNA, complete cds, clones lambda-AR1
HUMCNR	Human calcineurin B mRNA, complete cds.
HUMGFIBPL	Human insulin-like growth factor binding protein mRNA, complete
HUMTSG6A	Human tumor necrosis factor-inducible (TSG-6) mRNA fragment,
HUMPTCAA	Human papillary thyroid carcinoma-encoded protein mRNA, complete

HUMDAFB	Human decay-accelerating factor mRNA, complete cds.
HUMSRICPA	Human sorcin CP-22 mRNA, complete cds.
HUMHBLOD	Human GDP-L-fucose:beta-D-galactoside 2-alpha-1-fucosyltransferase
HUMGROB5	Human cytokine (GRO-beta) mRNA, complete cds.
HUMGROG5	Human cytokine (GRO-gamma) mRNA, complete cds.
HUMCSDF1	Human macrophage-specific colony-stimulating factor (CSF-1) mRNA,
HUMP58GTA	Human p58/GTA (galactosyltransferase associated protein kinase)
HUMMEMGL1	Human MEM-102 glycoprotein mRNA, complete cds.
HUMRARGA	Human retinoic acid receptor gamma 1 mRNA, complete cds.
HUMINTAZ	Human interferon-alpha mRNA, complete cds.
HUMIL6CSF	Human interleukin 6 mRNA, complete cds.
HUMPIM1LE	Human h-pim-1 protein (h-pim-1) mRNA, complete cds.
HUMKRASM	Human K-ras oncogene protein mRNA, complete cds.
HUMSYTA	Human synaptotagmin mRNA, complete cds.
HUMIL10	Human interleukin 10 (IL10) mRNA, complete cds.
HUMGROB	Human gro-beta mRNA, complete cds.
HUMIDSX	Human iduronate 2-sulfatase mRNA, complete cds.
HUMELFTL	Human ELAM-1 ligand fucosyltransferase (ELFT) mRNA, complete cds.
HUMECK	Human protein tyrosine kinase mRNA, complete cds.
HUMA20	Human tumor necrosis factor alpha inducible protein A20 mRNA,
HUMCD48	Human pan-leukocyte antigen (CD48) mRNA, complete cds.
HUMHBEGF	Human heparin-binding EGF-like growth factor mRNA, complete cds.
HUMTGFBC	Human transforming growth factor-beta (tgf-beta) mRNA, complete
HUMKGF	Human keratinocyte growth factor mRNA, complete cds.

HUMCS1PA	Human cleavage signal 1 protein mRNA, complete cds.
HUMGABAR	Human gamma-aminobutyric acid receptor type A rho-1 subunit (GABA-A)
HUMLHCGCR	Human luteinizing hormone-choriogonadotropin receptor mRNA,
HUMRACPC	Human rac protein kinase alpha mRNA, complete cds.
HUMPHLAM	Human phospholamban mRNA, complete cds.
HUMCALD	Human caldesmon mRNA, complete cds.
HUMET2A	Human endothelin 2 (ET2) mRNA, complete cds.
HUMNKSFP40	Human natural killer cell stimulatory factor (NKSF) mRNA, complete
HUMNKSFP35	Human natural killer cell stimulatory factor (NKSF) mRNA, complete
HUMCDC2A	Human cdc2-related protein kinase mRNA, complete cds.
HUMPLA2	Homo sapiens phosphatidylcholine 2-acylhydrolase (cPLA2) mRNA,
HUMGATA	Human GATA-binding protein (GATA2) mRNA, complete cds.
HUMMAD3A	Homo sapiens MAD-3 mRNA encoding IkB-like activity, complete cds.
HUMLHCGCR	Homo sapiens lutropin/choriogonadotropin receptor (LHCGR) mRNA,
HUMHKATPB	Human H,K-ATPase beta subunit mRNA, complete cds.
HUMGATA2A	Human transcription factor GATA-2 (GATA-2) mRNA, complete cds.
HUME16GEN	Human E16 mRNA, complete cds.
HUMHEB	Human HEB helix-loop-helix protein (HEB) mRNA, complete cds.
HUMGAD67A	Human glutamate decarboxylase (GAD67) mRNA, complete cds.
HUMCDSM	Human aorta caldesmon mRNA, complete cds.
HUMHTF4A	Homo sapiens transcription factor (HTF4A) mRNA, complete cds.
HUMFPR1A	Human formyl peptide receptor-like receptor (FPR1) mRNA, complete

HUMOPIODRE	Human putative opioid receptor mRNA, complete cds.
HUMMGDBEA	Human glycogen debranching enzyme mRNA, complete cds.
HUMACTN2A	Homo sapiens skeletal muscle alpha 2 actinin (ACTN20 mRNA, complete)
HUMKSAMI	Human fibroblast growth factor receptor (K-sam) mRNA, complete cds.
HUMPAX2A	Human paired-box protein (PAX2) mRNA, complete cds.
HUMCYCLOX	Homo sapiens cyclooxygenase-2 (Cox-2) mRNA, complete cds.
HUMCCND3A	Human D3-type cyclin (CCND3) mRNA, complete cds.
HUMCYCD3A	Homo sapiens cyclin D3 (CCND3) mRNA, complete cds.
HUMHOX2A	Human homeobox 2.1 protein (HOX2A) mRNA, complete cds.
HUMG0S24A	H.sapiens zinc finger transcriptional regulator mRNA, complete cds.
HUMIA1X	Human zinc-finger DNA-binding motifs (IA-1) mRNA, complete cds.
HUMCYP7	Human cholesterol 7-alpha hydroxylase (CYP7) mRNA, complete cds.
HUMPTPRZ	Human protein tyrosine phosphatase zeta-polypeptide (PTPRZ) mRNA,
HUMPLCB2A	Homo sapiens phospholipase C-beta-2 mRNA, complete cds.
HUMID2B	Human striated muscle contraction regulatory protein (Id2B) mRNA,
HUMNUCTIAR	Homo sapiens nucleolysin TIAR mRNA, complete cds.
HUMKALL	Homo sapiens Kallmann syndrome (KAL) mRNA, complete cds.
HUMGOOG	Human beta-1,6-N-acetylglicosaminyltransferase mRNA, complete cds.
HUMPDE2A	Human rolipram-sensitive, cAMP-specific phosphodiesterase (PDE2)
S40706	GADD153=growth arrest and DNA-damage-inducible gene [human]
S46622	calcineurin A catalytic subunit [human, testis, mRNA, 2134 nt].

S59184	RYK=related to receptor tyrosine kinase [human, hepatoma, mRNA]
S62138	TLS/CHOP=hybrid gene {translocation breakpoint} [human, myxoid]
S66427	RBP1=retinoblastoma binding protein 1 [human, Nalm-6 pre-B cell]
S67044	CD36=collagen type I/thrombospondin receptor {one exon} [human]
S70004	glycogen synthase [human, liver, mRNA, 2912 nt].
S73498	AgX-1 antigen [human, infertile patient, testis, mRNA, 2279 nt].
S75881	A-myb=DNA-binding transactivator {3' region} [human, CCRF-CEM]
S76473	trkB [human, brain, mRNA, 3194 nt].
S77770	voltage-gated chloride channel [human, placenta, Genomic/mRNA, 3440]
S78234	nuc2 homolog [human, fibroblasts, mRNA, 3320 nt].
S79851	thioredoxin reductase [human, placenta, mRNA, 3826 nt].
S82081	N8=tumor expression-enhanced gene [human, NCI H-69 cell line, mRNA]
S82592	Evi-1=Evi-1 protein {3' region, deletion region} [human]
S82692	interleukin-2 [human, placenta, term placentas obtained by cesarean
S82986	HOXC6=homeodomain-containing protein {clone 211} [human, MCF7]
S83309	germ cell nuclear factor [human, embryonal carcinoma NT2/D1, mRNA]
U00238	Homo sapiens glutamine PRPP amidotransferase (GPAT) mRNA, complete
U00672	Human interleukin-10 receptor mRNA, complete cds.
HSU02081	Human guanine nucleotide regulatory protein (NET1) mRNA, complete
HSU02882	Human rolipram-sensitive 3',5'-cyclic AMP phosphodiesterase mRNA,

HSU03272	Human fibrillin-2 mRNA, complete cds.
HSU03688	Human dioxin-inducible cytochrome P450 (CYP1B1) mRNA, complete cds.
HSU04313	Human maspin mRNA, complete cds.
HSU04840	Human onconeural ventral antigen-1 (Nova-1) mRNA, complete cds.
HSU06233	Human POU domain protein (Brn-3b) mRNA, complete cds.
HSU07132	Human steroid hormone receptor Ner-I mRNA, complete cds.
HSU07559	Human ISL-1 (Islet-1) mRNA, complete cds.
HSU07681	Human NAD(H)-specific isocitrate dehydrogenase alpha subunit
HSU07919	Human aldehyde dehydrogenase 6 mRNA, complete cds.
HSU08023	Human cellular proto-oncogene (c-mer) mRNA, complete cds.
HSU08839	Human urokinase-type plasminogen activator receptor mRNA, complete
HSU09564	Human serine kinase mRNA, complete cds.
HSU10301	Human glutamate receptor flip isoform (GluR3-flip) mRNA, complete.
HSU10417	Homo sapiens ileal sodium-dependent bile acid transporter
HSU11058	Homo sapiens calcium dependent potassium channel alpha subunit
HSU11287	Human N-methyl-D-aspartate receptor subunit NR3 (hNR3) mRNA,
HSU11700	Human copper transporting ATPase mRNA, complete cds.
HSU12128	Human protein tyrosine phosphatase 1E (PTP1E) mRNA, complete cds.
HSU12140	Human tyrosine kinase receptor p145TRK-B (TRK-B) mRNA, complete
HSU12535	Human epidermal growth factor receptor kinase substrate (Eps8)
HSU12767	Human mitogen induced nuclear orphan receptor (MINOR) mRNA,
HSU13047	Human nuclear respiratory factor-2 subunit gamma 1 mRNA, complete

HSU13048	Human nuclear respiratory factor-2 subunit gamma 2 mRNA, complete
HSU13219	Human forkhead protein FREAC-1 mRNA, complete cds.
HSU13913	Human large-conductance calcium-activated potassium channel (hSlo)
HSU14193	Human TFIIA gamma subunit mRNA, complete cds.
HSU14391	Human myosin-IC mRNA, complete cds.
HSU14407	Human interleukin 15 (IL15) mRNA, complete cds.
HSU16307	Human glioma pathogenesis-related protein (GliPR) mRNA, complete
HSU16954	Human (AF1q) mRNA, complete cds.
U17195	Homo sapiens A-kinase anchor protein (AKAP100) mRNA, complete cds.
HSU17714	Homo sapiens putative tumor suppressor ST13 (ST13) mRNA, complete
HSU17989	Homo sapiens nuclear autoantigen GS2NA mRNA, complete cds.
HSU18259	Human clone CIITA-8 MHC class II transactivator CIITA mRNA,
HSU18423	Human spinal muscular atrophy gene product mRNA, complete cds.
HSU18914	Human 19.8 kDa protein mRNA, complete cds.
HSU19252	Human putative transmembrane protein mRNA, complete cds.
HSU19878	Human transmembrane protein mRNA, complete cds.
HSU20362	Human Tg737 mRNA, complete cds.
HSU22680	Human X2 box repressor mRNA, complete cds.
HSU23851	Human atrophin-1 mRNA, complete cds.
HSU24183	Human phosphofructokinase (PFKM) mRNA, complete cds.
HSU25676	Human interleukin 2 (IL2) mRNA, complete cds.
HSU25997	Homo sapiens stanniocalcin precursor (STC) mRNA, complete cds.
HSU26312	Human heterochromatin protein HP1Hs-gamma mRNA, complete cds.

HSU26424	Human Ste20-like kinase (MST2) mRNA, complete cds.
HSU27193	Human protein-tyrosine phosphatase mRNA, complete cds.
HSU27655	Human RGP3 mRNA, complete cds.
HSU28687	Human zinc finger containing protein ZNF157 (ZNF157) mRNA, complete
HSU28926	Human beta2-chimaerin mRNA, complete cds.
HSU29165	Human MOP1 mRNA, complete cds.
HSU31383	Human G protein gamma-10 subunit mRNA, complete cds.
HSU32500	Human type 2 neuropeptide Y receptor mRNA, complete cds.
HSU32659	Human IL-17 mRNA, complete cds.
HSU34605	Human retinoic acid- and interferon-inducible 58K protein RI58
HSU37426	Human kinesin-like spindle protein HKSP (HKSP) mRNA, complete cds.
HSU37449	Human Mch3 isoform beta (Mch3) mRNA, complete cds.
HSU37529	Human substance P beta-PPT-A mRNA, complete cds.
HSU37546	Human IAP homolog C (MIHC) mRNA, complete cds.
HSU37707	Human dlg3 mRNA, complete cds.
HSU38654	Homo sapiens Rab27a mRNA, complete cds.
HSU38810	Human mab-21 cell fate-determining protein homolog (CAGR1) mRNA,
HSU39196	Human clone hGIRK1 G-protein coupled inwardly rectifying potassium
HSU39657	Human MAP kinase kinase 6 (MKK6) mRNA, complete cds.
HSU40281	Human cysteine protease CMH-1 mRNA, complete cds.
HSU40343	Human CDK inhibitor p19INK4d mRNA, complete cds.
HSU41766	Human metalloprotease/disintegrin/cysteine-rich protein precursor
HSU41816	Human C-1 mRNA, complete cds.
HSU42766	Human neuropeptide y2 receptor mRNA, complete cds.

HSU43030	Human cardiotrophin-1 (CTF1) mRNA, complete cds.
HSU43142	Human vascular endothelial growth factor related protein VRP mRNA,
HSU43653	Human obese protein (ob) mRNA, complete cds.
HSU46024	Homo sapiens myotubularin (MTM1) mRNA, complete cds.
HSU46573	Human eotaxin precursor mRNA, complete cds.
HSU47741	Human CREB-binding protein (CBP) mRNA, complete cds.
HSU48436	Homo sapiens fragile X mental retardation protein FMR2p (FMR2)
HSU49184	Human occludin mRNA, complete cds.
HSU49516	Human serotonin 5-HT2c receptor mRNA, complete cds.
HSU49837	Human LIM protein MLP mRNA, complete cds.
HSU49957	Human LIM protein (LPP) mRNA, partial cds.
HSU50078	Human guanine nucleotide exchange factor p532 mRNA, complete cds.
HSU50196	Human adenosine kinase mRNA, complete cds.
HSU50928	Human autosomal dominant polycystic kidney disease type II (PKD2)
HSU50929	Human betaine:homocysteine methyltransferase mRNA, complete cds.
HSU50964	Human G protein-activated inwardly rectifying potassium channel
HSU51166	Human G/T mismatch-specific thymine DNA glycosylase mRNA, complete
HSU51333	Human hexokinase III (HK3) mRNA, complete cds.
HSU52153	Human inwardly rectifying potassium channel Kir3.2 mRNA, complete
HSU52426	Homo sapiens GOK (STIM1) mRNA, complete cds.
HSU53476	Human proto-oncogene Wnt7a mRNA, complete cds.
HSU56085	Human periodic tryptophan protein 2 (PWP2) mRNA, complete cds.
HSU56236	Human Fc alpha receptor b mRNA, complete cds.

HSU56237	Human Fc alpha receptor b deltaS2 mRNA, complete cds.
HSU56417	Human lysophosphatidic acid acyltransferase-alpha mRNA, complete
HSU56998	Human putative serine/threonine protein kinase PRK (prk) mRNA,
HSU57627	Human fetal brain oculocerebrorenal syndrome (OCRL1) mRNA, complete
HSU57629	Human retinitis pigmentosa GTPase regulator (RPGR) mRNA, complete
HSU59269	Human hyaluronan synthase mRNA, complete cds.
HSU60319	Homo sapiens haemochromatosis protein (HLA-H) mRNA, complete cds.
HSU61234	Human tubulin-folding cofactor C mRNA, complete cds.
HSU61276	Human transmembrane protein Jagged 1 (HJ1) mRNA, complete cds.
HSU61500	Human GT334 protein (GT334) gene mRNA, complete cds.
HSU61835	Human cyclin G1 interacting protein (1500GX1) mRNA, complete cds.
HSU62136	Homo sapiens enterocyte differentiation associated factor EDAF-1
HSU62769	Human oxytocinase variant 2 mRNA, complete cds.
HSU63970	Human canalicular multispecific organic anion transporter (cMOAT)
HSU65785	Human 150 kDa oxygen-regulated protein ORP150 mRNA, complete cds.
HSU67319	Human Lice2 beta cysteine protease mRNA, complete cds.
HSU67320	Human Lice2 gamma cysteine protease mRNA, complete cds.
HSU67615	Human beige protein homolog (chs) mRNA, complete cds.
HSU68727	Human homeobox-containing protein mRNA, complete cds.
HSU70136	Human megakaryocyte stimulating factor mRNA, complete cds.
HSU70323	Human ataxin-2 (SCA2) mRNA, complete cds.
HSU70426	Homo sapiens A28-RGS14p mRNA, complete cds.

HSU71300	Human snRNA activating protein complex 50kD subunit (SNAP50) mRNA,
HSU72206	Human guanine nucleotide regulatory factor (LFP40) mRNA, complete
HSU72671	Human telencephalin precursor mRNA, complete cds.
HSU76420	Human dsRNA adenosine deaminase DRADA2a (DRADA2a) mRNA, complete
HSU76421	Human dsRNA adenosine deaminase DRADA2b (DRADA2b) mRNA, complete
HSU78575	Human 68 kDa type I phosphatidylinositol-4-phosphate 5-kinase alpha
HSU79274	Human clone 23733 mRNA, complete cds.
HSU79751	Human basic-leucine zipper nuclear factor (JEM-1) mRNA, complete
HSU80191	Human TFIID subunit TAFII100 mRNA, complete cds.
HSU80802	Homo sapiens orphan nuclear receptor GCNF mRNA, complete cds.
HSU83192	Homo sapiens post-synaptic density protein 95 (PSD95) mRNA,
HSU84007	Human glycogen debranching enzyme isoform 1 (AGL) mRNA,
HSU84008	Human glycogen debranching enzyme isoform 2 (AGL) mRNA,
HSU84009	Human glycogen debranching enzyme isoform 3 (AGL) mRNA,
HSU84010	Human glycogen debranching enzyme isoform 4 (AGL) mRNA,
HSU84011	Human glycogen debranching enzyme isoform 6 (AGL) mRNA,
HSU84249	Homo sapiens basic-leucine zipper transcription factor MafG (MAFG)
HSU84487	Human CX3C chemokine precursor, mRNA, alternatively spliced
HSU84573	Homo sapiens lysyl hydroxylase isoform 2 (PLOD2) mRNA, complete
HSU87309	Human hVps41p (HVPS41) mRNA, complete cds.
HSU87460	Human putative endothelin receptor type B-like protein mRNA,

HSU88323	Human placental bone morphogenic protein PLAB mRNA, complete cds.
HSU89012	Homo sapiens dentin matrix acidic phosphoprotein 1 (DMP1) mRNA
HSU90142	Human unknown protein (BT2.1) mRNA, complete cds.
HSU90278	Human N-methyl-D-aspartate receptor 2B subunit precursor mRNA,
HSU90543	Human butyrophilin (BTF1) mRNA, complete cds.
HSU91618	Human proneurotensin/proneuroedin N mRNA, complete cds.
HSU91835	Human CX3C chemokine precursor, mRNA, alternatively spliced,
HSU91934	Human retina-derived POU-domain factor-1 mRNA, complete cds.
HSU91935	Human retina-derived POU-domain factor-1 mRNA, alternatively
HSU92459	Human metabotropic glutamate receptor 8 mRNA, complete cds.
HSU93091	Human Toll protein homolog mRNA, complete cds and LINE-1 reverse
HSU93869	Human RNA polymerase III subunit (RPC39) mRNA, complete cds.
HSIFR14	Messenger RNA for human leukocyte (alpha) interferon.
HSIFR9	Messenger RNA for human leukocyte (alpha) interferon.
HSPGK1	Human mRNA encoding phosphoglycerate kinase.
HSLYTR	Human mRNA for lymphotoxin.
HSTNFR	Human mRNA for tumor necrosis factor.
HSIL1AR	Human mRNA for interleukin 1-alpha.
HSCSIST	Human mRNA for c-sis gene (clone pSM-1).
HSIL1R	Human mRNA for interleukin-1 precursor (pre IL-1).
HSGCRAR	Human mRNA for alpha-glucocorticoid receptor (clone OB7).
HSTRKR	Human mRNA of trk oncogene.
HSATPBR	Human mRNA for Na/K-ATPase beta subunit.

HSLD78R	Human tonsillar lymphocyte LD78 mRNA induced by TPA or PHA TPA
HSBPGMR	Human erythrocyte 2,3-bisphosphoglycerate mutase mRNA EC 2.7.5.4.
HSIFNB2R	Human IFN-beta 2a mRNA for interferon-beta-2.
HSIL5R	Human mRNA for T-cell replacing factor (interleukin-5).
HSTHMOD	Human mRNA for thrombomodulin precursor.
HSTRK2H	Human mRNA for trk-2h oncogene.
HSRPHO2A	Human mRNA for protein phosphatase 2A (alpha-type).
HSI12SRN	Human 12S RNA induced by poly(rI), poly(rC) and Newcastle disease
HSLIF	Human mRNA for leukaemia inhibitory factor (LIF/HILDA).
HSCOL3AI	Human mRNA for pro-alpha-1 type 3 collagen.
HSGABAAA1	Human mRNA for GABA-A receptor, alpha 1 subunit.
HSTS	Human mRNA for thrombospondin.
HSTM2CEA	Human mRNA for transmembrane carcinoembryonic antigen BGPb
HSMBPC	Human mRNA for mannose-binding protein C.
HSTM1CEA	Human mRNA for transmembrane carcinoembryonic antigen BGPa
HSNMTDC	Human mRNA for NAD-dependent methylene tetrahydrofolate
HSABL	Human c-abl mRNA encoding p150 protein.
HSHOX2H	Human HOX2H mRNA from the Hox2 locus.
HSINTAL4	Human mRNA for integrin alpha-4 subunit.
HSINAL2	Human mRNA for integrin alpha-2 subunit.
HSBCASR	Human mRNA for beta-casein.
HSNCHIM	Human mRNA for n-chimaerin.
HSET3AA	H.sapiens endothelin 3 mRNA.
HSUDGM	Human mRNA for uracil-DNA glycosylase.

HSBNGFAC	Human mRNA for beta nerve growth factor.
HSCGJP	Human mRNA for cardiac gap junction protein.
HSLAG1CDN	Human LAG-1 mRNA.
HSMIP2B	Human mRNA for macrophage inflammatory protein-2beta (MIP2beta).
HSFCREC	Human mRNA for Fc receptor.
HSCREBA	H.sapiens cDNA for CREB protein.
HSITKBI	H.sapiens mRNA for 1D-myo-inositol-trisphosphate 3-kinase B
HSPMS	Human mRNA for pM5 protein.
HSSERR52	H.sapiens serotonin 5-HT2 receptor mRNA.
HMAIF	Human mRNA for adipogenesis inhibitory factor.
HSD1DORE	Human mRNA for D-1 dopamine receptor.
HSD13S106	Homo sapiens D13S106 mRNA for a highly charged amino acid sequence.
HSRR2SS	H.sapiens RR2 mRNA for small subunit ribonucleotide reductase.
HSZFX2	Human ZFX mRNA for put. transcription activator, isoform 2.
HSZFX3	Human ZFX mRNA for put. transcription activator, isoform 3.
HSPRAD1CY	Human PRAD1 mRNA for cyclin.
HSTCF1B	Human TCF-1 mRNA for T cell factor 1 (splice form B).
HSTCF1C	Human TCF-1 mRNA for T cell factor 1 (splice form C).
HSKALIG	H.sapiens KALIG-1 mRNA for neural cell adhesion and axonal
HSPTBMR	Human polypyrimidine tract-binding (PTB) mRNA for polypyrimidine
HSP2RNA	H.sapiens mRNA for P2 protein of peripheral myelin.
HSTRKT1	H.sapiens mRNA (TRK-T1) for 55 KD protein.
HSRSRFC4	Homo sapiens mRNA for serum response factor-related protein,
HSTRE210	H.sapiens mRNA for tre oncogene (clone 210).

HSTRE213	H.sapiens mRNA for tre oncogene (clone 213).
HSPMCATP	H.sapiens mRNA for plasma membrane calcium ATPase.
HSAPO1	H.sapiens mRNA for APO-1 cell surface antigen.
HSRDC1MR	H.sapiens mRNA for RDC-1 POU domain containing protein.
HSDBT	H.sapiens mRNA for transacylase (DBT).
HSMATUMN	H.sapiens MaTu MN mRNA for p54/58N protein.
HSHNRNPI	H.sapiens mRNA for heterogeneous nuclear ribonucleoprotein.
HS_CD40	H.sapiens mRNA for CD40 ligand.
HSMEF2	H.sapiens mRNA for myocyte-specific enhancer factor 2 (MEF2).
HSTRAPA	H.sapiens TRAP mRNA for ligand of CD40.
HSNC30	H.sapiens interleukin-13 mRNA.
HSCALRE	H.sapiens mRNA for calcitonin receptor.
HSFMR1A	H.sapiens FMR-1 mRNA.
HSTGFAA	H.sapiens mRNA for transforming growth factor alpha.
HSFUSCPA	Homo sapiens mRNA for FUS-CHOP protein fusion.
HSERGICA	H.sapiens ERGIC-53 mRNA.
HSREVERB2	H.sapiens mRNA encoding Rev-ErbAalpha (internal fragment).
HSNICE	H.sapiens mRNA for nicein B2 chain.
HSP130K	H.sapiens p130 mRNA for 130K protein.
HSVHATPE	H.sapiens mRNA for vacuolar H <sup>+</sup> ATPase E subunit.
HS25ABP	H.sapiens mRNA for 2-5A binding protein.
HSCATHO	H.sapiens mRNA for cathepsin-O.
HSGD3S	H.sapiens GD3 synthase mRNA.
HSHZF10	H.sapiens HZF10 mRNA for zinc finger protein.
HSSCA1	H.sapiens SCA1 mRNA for ataxin.
HSAUHMR	H.sapiens AUH mRNA.

HSERK3	H.sapiens ERK3 mRNA.
HSARCP5	H.sapiens mRNA (clone p5) for archain.
HSHTFIIAS	H.sapiens hTFIIAs mRNA for smallest (gamma) TFIIA subunit.
HSHE6	H.sapiens mRNA for HE6 Tm7 receptor.
HSHOK2H1	H.sapiens HOK-2 mRNA for zinc finger protein.
HSSTAF50	H.sapiens Staf50 mRNA.
HSACENT	H.sapiens mRNA for alpha-centractin.
HSBRN4	H.sapiens Brain 4 mRNA.
HSSMA4	H.sapiens SMA4 mRNA.
HSIDEM	H.sapiens mRNA for phosphatidylinositol 3 kinase gamma.
HSAPXL	H.sapiens APXL mRNA.
HSRNACINP	H.sapiens mRNA for cytokine inducible nuclear protein.
HSEP3C	H.sapiens mRNA for prostaglandin E receptor (EP3c).
HSPKX1MR	H.sapiens mRNA for protein kinase, PKX1.
HSTRPC1GN	H.sapiens mRNA for TRPC1 protein.
HSRNAESM1	H.sapiens mRNA for ESM-1 protein.
HSMTTP	H.sapiens mRNA for microsomal triglyceride transfer protein.
HSMHCIMIC	H.sapiens mRNA for MHC class I mic-B antigen.
HSNOV	H.sapiens mRNA for novel gene in Xq28 region.
HSTRAXGEN	H.sapiens mRNA for translin associated protein X.
HSPWP2GEE	H.sapiens mRNA for PWP2 protein.
HS14KDAPT	Homo sapiens mRNA for translational inhibitor protein p14.5.
HSTAFII10	H.sapiens mRNA for TAFII100 protein.
HSC1DPROT	H.sapiens mRNA for C1D protein.
HSCMRP	H.sapiens mRNA for canalicular multidrug resistance protein.
HSTIM17	H.sapiens mRNA for TIM17 preprotein translocase.

HSVITDITR	H.sapiens mRNA for protein induced by vitamin D.
HSCGM2ANT	H.sapiens mRNA for carcinoembryonic antigen family member 2, CGM2.
HSCH16FAA	H.sapiens mRNA for FAA protein.
HSBHLH	H.sapiens mRNA for B-HLH DNA binding protein.
HSRTRGCNF	H.sapiens mRNA for hRTR/hGCNF protein.
HSHAPRA	Human hap mRNA encoding a DNA-binding hormone receptor.
HSPA12R	Human mRNA for Arg-Serpin (plasminogen activator-inhibitor 2)
HSHMPFK	Human mRNA for muscle phosphofructokinase (E.C. 2.7.1.11).
HSMDNCF	Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic factor)
HSIBP1R	Human mRNA for insulin-like growth factor binding protein IBP-1
HS46KDA	H.sapiens mRNA for 46 kDa coxsackievirus and adenovirus receptor
HSSIRPBET	H.sapiens mRNA for SIRP-beta1.
HSWNT11	Homo sapiens mRNA for WNT11 gene.
HSRIMP	Homo sapiens mRNA for FIM protein.
HSY13834	Homo sapiens mRNA for farnesylated-proteins converting enzyme 1.
HSY13835	Homo sapiens mRNA for farnesylated-proteins converting enzyme 2.
HSDIF2	Homo sapiens mRNA for DIF-2 protein.
HSY15014	Homo sapiens mRNA
HSY15228	Homo sapiens mRNA for leukemia associated gene 2.
HSY16241	Homo sapiens mRNA for nebulette.
HSRSRFC9	Homo sapiens mRNA for serum response factor-related protein,
HSA16521	Homo sapiens mRNA for CDS2 protein.
HSY16645	Homo sapiens mRNA for monocyte chemotactic protein-2.

HSY17394	Homo sapiens mRNA for prefoldin subunit 3.
HOS18206	Homo sapiens mRNA for protein phosphatase 1 (PPP1R6).
HSNOCTPOU	H.sapiens mRNA for N-Oct 3, N-Oct5a, and N-Oct 5b proteins.
HSLAMB2T	H.sapiens mRNA for laminin.
HSALK2A	H.sapiens ALK-2 mRNA.
HSALK3A	H.sapiens ALK-3 mRNA.
HSA2CHIA	H.sapiens a2-chimaerin mRNA.
HSTROISOA	H.sapiens tropomyosin isoform mRNA, complete CDS.
HSUCEH3	H.sapiens (23k/3) mRNA for ubiquitin-conjugating enzyme UbcH2.
HSINPO5P	H.sapiens mRNA for 43 kDa inositol polyphosphate 5-phosphatase.
HSXKMTTP	Homo sapiens mRNA for membrane transport protein (XK gene).
HSCHK2	H.sapiens HK2 mRNA for hexokinase II.
HSSOX9MRN	Homo sapiens SOX9 mRNA.
HSCTLA8	H.sapiens CTLA8 mRNA.
HSPTPKAP	H.sapiens mRNA for phosphotyrosine phosphatase kappa.
HSTRPC1A	H.sapiens mRNA for TRPC1A.
HSCCCHK53	H.sapiens mRNA for CC-chemokine, eotaxin variant (clone 53).
HS326L13	Human DNA sequence from PAC 326L13 containing brain-4 mRNA ESTs

## Claims

What is claimed is

1. A method of selecting a set of nucleic acids for analyzing gene expression in a cell, said method comprising:
  - a) providing a database which comprises a plurality of nucleic acid sequences, each of said nucleic acid sequences comprising a full-length or partial length protein coding sequence and a 3' untranslated region sequence downstream and contiguous with said protein coding sequence;
  - b) extracting a set of said protein coding sequences from said database by identifying protein coding sequences located upstream and contiguous with a 3' untranslated region (UTR) which comprises one of the following target sequences:
    - i) a first target sequence, WU/T(AU/TU/TU/TA)U/TWWW, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U, or T; or
    - ii) a second target sequence, U/T(AU/TU/TU/T)n wherein n indicates that the second target sequence comprises from 3 to 12 of the tetrameric sequences within the parenthesis.
2. The method of claim 1 wherein said database comprises mRNA sequences, cDNA sequences, or both .
3. The method of claim 1 wherein said database comprises genomic sequences.
4. The method of claim 1 wherein said database comprises genomic sequences, and further comprising the step of excluding from said set the protein coding sequences of genes that have the target sequence in a region other than the 3'UTR.
5. A method of preparing a library of nucleic acid molecules for analyzing gene expression in a cell, comprising
  - a) obtaining a group of two or more nucleic acid molecules whose protein coding sequences have been selected according to the method of claim 1, wherein the protein coding sequence of each of said nucleic acid molecules is different from the protein coding sequences of the other nucleic acid molecules in said group, and
  - b) incorporating each of said nucleic acid molecules into a separate nucleic acid vector to provide the library.
6. The method of claim 5 further comprising the step of sequencing said nucleic acid molecules.
7. A nucleic acid library prepared according to the method of claim 5.

8. The nucleic acid library of claim 7 wherein the nucleic acid molecules comprise the coding sequences or a fragment thereof of the nucleic acids identified in Table 6.

9. The nucleic acid library of claim 8 wherein said library is substantially free of nucleic acid molecules whose protein coding sequences are contiguous with a 3'UTR which lacks a target sequence.

10. A method for preparing a customized array for analyzing expression of ARE genes in a cell, comprising

(a) determining the protein coding sequences of a plurality of the nucleic acid molecules selected according to the method of claim 1;

(b) attaching a gene probe for each of said nucleic acid molecules to a solid support to provide the array,

wherein each of said probes hybridizes under stringent conditions to a target region within said protein coding sequence or the complement thereof, and

wherein each of said probes is an oligonucleotide, cDNA molecule, or a synthetic gene probe which comprises nucleobases

11. A customized array prepared according to the method of claim 10.

12. The customized array of claim 11 wherein said array comprises a plurality of probes to the nucleic acids listed in Table 6.

13. The customized array of claim 12 wherein fewer than 20% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE genes

14. The customized array of claim 12 wherein fewer than 10% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE gene.

15. The customized array of claim 12 wherein the probes are oligonucleotides that are at least 10 nucleotides in length, wherein the GC content of said oligonucleotides is at least 40%, and wherein said oligonucleotides do not form hairpin structures.

16. The customized array of claim 11 wherein said protein coding sequences are selected by extraction from a genomic database.

17. A method of extracting ARE genes from a genomic database, comprising:

a) identifying genomic regions which comprise an ARE motif;

b) locating the protein coding regions which are upstream of said genomic regions; and

c) subjecting the genomic regions located in step b to a computer gene prediction program which gives an output of the coding region and predicted amino acid sequence.

18. The method of claim 17 wherein the genomic areas are located by analyzing the genomic area located between 6 and 20 kilobases upstream and from 1 to 3 kilobases downstream of the ARE motif.

19. A method of using the nucleic acids selected by the method of claim 1 to prepare a customized array of ARE genes, comprising:

- a) identifying a group of unique sequence within the protein coding sequence of the ARE genes selected according to claim 1;
- b) preparing a set of oligonucleotides or polynucleotides, wherein each oligonucleotide or polynucleotide in said set comprises one of the unique sequences in said group; and
- c) attaching said oligonucleotides or said polynucleotides to a solid support.

20. The method of claim 19 wherein the set of oligonucleotides or polynucleotides are prepared by

- a) obtaining a DNA or RNA sample;
- b) PCR amplifying said sample using primers which are specific for said unique sequences to provide said oligonucleotides or polynucleotides.

21. A method for identifying primer sets targeted to the initiation region of genes whose 3' untranslated region comprise ARE sequences, comprising:

- a) locating the start codon of the protein coding sequences of a plurality of genes whose 3' UTR comprises one of the following target sequences:
  - i) a first target sequence, WU/T(AU/TU/TU/TA)U/TWWW, SEQ ID NO. 1 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U, or T; or
  - ii) a second target sequence, U/T(AU/TU/TU/T)n, SEQ ID NO. 2, wherein n indicates that the second target sequence comprises from 3 to 12 of the tetrameric sequences within the parenthesis;
- b) grouping said genes into a class selected from the group consisting of:
  - i) the ATGa genes whose initiation codon has an attached to the 3' end,
  - ii) the ATGc genes whose initiation codon has a C attached to the 3' end,
  - iii) the ATGg genes whose initiation codon has a G attached to the 3' end, and
  - iv) the ATGt genes whose initiation codon has a T attached to the 3' end; and
- c) constructing a consensus sequence for each of said classes by analyzing the 9 nucleotides located immediately upstream of the initiation codon and the nucleotide located immediately downstream of the initiation codon,

wherein each of said consensus sequences is 13 nucleotides in length,

its wherein each of said consensus sequences encompasses at least 75% of the genes in related class, and

wherein the oligonucleotides encompassed by each of said four consensus sequences is a primer set.

22. The method of claim 21 wherein each of said consensus sequences encompasses the sequences of at least 90% of the genes in its related group.

23. A method for identifying primer sets targeted to the initiation region of genes whose 3' untranslated region comprise ARE sequences, comprising:

a) locating the start codon of the protein coding sequences of a plurality of genes whose 3' UTR comprises one of the following target sequences:

i) a first target sequence, WU/T(AU/TU/TU/TA)U/TWWW, SEQ ID NO. 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U, or T; or

ii) a second target sequence, U/T(AU/TU/TU/T)n, SEQ ID NO. 2, wherein n indicates that the second target sequence comprises from 3 to 12 of the tetrameric sequences within the parenthesis;

b) grouping said genes into one of the following sixteen classes

i) the AATGa genes whose initiation codon, ATG, has an A attached to the 5' end, and an A attached to the 3' end,

ii) the CATGa genes whose initiation codon, ATG, has a C attached to the 5' end, and an A attached to the 3' end,

iii) the GATGa genes whose initiation codon, ATG, has a G attached to the 5' end, and an A attached to the 3' end,

iv) the TATGt genes whose initiation codon, ATG, has a T attached to the 5' end, and an A attached to the 3' end,

v) the AATGc genes whose initiation codon, ATG, has an A attached to the 5' end, and an C attached to the 3' end,

vi) the CATGc genes whose initiation codon, ATG, has a C attached to the 5' end, and a C attached to the 3' end,

vii) the GATGc genes whose initiation codon, ATG, has a G attached to the 5' end, and a C attached to the 3' end,

viii) the TAGc genes whose initiation codon, ATG, has a T attached to the 5' end, and a C attached to the 3' end,

- ix) the ATGg genes whose initiation codon, ATG, has an A attached to the 5' end, and a G attached to the 5' end,
- x) the CATGg genes whose initiation codon, ATG, has a C attached to the 5' end, and a G attached to the 3' end,
- xi) the GATGg genes whose initiation codon, ATG, has a G attached to the 5' end, and a G attached to the 3' end,
- xii) the TATGg genes whose initiation codon, ATG, has a T attached to the 5' end, and a G attached to the 3' end,
- xiii) the ATGt genes whose initiation codon, ATG, has an A attached to the 5' end, and a T attached to the 3' end,
- xiv) the CATGt genes whose initiation codon, ATG, has a C attached to the 5' end, and a T attached to the 3' end,
- xv) the GATGt genes whose initiation codon, ATG, has a G attached to the 5' end, and a T attached to the 3' end, and
- xvi) the TATGt genes whose initiation codon, ATG, has a T attached to the 5' end, and a T attached to the 3' end; and

c) constructing a consensus sequence for each of said classess by analyzing the 9 nucleotides located immediately upstream of the initiation codon and the single nucleotide located immediately downstream of the initiation codon,

wherein each of said consensus sequences is thirteen nucleotides in length and comprises the initiation codon and the nucleotide attached to the 3' end thereof,

wherein each of said consensus sequences represents at least 75 % of the genes in its related group, and

wherein the oligonucleotides encompassed by each of said sixteen consensus sequences is a primer set,

24. The method of claim 60 wherein each of said consensus sequences encompasses the sequences of at least 90% of the genes in its related group.

25. A method of selectively amplifying ARE-gene transcripts, said method comprising

- a) reverse transcribing RNA molecules obtained from a cell which is expressing one or more ARE-genes using an oligo dT primer and a reverse transcriptase to provide a pool of single stranded DNA molecules;
- b) amplifying a portion of the ARE-containing DNA molecules within said pool by a polymerase chain reaction which employs

- i) a 3' primer which is from 13 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT, wherein said sequences are overlapping or non-overlapping;
- sets i) and one or more of the primers encompassed by one of the 5' primer obtained according the method of claim 21.

26. The method of claim 25 wherein said method employs two or more 5' primers whose sequences are encompassed by a consensus sequence selected from the group consisting of:

VRVVRVVATGAV, SEQ ID NO. 16,

VVVDRVATGCH, SEQ ID NO. 17,

VVBRVVATGGM, SEQ ID NO. 18,

VDBVRHVATGTY, SEQ ID NO. 19,

27. The method of claim 25 further comprising the step of sequencing the ARE-containing DNA molecules that are produced by step (b).

28. A method of preparing a library of nucleic acid molecules for analyzing gene expression in a cell comprising

a) obtaining a group of two or more nucleic acid molecules whose protein coding sequences have been identified according to the method of claim 27, wherein the protein coding sequence of each of said two or more nucleic acid molecules is different from the protein coding sequences of the other nucleic acid molecules in said group, and

b) incorporating each of said nucleic acid molecules into a separate nucleic acid vector to provide the library.

29. A nucleic acid library prepared according to the method of claim 28.

30. The nucleic acid library of claim 29 wherein the nucleic acid molecules comprise the coding sequences or a fragment thereof of the nucleic acid molecules identified in Figure 7.

31. The nucleic acid library of claim 30 wherein said library is substantially free of nucleic acid molecules whose protein coding sequences are not contiguous with a 3'UTR which comprises the target sequence.

32. A method for preparing a customized array for analyzing expression of ARE genes in a cell, comprising

(a) determining the protein coding sequences of a plurality of ARE nucleic acid molecules amplified according to the method of claim 25;

(b) attaching a gene probe for each of said nucleic acid molecules to a solid support to provide the array,

wherein each of said probes hybridizes under stringent conditions to a target region within said protein coding sequence or the complement thereof, and

wherein each of said probes is an oligonucleotide, cDNA molecule, or a synthetic gene probe which comprises nucleobases.

33. A customized array prepared according to the method of claim 32.

34. The customized array of claim 33 wherein the probes are oligonucleotides that are at least 10 nucleotides in length, wherein the GC content of said oligonucleotides is at least 40%, and wherein said oligonucleotides do not form hairpin structures.

35. A customized array for analyzing expression of ARE-genes, wherein said array comprises a plurality of probes which bind under stringent conditions to nucleic acids which comprises the sequences listed in Figure 7.

36. The customized array of claim 35 wherein fewer than 20% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE genes

37. The customized array of claim 35 wherein fewer than 10% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE gene.

38. The customized array of claim 35 wherein the probes are oligonucleotides that are at least 10 nucleotides in length, wherein the GC content of said oligonucleotides is at least 40%, and wherein said oligonucleotides do not form hairpin structures.

39. A method of selectively amplifying ARE-gene transcripts, said method comprising

a) reverse transcribing RNA molecules obtained from a cell which is expressing one or more ARE-genes using an oligo dT primer and a reverse transcriptase to provide a pool of single stranded DNA molecules;

b) amplifying a portion of the ARE-containing DNA molecules within said pool by a polymerase chain reaction which employs

i) a 3' primer which is from 13 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT, wherein said pentameric sequences are overlapping or non-overlapping;

ii) and one or more of the primers encompassed by one of the 5' primer sets obtained according the method of claim 23.

40. The method of claim 39 wherein said method employs two or more 5'primers whose sequences are encompassed by a consensus sequence selected from the group consisting of

BHDVMMMAATGAV, SEQ ID NO. 20,

BSHMRVCATGAV, SEQ ID NO. 21,

HBVVRVGATGAD, SEQ ID NO. 22,

BDDVRHTATGAM, SEQ ID NO. 23

HDDVRBAATGCD, SEQ ID NO. 24,  
VRSVRMCATGCB, SEQ ID NO. 25,  
SSBBRMGATGCB, SEQ ID NO. 26,  
VBDWWRTATGCM, SEQ ID NO. 27  
VVBVRMAATGGV, SEQ ID NO. 28  
VVVVRSCATGGM, SEQ ID NO. 29,  
BVVSRVGATGGM, SEQ ID NO. 30  
VDBHRBTATGGM, SEQ ID NO. 31  
DRBVRMAATGTY, SEQ ID NO. 32  
BVBMRYCATGTS, SEQ ID NO. 33,  
VDBVRRGATGTY, SEQ ID NO. 34,  
DVBVWDTATGTY, SEQ ID NO. 35 and combinations thereof.

41. The method of claim 39 further comprising the step of sequencing the ARE-containing DNA molecules that are produced by step (b).
42. A method of preparing a library of nucleic acid molecules for analyzing gene expression in a cell comprising
  - a) obtaining a group of two or more nucleic acid molecules whose protein coding sequences have been identified according to the method of claim 41, wherein the protein coding sequence of each of said two or more nucleic acid molecules is different from the protein coding sequences of the other nucleic acid molecules in said group, and
  - b) incorporating each of said nucleic acid molecules into a separate nucleic acid vector to provide the library.
43. A nucleic acid library prepared according to the method of claim 204.
44. The nucleic acid library of claim 43 wherein said library is substantially free of nucleic acid molecules whose protein coding sequences are not contiguous with a 3'UTR which comprises the target sequence.
45. A method for preparing a customized array for analyzing gene expression in a cell, comprising
  - (a) determining the protein coding sequences of a plurality of ARE nucleic acid molecules amplified according to the method of claim 39;
  - (b) attaching a gene probe for each of said nucleic acid molecules to a solid support to provide the array,

wherein said probe hybridizes under stringent conditions to a target region within said protein coding sequence or the complement thereof, and

wherein said probe is an oligonucleotide, cDNA molecule, or a synthetic gene probe which comprises nucleobases.

46. A customized array prepared according to the method of claim 45.

47. The customized array of claim 46 wherein fewer than 20% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE genes

48. The customized array of claim 46 wherein fewer than 10% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE gene.

49. The customized array of claim 46 wherein the probes are oligonucleotides that are at least 10 nucleotides in length, wherein the GC content of said oligonucleotides is at least 40%, and wherein said oligonucleotides do not form hairpin structures.

50. A method of selectively amplifying ARE-gene transcripts, said method comprising

a) reverse transcribing RNA molecules obtained from a cell which is expressing one or more ARE-genes using a reverse transcriptase and an oligo dT primer that has an NH<sub>2</sub> group at the 5' end thereof to provide a pool of single stranded cDNA molecules;

b) ligating an oligomer to said cDNA molecules, said oligomer being from 50 to 70 nucleotides in length, said oligomer being phosphorylated at its 3' end and protected at its 5' end with an NH<sub>2</sub>, said oligomer having a sequence which does not hybridize under stringent conditions to human mRNA molecules;

d) PCR amplifying the ARE-containing DNA molecules within the cDNA molecules produced in step (c) by a polymerase chain reaction which employs

- i) a 3' primer which is from 13 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT, wherein pentameric sequences are overlapping or non-overlapping; and
- ii) a 5' primer whose sequence is identical to a sequence contained within the oligomer.

51. The method of claim 50 wherein the CG content of said 3' primer is at least 40%.

52. The method of claim 50 further comprising the step of sequencing the ARE-containing DNA molecules that are produced by step (d).

53. A method of preparing a library of nucleic acid molecules for analyzing gene expression in a cell comprising

a) obtaining a group of two or more nucleic acid molecules whose protein coding sequences have been identified according to the method of claim 301, wherein the protein

coding sequence of each of said two or more nucleic acid molecules is different from the protein coding sequences of the other nucleic acid molecules in said group, and

b) incorporating each of said nucleic acid molecules into a separate nucleic acid vector to provide the library.

54. A nucleic acid library prepared according to the method of claim 53.

55. The nucleic acid library of claim 54 wherein said library is substantially free of nucleic acid molecules whose protein coding sequences are not contiguous with a 3'UTR which comprises the target sequence.

56. A method for preparing a customized array for analyzing gene expression in a cell, comprising

(a) determining the protein coding sequences of a plurality of ARE nucleic acid molecules amplified according to the method of claim 50;

(b) attaching a gene probe for each of said nucleic acid molecules to a solid support to provide the array,

wherein said probe hybridizes under stringent conditions to a target region within said protein coding sequence or the complement thereof, and

wherein said probe is an oligonucleotide, cDNA molecule, or a synthetic gene probe which comprises nucleobases.

57. A customized array prepared according to the method of claim 56.

58. The customized array of claim 57 wherein fewer than 20% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE genes

59. The customized array of claim 57 wherein fewer than 10% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE gene.

60. The customized array of claim 57 wherein the probes are oligonucleotides that are at least 10 nucleotides in length, wherein the GC content of said oligonucleotides is at least 40%, and wherein said oligonucleotides do not form hairpin structures.

61. A method of selectively amplifying ARE-gene transcripts, said method comprising

a) reverse transcribing said RNA obtained from a cell to provide a pool of single-stranded DNA molecules, wherein said reverse transcription employs a reverse transcriptase and a 3' primer which is from 13 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT, wherein said pentameric sequences are overlapping or non-overlapping;

b) amplifying the ARE-containing DNA molecules within said pool by a polymerase chain reaction which employs

- i) a 3' primer which is from 15 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT, wherein said pentameric sequences are overlapping or non-overlapping;
- ii) and one or more of the primers encompassed by one of the 5' primer sets obtained according the method of claim 21.

- 62. The method of claim 61 wherein the reverse transcriptase is stable at 60° C.
- 63. The method of claim 61 wherein trehalose is included in the reverse transcription step.
- 64. The method of claim 61 wherein said method employs two or more 5' primers whose sequences are encompassed by a consensus sequence selected from the group consisting of:

VRVVRRVVATGAV, SEQ ID NO. 16,

VVVDRVBATGCH, SEQ ID NO. 17,

VVBRVVATGGM, SEQ ID NO. 18,

VDBVRHVATGTY, SEQ ID NO. 19, .

- 65. The method of claim 61 further comprising the step of sequencing the ARE-containing DNA molecules that are produced by step (b).
- 66. A method of preparing a library of nucleic acid molecules for analyzing gene expression in a cell comprising

- a) obtaining a group of two or more nucleic acid molecules whose protein coding sequences have been identified according to the method of claim 65, wherein the protein coding sequence of each of said two or more nucleic acid molecules is different from the protein coding sequences of the other nucleic acid molecules in said group, and
- b) incorporating each of said nucleic acid molecules into a separate nucleic acid vector to provide the library.

- 67. A nucleic acid library prepared according to the method of claim 66.

- 68. The nucleic acid library of claim 67 wherein said library is substantially free of nucleic acid molecules whose protein coding sequences are not contiguous with a 3'UTR which comprises the target sequence.

- 69. A method for preparing a customized array for analyzing expression of ARE genes in a cell, comprising
  - (a) determining the protein coding sequences of a plurality of ARE nucleic acid molecules amplified according to the method of claim 61;
  - (b) attaching a gene probe for each of said nucleic acid molecules to a solid support to provide the array,

wherein each of said probes hybridizes under stringent conditions to a target region within said protein coding sequence or the complement thereof, and

wherein each of said probes is an oligonucleotide, cDNA molecule, or a synthetic gene probe which comprises nucleobases

70. A customized array prepared according to the method of claim 69.

71. The customized array of claim 70 wherein the probes are oligonucleotides that are at least 10 nucleotides in length, wherein the GC content of said oligonucleotides is at least 40%, and wherein said oligonucleotides do not form hairpin structures.

72. A method of selectively amplifying ARE-gene transcripts, said method comprising

- a) reverse transcribing said RNA obtained from a cell for provie a pool of single-stranded DNA molecules, wherein said reverse transcription employs a reverse transcriptase and a 3' primer which is from 13 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT, wherein said pentameric sequences are overlapping or non-overlapping;
- b) amplifying a portion of the ARE-containing DNA molecules within said pool by a polymerase chain reaction which employs
  - i) a 3' primer which is from 13 to 50 nucleotides in length and comprises from 2 to 10 pentamers having the sequence TAAAT, wherein said sequences are overlapping or non-overlapping;
  - ii) and one or more of the primers encompassed by one of the 5' primer sets obtained according the method of claim 23.

73. The method of claim 72 wherein said method employs two or more 5'primers whose sequences are encompassed by a consensus sequence selected from the group consisting of:

BHDVMMMAATGAV, SEQ ID NO. 20,

BSHMRVCATGAV, SEQ ID NO. 21,

HBVVRVGATGAD, SEQ ID NO. 22,

BDDVRHTATGAM, SEQ ID NO. 23

HDDVRBAATGCD, SEQ ID NO. 24,

VRSVRMCATGCB, SEQ ID NO.25,

SSBBRMRMGATGCB, SEQ ID NO. 26,

VBDWWRTATGCM, SEQ ID NO. 27

VVBVRMAATGGV, SEQ ID NO. 28

VVVVRSCATGGM, SEQ ID NO. 29,  
BVVSRVGATGGM, SEQ ID NO. 30  
VDBHRBTATGGM, SEQ ID NO. 31  
DRBVRMAATGTY, SEQ ID NO. 32  
BVBMRYCATGTS, SEQ ID NO. 33,  
VDBVRRGATGTY, SEQ ID NO. 34,  
DVBVWDTATGTY, SEQ ID NO. 35 and combinations thereof.

74. The method of claim 72 further comprising the step of sequencing the ARE-containing DNA molecules that are produced by step (b).

75. A method of preparing a library of nucleic acid molecules for analyzing gene expression in a cell comprising

a) obtaining a group of two or more nucleic acid molecules whose protein coding sequences have been identified according to the method of claim 72 wherein the protein coding sequence of each of said two or more nucleic acid molecules is different from the protein coding sequences of the other nucleic acid molecules in said group, and

b) incorporating each of said nucleic acid molecules into a separate nucleic acid vector to provide the library.

76. A nucleic acid library prepared according to the method of claim 75.

77. The nucleic acid library of claim 76 wherein said library is substantially free of nucleic acid molecules whose protein coding sequences are not contiguous with a 3'UTR which comprises the target sequence.

78. A method for preparing a customized array for analyzing gene expression in a cell, comprising

(a) determining the protein coding sequences of a plurality of ARE nucleic acid molecules amplified according to the method of claim 72;

(b) attaching a gene probe for each of said nucleic acid molecules to a solid support to provide the array,

wherein said probe hybridizes under stringent conditions to a target region within said protein coding sequence or the complement thereof, and

wherein said probe is an oligonucleotide, cDNA molecule, or a synthetic gene probe which comprises nucleobases.

79. A customized array prepared according to the method of claim 78

80. The customized array of claim 79 wherein fewer than 20% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE genes

81. The customized array of claim 79 wherein fewer than 10% of the probes on the array bind under stringent hybridization conditions to the protein coding sequences of non-ARE gene.

82. The customized array of claim 79 wherein the probes are oligonucleotides that are at least 10 nucleotides in length, wherein the GC content of said oligonucleotides is at least 40%, and wherein said oligonucleotides do not form hairpin structures.

83. A method of obtaining an ARE expression profile in a subject, comprising:

a) extracting RNA from a tissue sample obtained from the subject;

b) labeling said RNA with a detectable tag; and

c) contacting said labeled RNA with a microarray selected from the group consisting of the microarray of claim 11, the microarray of claim 33, the microarray of claim 46, the microarray of claim 57, the microarray of claim 70 and the microarray of claim 76.

d) determining the sequence or pattern of the labeled RNA molecules which hybridize under stringent conditions with the probes present on said microarray.

Fig. 1.




Fig. 2.






Fig.3.



BEST AVAILABLE COPIE

Fig. 4.



BEST AVAILABLE COPY

Fig. 5.




Fig. 6.




Fig. 7

A2 R20

R9

GAACCTCCACAACCACGACACACAGTAGGCACCAATAAAATCCTTGAATGAATTAA  
AAAATGAATGTGTATCACTAGTGCGCTGATTCTTAATCTGATCAGTAAGTCTGGA  
TGACTGAATCAATCGCTGATGGAAGGAACAATTATGCCTCATTCAGGCCGTAAC  
ATGGGAACCTTGCATACAGCAGGTGCTAATAAAATGCTGGGGCACATGAAACAG  
ATGAAGAGGGCTTGGTTCTCCCAATTCCCCAGGGCCAAGCCCTGTTGCTGGCAT  
GCAGTAGGCACCTCCATTAATGCTGCCTGTGACGTGATTGCTTAGCAAGAGCT  
GGCTGGACACCACCCCCACACGAGAGAGGCCCTGTGGCCTGCCAAGGGGTCCAGAG  
GTGGGGGCTTCTCCTCAAAACTGCAGACGCGTTACGTATCGGTTCTTATTAGG  
TGACCACTATAGAATTCCGATATGTGGTCGACAAGCTTCTCGAGCCTAGGCTAGC  
TCTAGACCACACT

R8

GAATTCGACCGAGCTTGTGGTCACTGGCCACCGCTTGTCTGG  
GGACCCAGGTATCCCTGGATTACTGACTCCTGCTAATCTGGGCTGAGCCCTCTGG  
CACCTTGACCAGTGAATCCCAGTCTCAATAAACCTATGAGTTCATGAACACA  
TTCTTCTAAAAATCAGCTTCTGTCTCCCAGATTATCTTCATCTGGAGGAG  
ATGAGGTTGATTCACCTGCTGGAAGTCCAACCCAGAAAGATCCCAGGACTTAT  
GAGGAAGAAAGGCTCGGTGAGGACTTCAAGCAGCAGGGAGTCCTTACATCCAG  
ACGCTGCTGGACATCGTCTTCTTATGGCAAGGGCTATGTGTCGTGGTGTGGA  
GTCGGGCTTGTGTCGTACGTGCCACCGTACCGCTGCGATGTGCTGGCG  
TTCGAATTAGCAGCAGCGGTTCTTGGTAACACCCATGGTGGCCAAAGTTGAG  
CGTTTATTCTGAGCTCTGC

R7

GAATACGCACGGCTCGGGGTATCCGTGTGCTTGCAGAGTTGACACTCCTGGCCACCCTTGTCTGG

GGACCAGGTATCCCTGGATTACTGACTCCTGCTAATCTGGGTCTGAGCCCTCTGG  
CACCTTGGACCAGTGAATCCCAGTCTCAATAACCTATGAGTCATGAACACA  
TTCTTCTTAAAAATCAGCTCTGCTTCCCAGATTTATCTTCATCTGGAGGAG  
ATGAGGTTGATTCACCTGCTGGAAGTCCAACCCAGAACAGATCCCAGGACTTTAT  
GAGGAAGAAAGGCTCGGTGAGGACTTCAAGCAGCGGGAGTCCTTACATCCAG  
ACGCTGCTGGACATCGTCTCTTATGGCAAGGGCTATGTGTCGTGGTTGTGGA  
GTCGGGCTCTGTCGTGCATCGTGCCACCGGTACCGCTGTCATGTGCTGGCG  
TTCGAATTAGCAGCAGCGGTTCTTGGTAACACCCATGGTGGCCAAAGTTGAG  
CGTTATTCTGAGCTCTGC

R6

GACTCCACAACCACGACACATTCTGGTGTAAATTGCTCTGGAGCAGGACTTGGATG  
TCAGTGTAGTACAGCTTCTCCAGGTGATTCTAATGTGTGTCGTGGTTGTGGAGTC  
GGGCTCTTGTGTCGTCGTACGCCACCGGTACCGCTGTCGATGTGCTGGCGTT  
CGAATTAGCAGCAGCGGTTCTTGGAACACCCATGGTGGGCCAAAGTTGAAC  
CGTTTATTCCTGAGCCTTCTGCAAAAAGAACAAACGAG

R4

GACTCCACAACCACGACACATTCTGGTGTAAATTGCTCTGGAGCAGGACTTGGATG  
TCAGTGTAGTACAGCTTCTCCAGGTGATTCTAATGTGTGCGTGGTTGTGGAGTC  
GGGCTCTTGTGCGTCGTACCGCTGCCACCGGTACCGCTGTCGATGTGCTGGCGTT  
CGAATTTAGCAGCAGCGGTTCTTGGAACACCCATGGTGGGCCAAAGTGAAC  
CGTTTATTCTGAGCCTTCTGCAAAAAGAACACGAG

R3

GACTCCACAACCACGACACACTCAGAAAACCTCCTCCATAAAGACACTGGCTC  
AAAAAAAAGAACCCCTGCCCTTCAAATTAGAAGAGAAAAGGACACGAAGATAA  
GTCAGCAGACTGGCTTACCCCTGCCAGAGCGCGCCTCAAACCTCCTTCAGTG  
AGAACTGCCCTTTCCAGACAGAATTCCGTACGTGCACCCCTGGCTCAAGGCTG  
GACAAATTCCCTCTGGAGCCTCTGACGGAAGATGTGATGTCACCGTGGGGCC  
TCCCTTGCTCCCTAAAAAGGGCATTCACACCAAAGAAAGGAATTAAACCTC  
CTTCGGAAAAGGCCCTGGCCCCCTCCCCTGGCTTGGCCGGAACCTTGGAAAGGGC  
ACCGGGATTCCCCAGCCAGAAACAGGGCCGGCTGCTCCGTGTACGGTTCAA  
GGGCTGAGCAGGGGAGGCAAGGAAGCTGGCGGGTTAAAGGTGAATCAGTTAGC  
ATTGATGTGAATCAGTTACCAACTGTCTTTTCCGCAATTAGAGGTGGCCCTGG  
GACAAGCAGGGATTGATTCCCCGGGTATTAAGGCAGAAAAAATCTGAAAG  
ACCCCTGGAGAAAATCTCCCGTTAGACAGACTTTCAAGGACAGCCTGTGTCGTGGTT  
GTGGAGTCGGCTCTCCTCAAAACTGCAGACGCGTTACGTATCGGATCCTTATT  
TAGGTGACACTATAGAATTCCGATATTGGTCGACAAGCTCTCGAGCGTAGGCTA  
GCTCTAGACCACACGTGTGGGGCCGACTC

R12

GAATCCACAAACCACGACACACTCAGAAAACCTCCATAAAGACACTGGCCTC  
 AAAAAAAGAACCCCTGTCCCTTCAAATTAGAAGAGAAAAGGACACGAAGATAA  
 GTCAGCAGACTGGCTTACCCGCCAGAGCGCGCCTCAAACCTCCCTCAGTG  
 AGAACTGCCCTTTCCAGACAGAAATTCTGACGTGCACCCCTGGGCTCAAGGCTG  
 GACAAATTCCCTCCGGAGCCTGACGGAAGATGTGATGTTACCGTGGGGCC  
 TCCCTTGCTCCCTAAAAAGGGCATTCACACCAAAGAAAGGAATTAAACCTC  
 CTTTCGGAAAAGGCCTGGCCCCCTCCCTGGCTTGGCCGGAACCTGGAAGGGC  
 ACCGGGATTCCCCAGCCAGAAACAGGGCCGGCTGCTCCGTGTCACGGTCAA  
 GGGCTGAGCAGGGGAGGCAAGGAAGCTGGCGGTTAAAGGTGAATCAGTTAGC  
 ATTGATGTGAATCAGTTACCACTGTCTTTCGGCAATTCAAGAGGTGGGCC  
 GACAAGCAGGGATTGATTCCCCGGGGTATTAGGCAGCAAAAATCTGAAAG  
 ACCCTGGAGAAATCTCCGTTAGACAGACTTTCAAGGACAGCCTGTGTC  
 GTGGAGTCGGCTTCTCCTCAAAACTGCAGACGCGTTACGTATCGGATCCTTATT  
 TAGGTGACACTATAGAATTCCGATTGGTCGACAAGCTCTCGAGCGTAGGCTA  
 GCTCTAGACCACACGTGTGGGGCCGACTC

R11

GAATCCACAAACCACGACACACTCAGAAAACCTCCATAAAGACACTGGCCTC  
 AAAAAAAGAACCCCTGTCCCTTCAAATTAGAAGAGAAAAGGACACGAAGATAA  
 GTCAGCAGACTGGCTTACCCGCCAGAGCGCGCCTCAAACCTCCCTCAGTG  
 AGAACTGCCCTTTCCAGACAGAAATTCTGACGTGCACCCCTGGGCTCAAGGCTG  
 GACAAATTCCCTCCGGAGCCTGACGGAAGATGTGATGTTACCGTGGGGCC  
 TCCCTTGCTCCCTAAAAAGGGCATTCACACCAAAGAAAGGAATTAAACCTC  
 CTTTCGGAAAAGGCCTGGCCCCCTCCCTGGCTTGGCCGGAACCTGGAAGGGC  
 ACCGGGATTCCCCAGCCAGAAACAGGGCCGGCTGCTCCGTGTCACGGTCAA  
 GGGCTGAGCAGGGGAGGCAAGGAAGCTGGCGGTTAAAGGTGAATCAGTTAGC  
 ATTGATGTGAATCAGTTACCACTGTCTTTCGGCAATTCAAGAGGTGGGCC  
 GACAAGCAGGGATTGATTCCCCGGGGTATTAGGCAGCAAAAATCTGAAAG  
 ACCCTGGAGAAATCTCCGTTAGACAGACTTTCAAGGACAGCCTGTGTC  
 GTGGAGTCGGCTTCTCCTCAAAACTGCAGACGCGTTACGTATCGGATCCTTATT  
 TAGGTGACACTATAGAATTCCGATTGGTCGACAAGCTCTCGAGCGTAGGCTA  
 GCTCTAGACCACACGTGTGGGGCCGACTC

R1

GAATCCACCAACCACGACACAGACATGGAACAGAACCCATACATGCTATTAAAA  
 AGGGGAAAAAAACAGAACAGACCCTAGCTACAAAGCTTAAATACTGCATGCTACG  
 CACCTCGTGGGTCAAGGGTCACGCGTGGGTGGCGTGGAAAGCAAGAACGGCCC  
 AACAAAGGCCAGGGCAGGCAAGAACAGCTGCCCTCCATTGGTGAATAACGTT  
 CATGAATCTAAAGGGTGGCGTTGGCCAGGCGCCGGTTCCCTCGGACACAG  
 CTCCCTGGATTAGTTAGGAAACCCGTCAGTGTGTCGTGGTTGTGGAGTCGGCTCT  
 TGTCGTCATCGCTGCCACCGGTACCGCTGTCATGTGTCGTGGCGTCAATT  
 AGCAGCAGCGGTTCTTGGTAACACCCATGGTGGCCAAAGTTGAGCGTTATT  
 TGAGCTCTGCAAAAAGAACACAAGCGA

## MCF12-S3

AATGAGTCATGATAATGCACGTCGCTATAGTCATCCATTCACTGCTGTATAAT  
ATTCTACTTAATGAATTGCATGGTATGACCTCCATTGGTTCTCTAACGGCTGCAT  
TATTATTTATTAGCC

## MCF12-S2

ACANATCAACATGAATTTGAAGGGGATGCTACAATCAAACCATAGCACAGGTT  
TTTACGCATTTACAATTTAGCCATGTGTAGTGGGACCATTATATTAGTGGGA  
CAATTATTTGCTTAAGATTTGCATGTTCTATATCCAAAATGTTACTGA  
GAAACATGATTTAATTGGCTATATGTATAACTTGTAAATTATTAGCCCGG  
ATCCGCC

## MCF12-S1

NCNATATTGATATTATGTGTGCGTAACTAAAACAAGTNTTCAAACACTGTN  
TTATGCTTCCTAAATGAGCTGCATTATTTAATTGATTATTAGCC  
CGGATCC

## LR5-15

GGCGGATCCGGGCTAAATACATAAATAAGAAAATGGCGCTCAGTGGCCAGAAAA  
CAGCACTTCCAATTCTCTATTGTGGGACTTAGACAACCTCTATGGAAAAATG  
GGCAAATGGGTCTGAGGTACCCCTACTCCAGGTATTTTACATACGATCTCTCCC  
TAGCCTATGCTCCAATGTAATCCATCCCCAATTCCTATTCCCTGTCTAC  
CCCTCCCTCTCCACTGGCGATGCTGAACCATCTCCTGTCCATAGTGAGT  
CGT

## LR5-13

CTCACTATAGGAACAGACCGAGATGAGGGTTGGCAGAGGGAGAAAATAAGCCAG  
CCACGGCAGTCGCTTGGTTCCAGGTGGAATGGCAAAAGGAGATGATGGAA  
CCTGTCCCGCAGTCCCTGCATGACCATGGCCCTGCTGGCCTGGCGATGTGGCA  
TCCTGGGTTCTTAGGGTCCAGAACACAAGGCCCAAGCAAGCTGGAACCTGGGT  
GGGAAGGGACATGAAGAAGATAAACAGCTGACTGTGGCTCCAAGGAACATCA  
GGGCCAACCCCCAATTCTCAGTGTCTACTCCCTGGCAAAGGAATTGGGTT  
TGGGATTCAAAAATTGTTAAAATTAAATATTTGTTCCAGTGGATTAGGAAC  
CAACACTTGTAAACATAAAAACCAATTGTCAATTCTAACAAAGTTAGA  
ATGTGAGGAAGGGAATGAAACATGAGTGTGGAACTGCCTTGGGGCTGG  
CGTGGCGTCCCGCATTGGGGTGTCTCGCTCTGGGCTGCTATGTTGCCCGGC  
CCAGGTCCCCCTGTGTGTTGCCAGACGGGCCTCATGGTCTGCTGAGAGAG

AGGCAGGAAGGATCCCTGAAGAGTCTTGGAGAAAGGTTCTGTGCCCTCAGGTGG  
GGCTTACCCCTCGTATTATAATCTTATTATATTAGCCCGATCCGCC

LR11-12

ACGACTCACTATAGGAACAGAACGTYATGGAAACATTAAAGTAGGTTAACAT  
CTCAGGTGATGAATCACATTAACTCTTACATCACAAATAATCATAAGATCCA  
GAAGAACACCACGTACATTAAATAAACACTCTAATTACTAGAATTGAAGATGATC  
AAGATGCACAAGCATCACAGGTGGCGATGATTATCAAATCCCTTGGAGCTG  
ATTTTAAATCACATAAGTCAAAATCTAACACCTACAAACAAACAAACCMTT  
AATTATATATTAGCCCCGGATCCGCC

LR11-11

ACGACTCACTATAGGAACAGACCGATATGGAAACATCTTCCCATTCTCAGAATA  
CAATGCAGGCATGGGATCCACACAGTAACAAGGCCCTAAGAGGTTGAAGAGAA  
GTCATGCTAACAAAGCGAGGATGATGCAGCATGAAGGAAATATGAAGAAAGCTGAC  
AGTCTGATGTTGCTGTGCAAGACTTATTACCCAGTGCAGGTGGAACCTGACAGG  
NAGACTTTNAGGACCTGCTGTGGATCTAACNACAAGGCAGTTGGNACCTGTT  
ATTNATATATTNAGCCNGGATCCGCC

LR7-4

ACGACTCACTATAGGAACAGACAGTTATGAACCCAGGTGATTGAATCTGGGACC  
AACATCAGGCCTGCTTTGATCTCACCAAGTCGTTCATGAACCCGTTCATCCTCT  
TCTTCCTTGTCCTCAGGGCAGGCCTCCTTGTGCTTCTTCTATTGTTAGCCA  
ACGGCAAGGCCAGTACCTTGCTCTCATCAGGACAGGGTCAGTCTGCTCCCTCA  
NGACAAACTCACTGCTTTGAAGTGCAGTCCACTTGTGTTACCTGCTCATC  
CACTGCGGGGNTGTANTCTCCTCAAAGGCAAATTGGCATCTCAAATGAAATT  
NGGGGGCCCCCTTGTGNCATNAGGANANGGCAGGAACCATTCCCCANGTN  
GGTCAACCCAATCCCGTTTCNATNGTTGGGANAAAGGGGAAATTNT

LR7-2

ACGACTCACTATAGGAACAGAGCACCATGAAGAGTGAAGCGAATCTATGGGGAGGA  
AAGAAGTGGGTGAACCTCGAAGATTCTGATATTAGGAAGTGCTGCCGGTCCC  
AAAAGCTTGGGCCANCCTGNGGAAGAAAGGGAAAATCGGATAAACATCTGCC  
TCTAGGGGCTCTATATATACCCCTATGCCCTCTCCATTGCCCTCTTCAG  
CTAGGGCTGTGCGGGCCCATTGCACCTCTGGGGGGAGACAGACTTATTACACN  
GGTTAAAGAAACCNAATTCCACCAACTGGCCGGCGTTACNNATGGATCCNA  
CNCCGGTACCNANCNTGGC

K1

ACGACTCACTATAGGAACAGAGGCGAATGCCAAAAAAATGAACAGAGGA  
AAAAAAACAAACAAATGGACAAAAGAGACAGAAAGTCGAAATTATTATAGAA  
AATAATACATGTTAATAAAAACATCTAATGCCAATTTTCAAAACTTATTTGA  
TCAGGTCTGAAGGCATAAGAAAACATTAATATTGAGGGTAATTATATATTAA  
GCCCGGATCCGCCA

ISG-L1

ACGAATCTCACTNATGANNGGAACAGAACAGAGGATGAAAACATTAGAGGTA  
GGTTAACATGTCAGGGNGATGNGAATCACATTAACTCTTACATCACAATATA  
AACATAAGATCCAAGAAGAACCGACGTACATTAAATAAACACTCTAATTACTTAG  
AATTGAAGATGATCAAGATGCACAAGCATCACAAAGGTGGCGATGATTATCAA  
ATCCCTTGAGCTGATTTAAATCACATAAGTTCAAAACTAATCACCTACAA  
CAACAAAACCATTAAATTATTAGCCGGATYCSCC

DLP10-3

ACGACTCACTATAGGAACAGATAAACATGAAAGTCATTAAGACAGTGAGATTG  
GGAATAAAATAGCTTTGTTAACATTATTCTCAGAACATCCAGGATAAAATCTA  
GTAATCTCATGGGATTCTCCTGTCATTACGTAGCCATTACATGTGGTCACA  
AAGTCAAGTCAGCTGCTCATGTTATTCATGTTNTCTGTTCTATAGTGAGTCGT  
AAGCCGAATTCCAGCACACTGGCGGGCGTTACTARTGG

DLP10-2

ACGACTCACTATAGGAACAGATAAACATGAGATTGGTGGGACACATATCCNN  
AAATTGCATCATCAATCTTGAATATAAGACATCCACAGCAGGCTTATCCAGC  
CAACTTCTTGAGACTCTTATAGAGTTGAGGTCTAGAGCATATACACTANAAA  
TATTCACTTCGAAAAGCANNATAAGTGGTATTATCATTTCACAAAGTTACA  
GCAGTWGTTAAGGCATTCATARTATGAATT

DLP10-1

ACGACTCACTATAGGAACAGATAAACATGATTAGTGAACCCAAGGATCAGTTACG  
 GAAACGATGCTCTCATGCCATCTTGACCAGAAAACCAACCGTGGAGCTCCT  
 TCCCCTGAATGGAGAGTTCAGCCTGGACGATCTCCAGCCGTGGCATTCTTGGG  
 GCTGACTCTGTGCCAGCCAACACAGAAAACGAARTGARCCCTGTTGATGCCGCC  
 CTGCTGCCGAACCGAAGACTGACCACTCCAACCAGGTTCTGGGGTGAACAAAT  
 TTCCGAACGGAGGAAATCTCTGAAATTGAAATTGGATGCCNAATTCCC

B1

ACGACTCACTATAGGAACAGAGCGCCATGACAACACATAATTAAATAACAGC  
 ATTAAGGGGAAAAAACGTGGCTTGGAGTATTCTGCAATCAGCCTGCCAACTACT  
 ATTCTCTTAATTATATTAGCCGGATCCGCC

AUR3-4

ACGACTCACTATAGGAACAGATTARAATGGGAGTTACTCATGATTGGCTCTCC  
 GTTGTCTGTTATTGGTGTATAGGAATGCCGTGATTTGCACATTGATTGTA  
 TCTGGAGAATTGCTGAATTGCTTATCAGCTTAAGGAGATTCTGGGCTGACACG  
 ATGGGGTTTCTAACATACAATCATGTCATCTGCAAATAGAGACAATTGACTT  
 GCTCTTCTTAACTGAATAACCTTATTATWTATTAGCCGGATCCGCCAAGC  
 CGAATTCCAGCACACTGGCGGGCGTTACTAGTGGATCCGARCTCGGTACCAAGCT  
 TGGCGTTAA

AUR3-3

GGCGGATCCGGCTAAATAAATAAATTAAAAGGTGCATTTTAAATGATGCTA  
 CTGCAATGCAATGGTTAAATACCAAAAAACTGAGAAAATGAGCTGTCTGTGAT  
 CCAGCATTAAAGAACATACTAAAAAAGAGCATTATGAAATTAGTAGAAAGG  
 GGATCAAAAATTGAACTAACCAAGTTGTGCAGTATTGTAGCCAGGCTCTAAAA  
 TTAGATGTAGAAAATATAAATAGACTGCTTAGGTAGTGAGCCACAGTGYCCA  
 AAAAARGGAATGAAATNAAGAAAAAGCTCAGTTAACTTGATCCAAAGCYCNTGA  
 ATAATTCTCCCTGCAATAGTTCTGCTGGCCTGTTAGGACATAACTTCC

AU17

ACGACTCACTATAGGAACAGACAACCATGAAGAMCATTGGGAARGAGTATGAC  
 AGAACAAAGAAAATGAGAGCTCTGGGCACAGGTAGTCTGGTTCCAACCCCACT  
 ACATTTGCCATCTGCATGGTTGGATCCGTTAACCTCTGAGTCTGAT  
 TTCCTTATTATTTAGCCGGATCCGCC

## ADH2 4M2

ACGACTCACTATAGGAACAGAGTCGAATGGAAACGAGTGGGGAAAGATGGACTTG  
 TGTGATGAGAGCTCCCCCATCNTACCTTTTATCAAATATCTGCTCTGCGAA  
 GTGGAGTTTAATCGGCTCGAGTCTGGATTAGTCAGCACTGCAGAAAAGGGC  
 AAGTGAGAACGACAAAGCAGAAGAATGGAAATTAGCTATTATATTTAGCC  
 CGGATCCGCC

## 550BAND

GACTCCACWACCACGACACACAGCAGGAGCAGGAGCCACACAGGAACACTCCG  
 CCGTGARGGCAACAGATGCAGCTGGCACRACGTGCCACAGCCACARARAACA  
 GGGCAGTTCATGGGAACCCAAGGAGYTYTGGAACCAMRAMCCTYTTCAAGG  
 WTARAAAGGSCMMMTYKTCMCCMACAMWGCCATGGSCCTYCCCTYMMKTT  
 WKTTARAGGCMMTGGARARARAAAAGYTWATKWKATTGGCAMACARAVCC  
 CMKTGAAYTKTIDCCCBAAGCCTTAAGGAAAGGTGCCGGAATTCMACTTGAAM  
 DTTCSGAAGGCCRGGGARAAHRAKITTYATGGSCMCACMGGGAMTTKGKTCG  
 RAAGGGGCSWWGAARTTGGAAASCATCCCCMVGCKTKTARGTTWVCAGGGA  
 AGGGGGCTKGGCSCAGGCSYTTGTGGRAATTYSACTKTKTAAARAAAKTCS  
 CAGGCCAGCAGGCTGKWTCTGGAACCTGCCAACSTTGCAGGCCTGGTAGC  
 GGTAAGGTGTGCTGGAAAAGGTGGGTCCATTTCAGTGCAGCTGTGCGT  
 GGTTGTGGAGTC

## 20-3

ATTCACGATCAGATCTGTTAAAGCAAAATTGGTGGATGCCGTATTAATCAAATA  
 CCTGTTATTCTGCTTGCATTATTGCATAACATCTTCATCCATTAAATTATTATT  
 TAGCCCGGATCCGC

## 20-2

GGCAGCATRGAAAAGGGGACATGCTTATCCAATACACCTGCTGAGCTGACTGC  
 CAGGATTCTAAAACCTAGGTCCAATGGTAGTTAGTGTGTTGCTTGTAACTCTA  
 ACACTAGTTGACATCCTACTACAGTTCTCTCCATTCCACAGACTTCTTCTAAT  
 TTATATATTAGCCGGATCCGCC

## 20-1

CTTATGTATCAGTGTAACTGTCATTATGTTTCTAACTATTAATTCACTTTT  
 TCTTTGTTAATTGCATACCGCTGCTTATTAGATTGTTCATGTACTTTATAA  
 CACTTTAGTCTTATTATTGATTATTGTTCTTCTAAATTAAAATTGATCT  
 ACAGTTAAAGCTATGAATTGTTCTCTGCAGTGTGTTGGCAATTCCAAAAGT  
 CTTGATCTGGAGCTTTAAAAATCATTCTATAAAGGAAATTACCAATTCAAGT  
 ATGTATTCTCTTATCCTAAAAGTAATTCAAGATCAATTACTTAAACTTGCCA

**WO 01/83691**

**PCT/US01/11993**

**GGTGATTGAGTCTTTCATTTCTGAGTKTTTATTGAGWGTGAGTCTTATTGGGA  
TTATACTCAGATACCATGGKCMGCAATATACTTTGG**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number  
**WO 01/83691 A3**

- (51) International Patent Classification<sup>7</sup>: G06F 19/00. (74) Agent: DOCHERTY, Pamela, A.; Calfee, Halter & Griswold LLP, 1400 McDonald Investment Center, 800 Superior Avenue, Cleveland, OH 44114 (US).
- (21) International Application Number: PCT/US01/11993
- (22) International Filing Date: 12 April 2001 (12.04.2001).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/196,870 12 April 2000 (12.04.2000) US
- (71) Applicants (for all designated States except US): THE CLEVELAND CLINIC FOUNDATION [US/US]; 9500 Euclid Avenue, Cleveland, OH 44195 (US). KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE [SA/SA]; P.O. Box 3354 - MBC-03, 11211 Riyadh (SA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ABU-KHABAR, Khalid, S. [SA/SA]; P3354, MBC-03, 11211 Riyadh (SA). WILLIAMS, Bryan, R., G. [NZ/US]; 2909 Fairfax Road, Cleveland, OH 44118 (US). FREVEL, Mathias [DE/US]; 4470 Chagrin River Road, Chagrin Falls, OH 44022 (US). SILVERMAN, Robert, H. [US/US]; 24607 Letchworth Road, Beachwood, OH 44122 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
23 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/83691 A3

(54) Title: SYSTEM FOR IDENTIFYING AND ANALYZING EXPRESSION OF ARE-CONTAINING GENES

(57) Abstract: Adenylate-uridylic acid-rich (ARE) elements present in the 3' untranslated region (UTR) of gene and mRNA sequences are disclosed. THE ARE motif comprises a sequence encompassed by: SEQ ID NO: 1 or 2, with further limitations. Computational methods of identifying genes or coding sequences in a database which comprise ARE elements are disclosed. The computational methods can be used for gene discovery, and sequence analysis. Methods of identifying, isolating and amplifying ARE-element-associated polynucleotides using PCR, RT-PCR, hybridization, etc. are disclosed. PCR primers, oligonucleotide arrays, polynucleotide libraries, computer programs, and computer systems relating to ARE elements are disclosed.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/11993

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : G06F 19/00; G01N 33/483  
US CL : 702/19, 20; 435/6, 92.2; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 702/19, 20; 435/6, 92.2; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EAST, DERWENT, Medline, Scisearch, CAPLUS, JAPIO, JICST-EPLUS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, E	US 6,238,863 B1 (SCHUMM et al.) 29 May 2001, see columns 21-24.	1-20, 50-52, 56-60
X	US 5,444,149 A (KEENE et al.) 22 August 1995, see Figures 3, 4, columns 5-7, 11-13, 15-17.	1-20, 50-52, 56-60, 83
Y		21-23, 25-42, 45-49, 61-82
X	US 5,525,495 A (KEENE et al.) 11 June 1996, see entire document.	1-20, 50-52, 56-60, 83
Y		21-23, 25-42, 45-49, 61-82
X	US 5,866,680 A (KEENE et al.) 02 February 1999, see entire document.	1-20
Y		21-23, 24-42, 45-52, 55-83
Y	US 6,030,784 A (SUTCLIFFE et al.) 29 February, 2000, see entire document.	21-23, 25-42, 45-49, 61-72
Y	BABENKO et al. Investigating extended regulatory regions of genomic DNA sequences. Bioinformatics. July 1999, Vol. 15, No. 7/8, pages 644-653 see entire document.	1-23, 25-42, 45-49

Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	-T-	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	-X-	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	-Y-	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	&	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

05 September 2001 (05.09.2001)

Date of mailing of the international search report

29 OCT 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Mary K Zeitman

Telephone No. 703 308 0196

Form PCT/ISA/210 (second sheet) (July 1998)

**BEST AVAILABLE COPY**

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US01/11993

**C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BURLAND, T.G. DNASTAR's Lasergene Sequence Analysis Software. Methods in Molecular Biology. January 2000, Vol. 132, pages 71-91 see entire document.	1-23, 25-42, 45-49
Y	ROZEN, S. et al. Primer3 on the WWW for General Users and for Biologist Programmers. Methods in Molecular Biology. January 2000, Vol. 132, pages 365-386, see entire document.	1-23, 25-42, 45-49
Y	SZE, S-H. et al. Algorithms and software for support of gene identification experiments. Bioinformatics. 1998, Vol. 14, No. 1 pages 14-19, see entire document.	1-23, 25-42, 45-49

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/11993

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claim Nos.: 24, 43, 44 and 53-55 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/11993

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-20, drawn to methods of selecting a set of two nucleic acids having particular features, methods of preparing libraries of those nucleic acids, methods of preparing arrays of those nucleic acids, arrays, libraries, and methods of extracting the genes from a database.

Group II, claim(s) 21, 22, and 25-38, drawn to methods of identifying primer sets which are then classified into 4 separate classes. Consensus sequences are determined within each set. These sets are then used to selectively amplify gene transcripts by RT-PCR. Amplified fragments are used to populate a library, and are also used to make arrays.

Group III, claim(s) 23, 24 and 39-49, drawn to methods of identifying primer sets which are then classified into 16 separate classes which are different from the classes of Group II. Consensus sequences are determined within each set. These sets are then used to selectively amplify gene transcripts by RT-PCR. Amplified fragments are used to populate a library, and are also used to make arrays.

Group IV, claim(s) 50-60, drawn to methods of selectively amplifying ARE-gene transcripts wherein RNA from a cell is used for RT-PCR. The fragments are ligated to an oligomer, then amplified again by PCR. These molecules are used to populate a library and an array.

Group V, claim(s) 61-71, drawn to methods of selectively amplifying ARE-gene transcripts wherein RNA from a cell is used for RT-PCR with a specific 3' primer having a particular repeat sequence. These molecules are again amplified by PCR using a second set of primers, wherein the 5' primer is specified as being from claim 21. These molecules are used to populate a library and an array.

Group VI, claim(s) 72-82; drawn to methods of selectively amplifying ARE-gene transcripts wherein RNA from a cell is used for RT-PCR with a specific 3' primer having a particular repeat sequence. These molecules are again amplified by PCR using a second set of primers, wherein the 5' primer is specified as being from claim 23. These molecules are used to populate a library and an array.

Group VII, claim(s) 83, drawn to a method of obtaining a gene expression profile in a subject by hybridization with a nucleic acid array.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Each of the groups comprises a differing method, having differing steps, differing goals, and requiring differing methods of execution. For example, the method of determining an expression profile in a subject requires many steps which are not required for methods of selecting a set of nucleic acids from a database, such as selection of the subject and interpretation of the data. No single special technical feature connects all the inventions. However, within each separate method, the products and processes of using those processes share a special technical feature, and are considered a single invention as set forth above.

